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III. ABSTRACT 
 
Genetic and biochemical studies in C. elegans have shown that developmental programmed cell death 
requires a CED-4 mediated activation of the caspase CED-3. CED-9 acts as a death protector by 
directly interacting with and inhibiting the function of CED-4. CED-9 can be prevented from acting by 
binding to the death factor Egl-1. This apoptotic machinery seems to be conserved between worms and 
mammals, at least at its base. Several CED-3-like caspases have been identified which either activate 
each other in a proteolytic cascade or depend on an adapter-like CED-4 homologue for their 
activation. Members of the Bcl-2 family are plentiful in mammals and consist of both survival factors 
(Bcl-2, Bcl-xL), which are CED-9 homologues, and death factors (Bax, Bak), which are Egl-1 
homologues, neutralizing each other through heterodimerization. However, as Bcl-2 and Bcl-xL do 
not simply act via Bax/Bak neutralization, they must somehow interact and work through mammalian 
CED-4 homologues if the death pathway is evolutionary conserved. 
The first CED-4 homologue identified was Apaf-1. In contrast to death signals in C. elegans, Apaf-1 
however depends for its caspase activation function (caspase-9) on a mitochondrial protein, 
cytochrome c, that is released into the cytosol upon apoptosis stimulation. Although it was previously 
published that Bcl-2 and Bcl-xL could interact with Apaf-1, many reports have shown that these 
proteins act upstream of Apaf-1 to block the release of cytochrome c. Thus, they probably interact 
with a CED-4 homologue that damages mitochondria directly or indirectly. In addition to this CED-4 
interaction model, the homology of the crystal structure of Bcl-xL and Bax with pore-forming 
bacterial toxin suggested that Bcl-2 family members could act as ion or protein conducting channels or 
pores. While one could easily imagine such a mode of action for Bax and Bak, because their function 
on mitochondria is to release cytochrome c, it is more difficult to envisage a pore forming function for 
the anti-apoptotic activity of Bcl-2 and Bcl-xL. 
The goal of this thesis was to get more insights into the interaction between Bcl-2 and Bax and 
whether these molecules could homodimerize and potentially form channels, to test whether Apaf-1 is 
indeed a protein target of Bcl-2 family members, to understand the mechanism by which Bax releases 
cytochrome c and to clone new survival factors. Firstly, we show that while Bax effectively di- or 
multimerizes, naturally occurring Bcl-2 does not readily form homodimers both in vitro and within 
cells even under conditions when Bcl-2 protects them from apoptosis. This indicates that Bcl-2 is 
probably not able to form a channel by itself. Secondly, we can not find any interaction between Apaf-
1 and Bcl-2, Bcl-xL or Bax both in vitro  and in intact cells. We therefore disfavor the notion that 
Apaf-1 forms a mammalian apoptosome with Bcl-2 or Bcl-xL even when they act as survival factors. 
Nevertheless, it is still possible that the interaction between Apaf-1 and the Bcl-2 family members is 
indirect or via another CED-4 homologue. Thirdly, we demonstrate that there is no other protein that 
associates stably in detectable amounts with Bcl-2, Bax or the heterodimer in normal and apoptotically 
stressed cells. Moreover, we reveal that the degree of protection against apoptosis does not correlate 
with the number of Bcl-2-Bax heterodimers but with the amount of Bcl-2 that is free of Bax indicating 
that Bcl-2 requires neither Bax nor major, stable interactions with other cellular proteins to exert its 
survival function. Fourthly, we were able to prove that Bcl-2 fails to prevent Bax-induced cytochrome 
c release in cells stably overexpressing both Bcl-2 and Bax. In addition, these cells show no signs of 
caspase activation and survive with significant amount of cytochrome c in the cytosol denoting that 
Bcl-2 can interfere with Bax killing downstream of and independently of cytochrome c release. 
Fifthly, we discover a crosstalk between the endoplasmic reticulum (ER) and mitochondria controlled 
by Bcl-2. Surprisingly, cytochrome c release induced by the drug brefeldin A (BFA) or tunicamycin is 
not only blocked by wild-type Bcl-2, but also by a Bcl-2 variant that is exclusively targeted to the ER. 
Finally, we isolate new putative survival factors from a functional assay where cells are rescued after 
transfecting a cDNA phagemid library from a human Burkitt lymphoma RNA source and exposing 
them to toxic doses of staurosporine. 
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IV. RESUME 
 
Des études génétiques et biochimiques du C. elegans ont montré que durant le développement, la mort 
cellulaire programmée requiert une activation de la caspase CED-3 par l’intermédiaire de CED-4. 
CED-9 agit lui comme protecteur de mort en interagissant directement avec CED-4 et en inhibant sa 
fonction. L’action de CED-9 peut être empêchée par liaison au facteur de mort Egl-1. Cette machine 
apoptotique semble être conservée entre les vers et les mammifères, du moins à sa base. Plusieurs 
caspases, similaires à CED-3, ont été identifiées. Elles s’activent les unes les autres soit directement en 
une cascade proteolytique, soit par l’intermédiaire d’un adaptateur homologue à CED-4. Les membres 
de la famille de Bcl-2 sont abondants chez les mammifères et se composent de facteurs de survie (par 
exemple Bcl-2 et Bcl-xL) qui sont des homologues de CED-9 ainsi que des facteurs de mort (par 
exemple Bax et Bak) qui sont des homologues de Egl-1. Ces deux sous-familles se neutralisent les 
unes les autres par hétérodimérisation. Par contre, comme Bcl-2 et Bcl-xL n’agissent pas simplement 
en neutralisant Bax et Bak, ils doivent d’une façon ou d’une autre interagir et fonctionner à travers des 
homologues mammifères de CED-4 si le processus de mort est conservé durant l’évolution. 
Le premier homologue de CED-4 à avoir été identifié, est Apaf-1. Cependant et contrairement aux 
signaux de mort dans le C. elegans, Apaf-1 dépend pour sa fonction d’activation des caspases (en 
l’occurrence caspase-9), d’une protéine mitochondriale, le cytochrome c, qui est libérée dans le 
cytosol par induction de l’apoptose. Bien que précédemment, il a été publié que Bcl-2 et Bcl-xL 
pouvaient interagir avec Apaf-1, beaucoup de comptes rendus ont montré que ces protéines agissent en 
fait en amont d’Apaf-1 afin de bloquer la libération du cytochrome c. Ils interagissent donc 
probablement avec un homologue de CED-4 qui endommage directement ou indirectement les 
mitochondries. En plus de ce modèle d’interaction de CED-4, la similitude des structures cristallines 
de Bcl-xL et de Bax avec la toxine bactérienne formant des pores, suggérait que les membres de la 
famille de Bcl-2 pouvaient agir comme des canaux ioniques ou protéiniques ou alors comme des 
pores. Un tel mode d’action serait facile à imaginer pour Bax et Bak étant donné que leur fonction sur 
les mitochondries est de libérer du cytochrome c, mais il est plus difficile d’envisager une fonction de 
formation de pores pour l’activité anti-apoptotique de Bcl-2 et de Bcl-xL. 
Cette thèse avait comme objectif d’obtenir plus d’informations dans l’interaction entre Bcl-2 et Bax, 
de savoir si ces molécules peuvent homodimériser et potentiellement former des canaux, de tester si 
Apaf-1 est vraiment une protéine cible des membres de la famille de Bcl-2, de comprendre le 
mécanisme par lequel Bax libère le cytochrome c et finalement de cloner des nouveaux facteurs de 
survie. Premièrement, nous montrons que Bcl-2 ne forme pas volontiers des homodimères autant in 
vitro qu’à l’intérieur de la cellule, cela même sous des conditions où Bcl-2 la protège de l’apoptose, 
alors que Bax effectivement di- ou multimérise. Ceci indique que Bcl-2 n’est probablement pas 
capable de former un canal de lui-même. Deuxièmement, nous n’avons pu trouver aucune interaction 
entre Apaf-1 et Bcl-2, Bcl-xL ou Bax, in vitro et dans des cellules intactes. Par conséquent, nous 
sommes défavorables à la notion que Apaf-1 forme un apoptosome mammifère avec Bcl-2 ou Bcl-xL, 
même lorsqu’ils agissent comme des facteurs de survie. Néanmoins, il est encore possible que 
l’interaction entre Apaf-1 et les membres de la famille de Bcl-2 soit indirecte ou via un autre 
homologue de CED-4. Troisièmement, nous démontrons qu’il n’y a aucune autre protéine qui 
s’associe stablement et en quantités détectables avec Bcl-2, Bax ou leur hétérodimère dans des cellules 
normales et apoptotiquement stressées. De plus, nous révélons que le degré de protection contre 
l’apoptose ne correspond pas au nombre d’hétérodimères Bcl-2/Bax, mais à la quantité de Bcl-2 qui 
est libre de Bax. Cela indique que Bcl-2 ne requiert ni Bax, ni d’interaction majeure et stable avec 
d’autres protéines cellulaires pour exercer sa fonction de survie. Quatrièmement, nous sommes 
capables de prouver que Bcl-2 ne réussit pas à prévenir la libération du cytochorme c provoquée par 
Bax dans des cellules surexprimant stablement Bcl-2 et Bax. De plus, ces cellules ne montrent aucun 
signe d’activation des caspases et survivent avec des quantités importantes de cytochorme c dans le 
cytosol, dénotant ainsi que Bcl-2 peut interférer avec la mort induite par Bax en aval et 
indépendemment de la libération du cytochrome c. Cinquièmement, nous découvrons une connexion 
entre le réticulum endoplasmique et les mitochondries contrôlée par Bcl-2. De manière surprenante, la 
libération du cytochrome c induite par la drogue brefeldine A (BFA) ou tunicamycine n’est pas 
seulement bloquée par le Bcl-2 wild-type, mais aussi par une variante de Bcl-2 exclusivement présente 
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sur le réticulum endoplasmique. Finalement, nous isolons de possibles nouveaux facteurs de survie par 
une analyse fonctionnelle. Elle consiste à sauver des cellules qui ont été précédemment transfectées 
avec une librairie de phagemides de cDNA préparée à partir d’une source ARN de lymphomes Burkitt 
humains et exposées à des doses toxiques de staurosporine. 
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1. INTRODUCTION  
 
1.1 The origin of cell death 
 
 
When a cell in an organism dies due to a process encoded by that organism for the purpose of 
killing its own cells, that death can be considered to be a physiological process. The great 
majority of our cells are destined to die just by such a mechanism; relatively few die through 
injury or inability to sustain their own viability. That cell death occurs in a predictable 
“programmed” fashion in physiological circumstances was first recognized by Carl Vogt who 
saw dying cells in the neuronal system of developing toad embryos (Vogt, 1842). However, 
the very first cells described, those from cork and named “cells” by Hooke in 1665, were also 
corpses that had died physiologically. Developmental biologists were also quick to realize 
that cell death was involved in the process of metamorphosis, both in insects and mammals. 
For example, Lockshin coined the phrase “programmed cell death” in 1965 to describe cell 
death in insect metamorphosis (Lockshin and Williams, 1965), and a year later Tata showed 
loss of the tadpole’s tail involved cell death that could be blocked by cycloheximide and 
therefore required expression of endogenous genes (Tata, 1966). When Kerr, Wyllie and 
Currie saw that the morphology of liver cells exposed to toxins, and lymphocytes treated with 
hormones, was the same as that described by the embryologist Glucksmann earlier in the 
century, they coined a new term, “apoptosis”, for cell deaths with this distinct morphology-
whether they be in response to physiologic or pathologic stimuli (Glucksmann, 1951; Kerr et 
al., 1972; Vaux and Korsmeyer, 1999).  
Although the first component of a cell death mechanism to be recognized was the mammalian 
gene Bcl-2 (Vaux et al., 1988), the first evidence that a genetic program existed purely for 
physiological cell death came from studying development in C. elegans (Horvitz et al., 1982; 
Ellis and Horvitz, 1986). The ability of human Bcl-2 to prevent programmed cell death in C. 
elegans showed that apoptosis in mammalian cells and programmed cell death in the 
nematode were the same highly conserved process (Vaux et al., 1992). At about the same 
time, investigators in a seemingly unrelated area, inflammation, were engaged in the study of 
pro-interleukin(IL)-1b  processing, in the hope that identification of the responsible protease 
would provide a starting point for the development of new therapeutic agents. This work led 
to the discovery of a novel protease, IL-1b  converting enzyme (ICE), now known as caspase-
1 (Ceretti et al., 1992; Thornberry et al., 1992). The connection between caspases and 
apoptosis was made late in 1993 when Yuan and her colleagues reported that caspase-1 is 
related to a C. elegans death gene, CED-3 (Yuan et al., 1993). This work not only reinforced 
the prevailing view that molecular mechanism of cell death were highly conserved, but 
established proteases, caspases in particular, as key mediators of this process (Thornberry, 
1999). 
 
1.2 Types and morphologies of cell death 
 
Based on morphological and biochemical analyses (Table 1), cell death can occur via two 
quite distinct mechanisms : necrosis, also called accidental or pathological cell death, and 
apoptosis. 
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Table 1 : Differential features and significance of necrosis and apoptosis. 
 
 
While necrosis occurs when cells are exposed to an extreme variance from physiological 
conditions, like complement attack, severe hypoxia, hyperthermia, lytic viral infection, 
exposure to toxins or respiratory poisons, leading to the rupture of the cell and an 
inflammation (Trump et al., 1981 ; Searle et al., 1982), apoptosis acts in a single cell and in 
response to defined stimuli. It proceeds via a genetically encoded cell suicide machinery that 
sometimes even requires RNA and protein synthesis. Therefore it is often called programmed 
cell death or PCD (Tata, 1966 ; Lockshin, 1969 ; Oppenheim et al., 1990).  
During necrosis, the cell swells, its mitochondria dilate, other organelles dissolve and the 
plasma membrane ruptures, releasing cytoplasmic material; this often elicits an inflammatory 
response. By contrast, during apoptosis, the cytoplasm shrinks and the chromatin condenses, 
but the organelles retain their integrity. The plasma membrane blebs and exposes 
phosphatidylserine on its outer surface, which is normally retained in the inner leaflet, but it 
does not rupture, preventing the release of cellular compounds into the extra-cellular medium. 
In vitro, apoptotic cells ultimately fragment into membrane-enclosed vesicles (apoptotic 
bodies), which swell and lyse resulting in the so-called “secondary necrosis” phase (Mills et 
al., 1999; Desagher and Martinou, 2000), whereas, in vivo, they are recognized and removed 
by either phagocytes or adjacent cells, thereby avoiding inappropriate inflammation. 
Biochemical hallmarks of apoptosis also include the activation of endonucleases, DNA 
degradation into oligonucleosomal fragments and the activation of a family of cysteine 
proteases called caspases (Desagher and Martinou, 2000). 
Nevertheless, there is increasing evidence that classical apoptosis and necrosis represent only 
the extreme ends of a wide range of possible morphological and biochemical deaths. The two 
classical types of demise can occur simultaneously in tissues or cell cultures exposed to the 
same stimulus and often, the intensity of the same initial insult decides the prevalence of 
either apoptosis or necrosis. For example, pre-emptying human T-cells of ATP switches the 
Necrosis Apoptosis
- Loss of membrane integrity
- Flocculation of chromatin
- Swelling of the cell and lysis
- No vesicle formation, complete lysis
- Disintegration (swelling) of organelles
Morphological features
- Membrane blebbing, but no loss of integrity
- Aggregation of chromatin at the nuclear membrane
- Cellular condensation (cell shrinkage)
- Formation of membrane bound vesicles (apoptotic bodies)
- No disintegration of organelle; organelles remain intact
Biochemical features
- Loss of regulation of ion homeostasis
- No energy requirement (passive process, also occurs at 4°C)
- Random digestion of DNA (smear of DNA after an agarose 
gel electrophoresis)                                            
- Postlytic DNA fragmentation (=late event of death)
- Tightly regulated process involving activation and enzymatic st ep
- Energy (ATP)-dependent (active process, does not occur at 4°C)
- Non-random mono- and oligonucleosomal lenght DNA fragmenta -
tion (ladder pattern after an agarose gel electrophoresis)
- Prelytic DNA fragmentation (=early event of cell death)
Physiological features
- Death of cell groups
- Evoked by non-physiological disturbances
- Phagocytosis by macrophages
- Significant inflammatory response
- Death of single, individual cells
- Induced by physiological stimuli
- Phagocytosis by adjacent cells or macrophages
- No inflammatory response
Morphological features
Biochemical features
Physiological features
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type of demise caused by two classic apoptotic triggers (staurosporine and CD95 stimulation) 
from apoptosis to necrosis (Nicotera et al., 1999).  
Moreover, for several years, a major discussion point was definition of the type of cell death : 
apoptosis, programmed, active, physiological, necrotic. Elucidation of some of the molecular 
pathways has resolved some of these issues, but has indicated that there is sufficient variation 
that one needs either to take a larger view of the meaning of the word “apoptosis” or to 
consider apoptosis to be one of a family of physiological cell deaths. For instance, in the last 
10 years, caspases have been identified as major players in apoptosis, and have even been 
proposed as the defining element of apoptosis, but we also now recognize that the certainly 
powerful caspase pathway is not necessary to kill cells. More recently, evidence has 
accumulated that non-caspases, including cathepsins, calpains, granzymes and the proteasome 
complex, also have roles in mediating and promoting cell death (Borner and Monney, 1999; 
Johnson, 2000). In addition, in many instances cells in which caspases are blocked or knocked 
out will die, even though they do not acquire apoptotic morphology. They look more like cells 
with elaborately developed autophagy, a form of death that is encountered, more commonly 
than acknowledged, in large post-mitotic epithelial and other cells, including insect organs 
and mammary epithelium in which lysosomal and perhaps other proteases are activated 
(Lockshin et al., 2000). Morphologically, autophagic cell death includes degradation of Golgi 
apparatus, polyribosomes, and endoplasmic reticulum, which precedes nuclear destruction. 
Intermediate and microfilaments are largely preserved; presumably the cytoskeleton is 
required for autophagocytosis (Bursch et al., 2000). 
 
1.3 Cell death and disease 
 
Programmed cell death plays a critical role in controlling the number of cells in development 
and throughout an organism’s life by the removal of cells at the appropriate time. It is an 
important biological process for the elimination of unwanted cells such as those with 
potentially harmful genomic mutations, autoreactive lymphocytes, or virally infected cells. 
Alterations of this normal process can result in the disruption of the delicate balance between 
cell proliferation and cell death and can lead to a variety of diseases (Thompson, 1995). For 
example, in many forms of cancer, key pro-apoptotic proteins are mutated or anti-apoptotic 
proteins are upregulated, leading to the accumulation of cells and the inability to respond to 
harmful mutations, DNA damage, or chemotherapeutic agents. Since effective chemotherapy 
depends on the induction of programmed cell death, cancers with defects in the cell death 
signaling pathways are particularly difficult to treat.  
PCD is also important for eliminating autoreactive T cells after an immune response. When 
this normal process is disrupted through mutations of the proteins that trigger apoptosis (e.g. 
Fas ligand or the Fas receptor), an autoimmune lymphoproliferative syndrome (ALPS) can 
result, with complications such as hypersplenism, autoimmune hemolytic anemia, 
thrombocytopenia, and neutropenia (Strauss et al., 1999).  
Inappropriate apoptosis also contributes to several neurologic disorders. In Alzheimer’s, 
Parkinson’s and Huntington’s disease, specific neurons prematurely commit suicide, which 
can lead to irreversible memory loss, uncontrolled muscular movements and depression 
(Fesik, 2000). 
While the relationship of apoptosis to disease has been postulated and argued in many 
settings, on one topic there is a building consensus. In diseases as diverse as AIDS, 
myocardial infarction (MI), hyperoxia in the lung epithelium, immunological irregularities, 
and autoimmune disease, there is substantial apoptosis, often including cells that appear not to 
be seriously damaged but may be bystanders activating their cell death pathways in response 
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to local events (Finkel et al., 1995; Finkel and Casella, 1998; Garaci et al., 1999; Gougeon 
and Montagnier, 1999). In some situations such as MI, massive apoptosis may result in 
incomplete clearance of apoptotic cells and consequent inflammation. There is growing 
evidence that the primary antigens of autoimmne disease result from immunization against 
apoptotic blebs. In all pathological situations, we often know the outline of the origin of the 
pathology, but we need to understand it with far greater subtlety: the means by which a cell is 
forced into apoptosis, following what appears to be longterm, chronic stress; by misreading or 
misdelivery of transcellular signals by other cells (death of bystander cells); by a self-
destructive turn of recruitment of phagocytic attack when a chronic infection allows T-cells to 
be recruited to destroy apoptotic blebs (in autoimmune disease); or the subtle changes in 
development or cancer in which, without abrogating the apoptotic response, patterns in which 
cell death occurs are shifted or the sensitivity of cells to normal controls is altered (Lockshin 
et al., 2000).    
 
1.4 Molecular biology of apoptosis 
1.4.1 The basic apoptosis machinery 
 
The past few years have seen significant advances in our understanding of both the machinery 
that executes apoptosis and the mechanisms by which this potentially catastrophic process is 
controlled. Much of our knowledge stems from studies of the developmentally invariant 
nematode C. elegans. During its ontogeny, 1090 cells are born, of which 131 die by suicide. 
Genetic analysis has identified four principal genes that are directly involved in the regulation 
and execution of each cell death : the products of the ced-3, ced-4 and egl-1 genes promote 
apoptosis, whereas the product of the ced-9 gene inhibits apoptosis (Meier and Evan, 1998). 
ced-3 encodes a caspase which is a cysteine protease that cleaves certain proteins after 
specific aspartic acid residues ; it exists as a zymogen which is activated through self-
cleavage (Salvesen and Dixit, 1997 ; Thornberry and Lazebnik, 1998). The ATPase CED-4 
binds to the inactive pro-form of CED-3 and facilitates autoactivation of the latter by 
oligomerization, whereas CED-9 interferes with this process by interacting with CED-4 
(Figure 1). EGL-1 sequesters CED-9 and allows death to proceed in a CED-4/CED-3-
dependent manner (Conradt and Horvitz, 1998). In living cells, CED-9 binds CED-4 on 
mitochondria, while in dying cells CED-4 is released from CED-9 and translocates to the 
nuclear membrane (Chen et al., 2000).  
 
Figure 1 : Apoptosis in C. elegans 
 
Vertebrates have evolved entire gene families that resemble C. elegans cell death genes. 
Mammalian caspases are similar to CED-3 (Salvesen and Dixit, 1997; Thornberry and 
Lazebnik, 1998). Apaf-1, Nod-1/CARD-4, Nod-2, DEFCAP and  NAC are the only 
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mammalian CED-4 homologue known so far. The products of the mammalian Bcl-2 gene 
family are related to CED-9 but include two subgroups of proteins that either inhibit (anti-
apoptotic) or promote (pro-apoptotic) apoptosis. These pro-apoptotic proteins might be the 
mammalian equivalent of EGL-1. But as expected, due to the higher degree of complexity of 
mammals, the mechanism of apoptosis is more elaborate and degenerate. For convenience, 
apoptosis can be divided into separate phases (Figure 2). The “initiation” phase, during which 
cells receive signals that may result in the activation of the death program. The 
“commitment”/“amplification” phase, the point after which death signals become irreversible 
and where multiple caspases are recruited to cooperate in the destruction of the cell. Finally, 
the “demolition” phase, where a panoply of active caspases dismantle cellular structures, 
either directly, or via activation of other enzymes such as CAD/DFF45 (Slee et al., 1999a). 
 
Figure 2 : Schematic representation of the routes to caspase activation within apoptosis. 
 
1.4.2 The initiation phase 
 
Initiators of the apoptosis machinery can be broadly grouped into three different categories : 
(a) death receptors, (b) the contents of cytotoxic T and NK cell granules, and (c) stimuli that 
provoke generalized cellular damage. 
 
(a) Death receptor-initiated cell death signals 
 
Death receptors belong to the tumor necrosis factor receptor (TNF-R) gene superfamily, 
which is defined by one to five similar, cysteine-rich extracellular domains (Smith et al., 
1994; Gruss and Dower, 1995). The death receptors contain in addition a homologous 
cytoplasmic sequence termed the “death domain” (DD) (Tartaglia et al., 1993; Nagata, 1997). 
Death domains typically enable death receptors to engage the cell’s apoptotic machinery, 
called the “extrinsic” pathway, but in some instances they mediate functions that are distinct 
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from or even counteract apoptosis. Some molecules that transmit signals from death receptors 
contain death domains themselves. 
The best characterized death receptors are CD95 (also called Fas or Apo1) and TNFR1 (also 
called p55 or CD120a) (Smith et al., 1994; Gruss and Dower, 1995; Nagata, 1997). 
Additional death receptors are death receptor 3 (DR3; also called Apo3, WSL-1, TRAMP, or 
LARD) (Chinnaiyan et al., 1996a; Kitson et al., 1996; Marsters et al., 1996a; Bodmer et al., 
1997; Screaton et al., 1997a), DR4 (also called TRAIL-R1) (Pan et al., 1997a), DR5 (also 
called Apo2, TRAIL-R2, TRICK 2, or KILLER) (Chaudhary et al., 1997; McFarlane et al., 
1997; Pan et al., 1997b; Schneider et al., 1997; Screaton et al., 1997b; Sheridan et al., 1997; 
Walczak et al., 1997; Wu et al., 1997), decoy receptor 1 (DcR1; also called TRID, TRAIL-
R3, or LIT) (Degli-Esposti et al., 1997a; McFarlane et al., 1997; Pan et al., 1997b; Schneider 
et al., 1997; Sheridan et al., 1997; Mongkolsapaya et al., 1998), DcR2 (also called TRAIL-R4 
or TRUNDD) (Degli-Esposti et al., 1997b; Marsters et al., 1997; Pan et al., 1998b) and DcR3 
(Pitti et al., 1998). The p75 nerve growth factor (NGF) receptor also contains a death domain 
(Liepinsh et al., 1997). The ligands that activate these receptors, with the exception of NGF, 
are structurally related molecules that belong to the TNF gene superfamily (Smith et al., 
1994; Gruss and Dower, 1995). CD95 ligand (CD95L) binds to CD95 and DcR3; TNF and 
lymphotoxin a bind to TNFR1; Apo3 ligand (Apo3L, also called TWEAK) (Chicheportiche 
et al., 1997; Marsters et al., 1998) binds to DR3 (Marsters et al., 1998); and Apo2 ligand 
(Apo2L, also called TRAIL) (Wiley et al., 1995; Marsters et al., 1996b ; Pitti et al., 1996;) 
binds to DR4 (Pan et al., 1997a), DR5 (Chaudhary et al., 1997; McFarlane et al., 1997; Pan et 
al., 1997b; Schneider et al., 1997; Screaton et al., 1997b; Sheridan et al., 1997; Walczak et 
al., 1997; Wu et al., 1997;), DcR1 (Degli-Esposti et al., 1997a; McFarlane et al., 1997; Pan et 
al., 1997b; Schneider et al., 1997; Sheridan et al., 1997; Mongkolsapaya et al., 1998) and 
DcR2 (Degli-Esposti et al., 1997b; Marsters et al., 1997; Pan et al., 1998b).   
 
Signaling by CD95 
 
CD95 is a widely expressed glycosyla ted cell-surface molecule of relative molecular mass 
~45’000-52’000 (335 amino-acid residues). It is a type I transmembrane receptor, but 
alternative splicing can result in a soluble form (Cascino et al., 1995). CD95 expression can 
be boosted by cytokines such as interferon-g and TNF but also by the activation of 
lymphocytes (Klas et al., 1993; Leithäuser et al., 1993). CD95L is a TNF-related type II 
transmembrane molecule (Krammer, 1999). 
CD95 and CD95L play an important role mainly in four types of physiologic apoptosis : (1) 
negative selection of pre-T lymphocytes that fail to rearrange their T-cell receptors (TCR) 
genes and CD95-positive B-cells killing by T-cells (Krammer, 2000); (2) peripheral deletion 
of activated mature T cells at the end of an immune response; (3) killing of targets such as 
virus- infected cells or cancer cells by cytotoxic T cells and by natural killer cells; and (4) 
killing of inflammatory cells at “immune-privileged” sites such as the testis and the eye. They 
are implicated also in pathological suppression of immune surveillance, namely, elimination 
of tumor-reactive immune cells by certain tumors that constitutively express CD95L. 
Furthermore, CD95L can be cleaved from the membrane by a metalloprotease (Mariani et al., 
1995; Yagita et al., 1995; Tanaka et al., 1996). This cleavage of membrane-bound FasL to a 
soluble form (sFasL) does not affect its ability to bind to Fas but drastically decreases its 
cytotoxic activity. Conversely, cross- linking epitope-tagged sFasL with anti-tag antibodies to 
mimic membrane-bound ligand results in a 1000-fold increase in cytotoxicity (Schneider and 
Tschopp, 2000). 
Like other TNF family members, CD95L is a homotrimeric molecule. The crystal structure of 
lymphotoxin a in complex with TNFR1 suggests by analogy that each CD95L trimer binds 
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three CD95 molecules (Smith et al., 1994; Gruss and Dower, 1995; Nagata, 1997; Ashkenazi 
and Dixit, 1998) (Figure 3). This oligomerization is required for transduction of the apoptotic 
signal. A complex of proteins associates with activa ted CD95 (Kischkel et al., 1995; Peter et 
al., 1998). This death- inducing signaling complex (DISC) forms within seconds of receptor 
engagement. First, the adaptor FADD (Fas-associated death domain protein, also known as 
Mort1) binds via its own death domain to the death domain in CD95. FADD also carries a so-
called death-effector domain (DED), and, again by homologous interaction, recruits the DED-
containing pro-caspase-8 (also known as FLICE, MACH or Mch5) or pro-caspase-10 (also 
known as Mch4) into the DISC (Krammer, 2000). The death effector domain is a specific 
example of a more global homophilic interaction domain termed CARD (caspase recruitment 
domain), which is found in several caspases, like caspase-2, -8, -9 and –10 (Hofmann et al., 
1997). Upon recruitment by FADD, caspase-8 (or –10) oligomerization drives its activation 
through self-cleavage (Muzio et al., 1998). Next, active caspase-8 (or –10) is released from 
the DISC into the cytoplasm and cleaves various proteins in the cell including pro-caspase-3 
and Bid, which results in their activation and completion of the cell death program. Various 
other proteins have been described to bind to activated CD95 and the DISC, such as them 
found in a certain class of herpes virus. These proteins contain two DEDs and inhibits the 
recruitment and activation of caspase-8, formerly known as FLICE ; hence their name v-
FLIPs (for viral FLICE-inhibitory proteins). In transfected cells, v-FLIP inhibited the 
apoptosis induced by several apoptosis- inducing receptors (CD95, TNF-R1, TRAMP/DR3 
and TRAIL-R1/DR4), indicating that these receptors use similar signaling pathways (Bertin et 
al., 1997; Hu et al., 1997; Thome et al., 1997). Two human homologues of v-FLIP have been 
identified by several groups at the same time and are known under a variety of names. 
Although it is widely assumed that the cellular FLIPs (c-FLIP) block apoptosis as well, the 
data are ambiguous and c-FLIP might be pro-apoptotic or anti-apoptotic depending on the 
cellular context. Recent results with cells from c-FLIP-deficient mice support the role of c-
FLIP as an anti-apoptotic molecule (Yeh et al., 2000). 
Studies with FADD gene knockout mice (Yeh et al., 1998; Zhang et al., 1998) and with 
transgenic mice expressing a dominant negative mutant of FADD (FADD-DN) in T cells 
(Newton et al., 1998; Zornig et al., 1998) establish that FADD is essential for apoptosis 
induction by CD95. Surprisingly, these mice display reduced proliferation of mature T cells in 
response to antigenic stimulation; moreover, FADD deletion causes embryonic lethality 
(Newton et al., 1998; Yeh et al., 1998; Zhang et al., 1998; Zornig et al., 1998). However, 
another sort of receptor, called decoy receptor 3 (DcR3) is able to inhibit apoptosis by 
blocking the CD95-FADD pathway. DcR3 has four cysteine-rich domains and is a secreted 
soluble protein which is able to bind to CD95L with an affinity equal to that of Fas, 
suggesting that DcR3 acts as a decoy receptor that competes with CD95 for binding to CD95 
ligand (Pitti et al., 1998). 
 
Recent ly, with the use of fluorescence resonance energy transfer, another model of CD95 
signaling has been worked out. Extracellular pre- ligand binding assembly domains (PLADs) 
were described for CD95 and TNF-R, which are supposed to aggregate the receptors before 
ligand binding. To prevent the premature signaling of pre-associated receptors, which is a 
dangerous situation, intracellular receptor-associated apoptosis blockers were postulated 
(Chan et al., 2000; Siegel et al., 2000). On the basis of the PLAD model, it is not entirely 
clear how ligand binding interferes with PLAD association and leads to receptor association, 
which initiates apoptosis. More structural work is needed to resolve these issues. It is also 
unclear whether the DISC model and the PLAD model complement each other to describe 
initial signaling events in vivo (Krammer 2000). 
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Figure 3 : The different death receptors with their respective ligands and adapters. 
 
 
Signaling by other death receptors  
 
Signaling of apoptosis by other members of the death receptor subfamily seems to follow the 
same basic rules and is initiated by the same sequential steps (Bodmer et al., 2000; Kischkel 
et al., 2000; Sprick et al., 2000) : a) ligand binding, b) receptor trimerization and DISC 
formation, c) attraction of the adapter molecule FADD into the DISC, d) association of pro-
caspase-8 (or –10), and e) autocatalytic cleavage of the pro-caspase and the formation of 
active caspase-8 (or –10). Active casapse-8 then serves as the initiator caspase, activating 
other further downstream executioner caspases that cleave cellular death substrates, resulting 
in the morphological and biochemical catastrophe termed apoptosis (Krammer, 2000). 
 
TNFR1 
 
TNF is produced mainly by activated macrophages and T cells in response to infection. By 
engaging TNFR1, TNF activates the transcription factor NF-kB and AP-1, leading to 
induction of pro- inflammatory and immunomodulatory genes (Tartaglia and Goeddel, 1992). 
In some cell types, TNF also induces apoptosis through TNFR1. Unlike CD95L, however, 
TNF rarely triggers apoptosis unless protein synthesis is blocked, which suggests the pre-
existence of cellular factors that can suppress the apoptotic stimulus generated by TNF. 
Expression of these suppressive proteins probably is controlled through NF-kB and JNK/AP-
1, as inhibition of either pathway sensitizes cells to apoptosis induction by TNF (Beg and 
Baltimore, 1996; Van Antwerp et al., 1996; Wang et al., 1996; Roulston et al., 1998).  
TNF trimerizes TNFR1 upon binding (Smith et al., 1994; Gruss and Dower, 1995), inducing 
association of the receptors’ death domains (Figure 3). Subsequently, an adapter termed 
TRADD (TNFR-associated death domain) (Hsu et al., 1995) binds through its own death 
domain to the clustered receptor death domains. TRADD functions as a platform adapter that 
recruits several signaling molecules to the activated receptor : TNFR-associated factor-2 
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(TRAF-2) (Rothe et al., 1995; Hsu et al., 1996a) and receptor- interacting protein (RIP) (Hsu 
et al., 1996b; Ting et al., 1996) stimulate kinase pathways leading to activation of NF-kB and 
of JNK/AP-1, whereas FADD couples the TNFR1-TRADD complex to activation of caspase-
8 (or –10), thereby initiating apoptosis (Chinnaiyan et al., 1996b; Hsu et al., 1996a; 
Varfolomeev et al., 1996). TRAF-2 also binds to cIAP1 and cIAP2 (cellular inhibitor of 
apoptosis-1 and –2) (Shu et al., 1996), which belong to a family of mammalian and viral 
proteins with anti-apoptotic activity.  
Cells from FADD knockout mice are resistant to TNF-induced apoptosis, demonstrating an 
obligatory role of FADD in this response (Yeh et al., 1998; Zhang et al., 1998). Besides 
FADD, TNFR1 can engage an adapter called RAIDD or CRADD (Ahmad et al., 1997; Duan 
and Dixit, 1997). RAIDD binds through a death domain to the death domain of RIP and 
through a CARD motif to a similar sequence in the death effector caspase-2, thereby inducing 
apoptosis (Ashkenazi and Dixit, 1998). 
 
DR3 
 
DR3 shows close sequence similarity to TNFR1 (Chinnaiyan et al., 1996a; Kitson et al., 
1996; Marsters et al., 1996a; Bodmer et al., 1997; Screaton et al., 1997a). Upon 
overexpression, DR3 triggers responses that resemble those of TNFR1, namely, NF-kB 
activation and apoptosis. Like TNFR1, DR3 activates NF-kB through TRADD, TRAF2, and 
RIP and apoptosis through TRADD, FADD and caspase-8 or –10 (Figure 3). DR3 binds to 
Apo3L, which is related most closely to TNF (Marsters et al., 1998). Apo3L activates NF-kB 
through TRADD, TRAF2, RIP and triggers apoptosis through TRADD, FADD and caspase-8 
(or –10), consistent with signaling through DR3. Thus, with respect to the regulation of NF-
kB and apoptosis, Apo3L closely resembles TNF. There are notable differences, however, in 
the expression of these ligands and receptors. TNF expression occurs mainly in activated 
macrophages and lymphocytes (Tartaglia and Goeddel, 1992), whereas Apo3L messenger 
RNA is expressed constitutively in many tissues (Chicheportiche et al., 1997; Marsters et al., 
1998). Conversely, TNFR1 is expressed ubiquitously (Tartaglia and Goeddel, 1992), whereas 
DR3 transcripts are present mainly in spleen, thymus, and peripheral blood and are induced 
by activation in T cells (Chinnaiyan et al., 1996a; Kitson et al., 1996; Marsters et al., 1996a; 
Bodmer et al., 1997; Screaton et al., 1997a). Hence, despite overlapping signaling 
mechanisms, Apo3L-DR3 and TNF-TNFR1 interactions probably have distinct biological 
roles (Ashkenazi and Dixit, 1998). 
 
DR4, DR5 and modulation by decoy receptors  
 
A TNF family member that shows the most similarity to CD95L was identified independently 
by two groups who named it TRAIL or Apo2L (Wiley et al., 1995; Pitti et al., 1996). Similar 
to CD95L, Apo2L triggers rapid apoptosis in many tumor cell lines (Wiley et al., 1995; 
Marsters et al., 1996b; Pitti et al., 1996; Mariani et al., 1997; Mariani and Krammer, 1998). 
Unlike expression of CD95L, which is restricted mainly to activated T cells and NK cells, and 
to immune-privileged sites (Nagata, 1997), Apo2L messenger RNA expression is constitutive 
in many tissues (Wiley et al., 1995; Pitti et al., 1996); however, like CD95L, Apo2L 
transcription is elevated upon stimulation in peripheral blood T cells (Screaton et al., 1997b; 
Jeramias et al., 1998; Martinez-Lorenzo et al., 1998). A subset of mature T cells acquires 
sensitivity to Apo2L-induced apoptosis after stimulation by interleukin-2, suggesting that 
Apo2L may play some role in peripheral T cell deletion (Marsters et al., 1996b; Martinez-
Lorenzo et al., 1998). In addition, T cells from human immunodeficiency virus- infected 
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individuals show increased sensitivity to Apo2L, implicating this ligand in the killing of 
virus- infected cells (Jeramias et al., 1998). 
Apoptosis induction by TRAIL requires caspase activity (Marsters et al., 1996b; Mariani et 
al., 1997; Mariani and Krammer, 1998; Martinez-Lorenzo et al., 1998). Overexpression of 
DR4 or DR5, which bind to Apo2L, triggers apoptosis via FADD and caspase-8 (Kischkel et 
al., 2000) (Figure 3). Cells from FADD-deficient mice, which are resistant to apoptosis 
induction by CD95, TNFR1, and DR3, show also a jamming of TRAIL-induced apoptosis 
(Suliman et al., 2001). 
Like the Apo2L mRNA, DR4 and DR5 transcripts are expressed in several tissues, suggesting 
that there may be mechanisms that protect cells from apoptosis induction by Apo2L. One type 
of protection is based on a unique set of decoy receptors (DcR), which compete with DR4 and 
DR5 for binding to Apo2L (Golstein, 1997) (Figure 3). DcR1 (also called TRID, TRAIL-R3, 
or LIT) is a glycosyl phophatidylinositol (GPI)-anchored cell surface protein that resembles 
DR4 and DR5, but lacks a cytoplasmic tail. DcR1 binds to Apo2L, and its transfection into 
Apo2L-sensitive cells substantially reduces responsiveness to the ligand (Pan et al., 1997b; 
Sheridan et al., 1997; Mongkolsapaya et al., 1998). Treatment of DcR1-bearing cells with a 
phospholipase that cleaves the GPI anchor results in marked sensitization to Apo2L-induced 
apoptosis (Sheridan et al., 1997). Thus, DcR1 appears to function as a decoy that prevents 
Apo2L from binding to its death receptors. DcR2 (also called TRAIL-R4 or TRUNDD) is 
another receptor that resembles DR4 and DR5, but it has a substantially truncated cytoplasmic 
death domain. DcR2 transfection inhibits apoptosis induction by Apo2L; deletion of the DcR2 
cytoplasmic region does not abrogate the inhibitory activity (Marsters et al., 1997), indicating 
that this receptor acts as a decoy that competes with DR4 and DR5 for binding to Apo2L. 
Overexpression of DcR2 seems to activate NF-kB. Osteoprotegerin (OPG) is a secreted, 
soluble receptor for the more distantly TNF homologue TRANCE/RANKL/OPGL. OPG is 
also able to bind to Apo2L/TRAIL and inhibits apoptosis induction by Apo2L suggesting that 
it is a decoy receptor for this latter ligand (Emery et al., 1998). 
 
More recently, a new member of the tumor necrosis factor (TNF) receptors family, termed 
death receptor-6 (DR6) was discovered. Like other death receptors, DR6 is a type I 
transmembrane receptor, possesses four extracellular cysteine-rich motifs and a cytoplasmic 
death domain. It is expressed in most human tissues and abundant transcript was detected in 
heart, brain, placenta, pancreas, thymus, lymph node and several non- lymphoid cancer cell 
lines. DR6 interacts with TRADD, which has previously been shown to associate with 
TNFR1. Furthermore, ectopic expression of DR6 in mammalian cells induces apoptosis and 
activation of both NF-kappaB and JNK. However, the ligand of DR6 is still unknown (Pan et 
al., 1998c). 
 
(b) Cytotoxic lymphocyte-initiated death signals 
 
Cytotoxic lymphocytes (T and NK cells) contain granules that can be discharged onto the 
surface of target cells, delivering what has been called “the kiss of death” (Figure 2). These 
granules contain, amongst other things, granzyme B (also called fragmentin-2), a serine 
protease which cleaves after Asp residues, and a pore-forming protein called perforin (or 
cytolysin) that is likely to permit entry of the other granule components into the target cell. 
This immediately suggests a mechanism for cytotoxic lymphocyte- initiated apoptosis where 
granzyme B enters the cell, with the help of perforin, and triggers the caspase cascade by 
directly cleaving and activating caspases (Darmon et al., 1995; Martin et al., 1996). 
Nevertheless, granzyme B was recently demonstrated to enter cells in a perforin- independent 
manner, thus predicting the existence of a cell surface receptor, which is the cation-
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independent mannose 6-phosphate/insulin- like growth factor receptor (CI-MPR) (Motyka et 
al., 2000). 
While it has been demonstrated that granzyme B (GzmB) can cleave most of the caspases in 
vitro, it appears that in cells its preferred target is caspase-8 (Medema et al., 1997) or caspase-
3 (Yang et al., 1998a), which then proceeds to activate downstream caspases. Nonetheless, 
the absolute requirement of caspase activation for GzmB-induced apoptosis is controversial. 
Another report demonstrated that GzmB can initiate apoptosis in the absence of caspase-3 
activity by directly cleaving DFF45/ICAD to liberate activated DFF40/CAD. DFF45/ICAD 
cleavage occurs less efficiently in cells that lack caspase-3 activity, suggesting that the 
caspases normally amplify the GzmB death signal. DFF45/ICAD-deficient mouse embryo 
fibroblasts are partially resistant to GzmB-induced death, demonstrating the biological 
importance of DFF45/ICAD for GzmB-mediated apoptosis (Thomas et al., 2000). Moreover, 
more recently, a group demonstrated that mitochondrial cytochrome c release is the primary 
mode of GzmB-induced apoptosis and that Bcl-2 is a potent inhibitor of this pivotal event. 
Caspase activation is not required for cytochrome c release, an activity that correlates with 
cleavage and activation of Bid, which they have found to be cleaved more readily by 
granzyme B than either caspase-3 or caspase-8. Bcl-2 blocks the rapid destruction of targets 
by granzyme B by blocking mitochondrial involvement in the process (Pinkoski et al., 2001). 
 
(c) Generalized cellular damage-initiated death signals 
 
All other stimuli that can provoke apoptosis have been grouped into this category, mainly 
because it is still far from clear how these stimuli engage the caspases components of the 
death machinery. This group includes diverse apoptosis-promoting stimuli such as 
chemotherapeutic or cytotoxic drugs (for example staurosporine), gamma- and UV-radiation, 
DNA damaging agents, heat shock, survival factor deprivation (for example NGF) and other 
cellular stresses like changes in redox state, energy metabolism or ionic concentrations (Ca2+, 
K+). The signals that these stimuli evoke within the cell are disparate, but the death pathways 
(also called the “intrinsic” pathway) engaged by the vast bulk of these stresses seem to 
converge on the mitochondria (Kluck et al., 1997). Furthermore, the anti-apoptotic Bcl-2 
family members (Bcl-2 and Bcl-xL) protect in the majority of these cases, again implicating 
the mitochondrial pathway as an important conduit for death signals triggered by stimuli 
within this group (Figure 2). 
 
1.4.3 The commitment/amplification phase 
 
Mitochondria are the well-known “powerhouses” of the cell, producing ATP to drive the 
various physiological functions and to maintain life itself. But they are also intimately 
involved in cell demise. The first sign that mitochondria play an active role in apoptosis came 
in 1994 with the observation that induction of nuclear apoptotic changes (chromatin 
condensation, nuclear fragmentation) in extracts of Xenopus eggs required the presence of 
mitochondria (Newmeyer et al., 1994). The stage was thus set for a period of rapid advance, 
leading to radically new insights into mitochondrial function (Crompton, 2000) such as the 
finding that, in apoptosis triggered by many stimuli, mitochondria play a pivotal role in 
coordinating caspases activation through the release of cytochrome c (Desagher and 
Martinou, 2000). 
Mitochondria are organized into several distinct spaces, based on reconstructions of 
mitochondria imaged by electron tomography (Perkins et al., 1997; Manella et al., 1998). The 
matrix is filled with the enzymes of the tricarboxylic acid cycle. Projecting through the matrix 
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space are hollow flattened or tubular structures, the cristae. The crista membranes are 
continuous with the rest of the inner mitochondrial membrane, and contain the electron 
transfer complexes. The intermembrane space can be functionally separated into two 
compartments, the cristal lumen and the intermembrane space that lies between the inner 
membrane and the outer membrane. It is estimated that 85-97% of the cytochrome c resides in 
the crystal lumen, with the remainder in the intermembrane space (Bernardi et al., 1999; 
Scorrano et al., 1999). Cytochrome c is electrostatically associated with cytochrome c 
reductase and cytochrome oxidase, and is also associated with cardiolipin, which is 
asymmetrically distributed across the lipid bilayer of the inner membrane. Also present in the 
intermembrane are pro-caspases-2, -3 and –9, apoptosis- inducing factor (AIF) (Mancini et al., 
1998; Susin et al., 1999a), and Smac/DIABLO (Du et al., 2000; Verhagen et al., 2000). The 
F0F1-ATPase decorates the matrix side of the crista membrane. The inner membrane/crista 
membrane is highly resistant to proton leakage, allowing the buildup of a significant 
membrane potential (about –220 mV). The accumulated protons on the outer face of the inner 
membrane (in the lumen of the cristae) leak back down their electrochemical gradient through 
the F0F1-ATPase to drive ATP synthesis. Cardiolipin is an anionic phospholipid that is only 
found in the mitochondrial inner membrane and is believed to contribute to the proton-
impermeable nature of the inner membrane. The outer mitochondrial membrane is generally 
considered to be permeable to small molecules (< 1000 Da) because of the presence of a very 
abundant protein, the voltage-dependent anion channel (VDAC). VDAC comprises as much 
as 20% of the protein of the outer membrane and is ordinarily open. The outer membrane is 
dimpled with contact points where the outer and inner membranes are closely juxtaposed. 
Contact points may represent two different biochemical entities: the protein translocation 
machinery made up of the translocase outer and inner membrane complexes (reviewed in 
Herrmann et al., 2000), and the components of the nucleotide transport system, including 
VDAC, the adenine nucleotide translocase (ANT) and creatine kinase. These latter 
components are also constituents of the permeability transition pore (PTP), whose opening is 
often believed to herald mitochondrial destruction and certain cell death. The PTP can be 
reconstituted with VDAC, ANT, and cyclophilin D (reviewed in Crompton, 1999). The 
association of cyclophilin D with the PTP is important, as it underlies the ability of 
cyclosporin A (ligand of cyclophilin D and inhibitor of this latter) to prevent pore opening 
and mitochondrial dysfunction with cyclosporin A (Andreeva et al., 1995). Additional 
proteins that may co-purify with the PTP include hexokinase, the peripheral benzodiazepine 
receptor, creatine kinase and the Bcl-2 family member Bax (Marzo et al., 1998a; Gottlieb, 
2000). 
 
Mitochondria and the Bcl-2 family proteins  
 
Currently, at least 15 Bcl-2 family proteins have been identified in mammals and several 
others in viruses (Chao and Korsmeyer, 1998; Gross et al., 1999). Bcl-2 family members can 
be grouped into three categories (Figure 4): 
 
1. Anti-apoptotic members such as Bcl-2, Bcl-xL, Bcl-w, Mcl-1, A1 (Bfl-1) and Boo, all 
of which exert anti-cell death activity and share sequence homology, particularly 
within four regions, Bcl-2 homology (BH) 1 through BH4, although some members 
lack an apparent BH4 domains. 
2. Pro-apoptotic members such as Bax, Bak, Bad, Bok (Mtd), Diva, which share 
sequence homology in BH1, BH2 and BH3 but not in BH4, although significant 
homology at BH4 has been noticed in some members. 
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3. “BH3-only proteins”, the pro-apoptotic proteins which include Bik, Bid, Bim, Hrk 
(DP5), Blk, Bnip3 and Bnip3L, and share sequence homology only in BH3. 
 
In addition, many of the Bcl-2 proteins contain a hydrophobic C-terminal tail that is 
responsible for localizing the proteins predominantly to the mitochondrial outer membrane, 
but also to the endoplasmic reticulum (ER) and nuclear membranes (Desagher and Martinou, 
2000; Fesik, 2000). 
One of the unique features of Bcl-2 family proteins is heterodimerization between anti-
apoptotic and pro-apoptotic proteins, which is considered to inhibit the biological activity of 
their partners (Oltvai et al., 1993; Yang et al., 1995). In fact, the relative levels of these 
proteins in a cell determine whether a cell will live or die (Yin et al., 1994). Mutagenesis 
established that the BH1, BH2, and BH3 domains strongly influence homo- and 
heterodimerization (Yin et al., 1994; Chittenden et al., 1995; Kelekar and Thompson, 1998), 
and the three-dimensional structure of Bcl-xL provided the explanation. Coalescence of the a 
helices in its BH1, BH2 and BH3 regions creates an elongated hydrophobic cleft, to which a 
BH3 amphipathic a helix can bind (Sattler et al., 1997). BH3-cleft coupling, reminiscent of 
ligand-receptor engagement, may account for all dimerization within the family. In addition to 
the BH1 and BH2, the BH4 domain is required for anti-apoptotic activity (Huang et al., 
1998). In contrast, BH3 is essential and, itself, sufficient for pro-apoptotic activity 
(Chittenden et al., 1995).  
 
 
 
Figure 4 : Schematic drawing of Bcl-2 and related proteins. 
BH1 to BH4 are conserved sequence motifs. Several functional domains of Bcl-2 are 
shown (see text). a1-a7 indicate helices identified in Bcl-xL, in which a core of two 
hydrophobic helices a5 and a6 is surrounded by five amphipathic helices. The region 
between a1 and a2 is called a flexible, non-conserved loop which appears to have a 
negative regulatory role in the signaling of apoptosis. A membrane-anchoring domain is 
not carried by all members of the family (Tsujimoto and Shimizu, 2000). 
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The principal mechanism by which Bcl-2 family proteins regulate apoptosis is probably by 
controlling the release of apoptogenic factors from mitochondria, such as cytochrome c. 
Overexpression of the anti-apoptotic proteins Bcl-2 or Bcl-xL in many cell types subjected to 
various cytotoxic treatments prevents cytochrome c release from mitochondria, caspase 
activation and cell death (Kluck et al., 1997; Vander Heiden et al., 1997; Yang et al., 1997). 
Moreover, the use of cell- free systems indicates that exogenous Bcl-2 must be associated with 
mitochondria to prevent cytochrome c release (Kluck et al., 1997). Conversely, ectopic 
expression of the death promoter Bax triggers cytochrome c release from mitochondria in the 
absence of any death signal (Eskes et al., 1998; Jürgensmeyer et al., 1998; Pastorino et al., 
1998; Rossé et al., 1998; Finucane et al., 1999). This loss of cytochrome c is associated with 
caspase activation and the induction of apoptosis. The direct addition of Bax to isolated 
mitochondria also induces cytochrome c release (Eskes et al., 1998; Jürgensmeyer et al., 
1998; Narita et al., 1998; Finucane et al., 1999; Kluck et al., 1999; Pastorino et al., 1999). 
These effects can be blocked by overexpression of Bcl-xL in intact cells or addition of 
recombinant Bcl-xL to isolated mitochondria (Jürgensmeyer et al., 1998; Narita et al., 1998; 
Finucane et al., 1999). However, caspase inhibitors do not affect Bax- induced cytochrome c 
leakage but they do effectively block caspase activation and delay apoptosis (Eskes et al., 
1998; Jürgensmeyer et al., 1998; Rossé et al., 1998; Finucane et al., 1999). These data thus 
suggest that Bax can directly induce the loss of cytochrome c and indicate that caspases do 
not participate in this event (Desagher and Martinou, 2000). 
Although Bcl-2 appears to be exclusively membrane bound, particularly in mitochondria and 
endoplasmic reticulum/nuclear membranes, other related proteins (e.g. Bid, Bad and Bim) are 
cytosolic but translocate to mitochondria during apoptosis (Desagher et al., 1999; Downward, 
1999; Puthalakath et al., 1999). These proteins play a major role in transducing signals from 
the cytosol to mitochondria, where they bind to and regulate the activity of the Bcl-2 family 
members that control the release of cytochrome c. Translocation of these proteins is triggered 
by specific posttranslational modifications such as dephosphorylation by the Ca2+-sensitive 
phosphatase calcineurin or the protein phosphatase 1a following a growth-factor deprivation 
(in the case of Bad, Downward, 1999) or by the death receptor and cytotoxic T/NK cell 
granule- initiated pathways which provoke the caspase-dependent route to mitochondrial 
damage via the cleavage of caspase-8 (in the case of Bid, Figure 2, Budihardjo et al., 1999). 
Similarly, under normal conditions, Bax appears to be predominantly cytosolic and, in some 
cells, in peripheral association with mitochondria (Desagher and Martinou, 2000). 
Following a death receptor-independent stimuli via as yet unidentified factors (Figure 2), 
several changes affect Bax that lead to its activation. First, Bax translocates from cytosol to 
mitochondria (Hsu et al., 1997; Gross et al., 1998) unless Bax is already loosely attached to 
the organelle (Goping et al., 1998; Desagher et al., 1999). Then, the conformation of Bax 
changes, unmasking its N-terminus (Goping et al., 1998; Desagher et al., 1999). This is 
accompanied  by an apparent oligomerization, which was detected by cross- linking 
experiments (Gross et al., 1998; Eskes et al., 2000). Finally, Bax inserts into the outer 
membrane of mitochondria and becomes an integral membrane protein (Goping et al., 1998; 
Eskes et al., 2000). This is rapidly followed by cytochrome c release from mitochondria. 
Interestingly, it has been shown that enforced dimerization of Bax is sufficient to induce Bax 
translocation, mitochondrial dysfunction and apoptosis, which indicates that the 
mitochondrial localization of Bax and its oligomerization play a crucial role in triggering 
apoptosis (Gross et al., 1998; Desagher and Martinou, 2000). 
These changes in Bax can be prevented by Bcl-2 and Bcl-xL (Gross et al., 1998; Desagher et 
al., 1999), and they can be reproduced in isolated mitochondria by treatment with 
recombinant full- length or truncated Bid (Desagher et al., 1999; Eskes et al., 2000). Both Bcl-
xL and Bid seem to exert their influence by interacting directly with Bax (Desagher et al., 
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1999; Eskes et al., 2000). Taken together, these data suggest that Bax or a Bax-like protein act 
as kind of on-off switch regulating cytochrome c release, and that Bax or a Bax- like protein is 
the focus of many apoptosis-regulating pathways (Desagher and Martinou, 2000). 
Finally, most effects of the Bcl-2 family proteins that have been described seem to be 
conditional on their mitochondrial localization. This does not exclude the possibility that Bcl-
2-related proteins could influence apoptosis independently of mitochondria. Consistent with 
this thesis, some Bcl-2 mutants that are not addressed to the mitochondrial membrane retain 
significant ability to inhibit apoptosis (Oltvai et al., 1993). Similarly, apoptosis in different 
cell lines induced by microinjection of cytochrome c is strongly reduced by Bcl-2 
overexpression (Zhivotovsky et al., 1998). In some circumstances, Bcl-2 has also been shown 
to inhibit Bax- induced caspase activation and cell death without blocking cytochrome c 
release (Rossé et al., 1998). Taken together, these observations suggest that anti-apoptotic 
proteins can also act downstream of cytochrome c release (Desagher and Martinou, 2000). 
Recently, Goldstein et al. (2000) studied the kinetics of cytochrome c release from 
mitochondria  using cytochrome c tagged with green fluorescent protein (GFP) and found that, 
during apoptosis induced by a variety of stimuli, all of the cytochrome c-GFP was released 
from all mitochondria of the cell within 5 min. They also reported that the release was 
temperature- independent. Although these observations were made using an artificial protein, 
they argue strongly against the involvement of enzymatic transport systems. However, what 
exactly are the mechanisms that underlie cytochrome c release ? Two prevailing theories have 
been postulated: the non-specific rupture of the outer mitochondrial membrane and the 
formation of cytochrome c-conducting channels (Desagher and Martinou, 2000). 
 
The non-specific outer mitochondrial membrane rupture  
 
According to the first theory, water and solutes enter the matrix during apoptosis, causing 
swelling of the mitochondria (Figure 5a,b). Because the inner membrane, with its numerous 
cristae, has a considerably larger surface area than the outer membrane, expansion of the inner 
membrane upon matrix swelling can break the outer membrane, and such rupture has been 
observed in different apoptotic systems (Vander Heiden et al., 1997). This would be expected 
to trigger the release and irreversible dilution in the cytosol of the whole content of the 
intermembrane space, because it is no longer constrained by the outer membrane. However, 
the content of the matrix is retained in mitochondria because the inner membrane remains 
intact even though it expands (Desagher and Martinou, 2000). 
Two models can account for matrix swelling. The first model implicates the initial 
hyperpolarization of the inner membrane that precedes cytochrome c release in some systems 
(Figure 5a) (Vander Heiden et al., 1997; Samali et al., 1999). According to Vander Heiden et 
al. (1999a), this hyperpolarization might result from the inability to exchange mitochondrial 
ATP for cytosolic ADP during apoptosis. This antiport is normally mediated by the voltage-
dependent anion channel (VDAC, or mitochondrial porin) and the adenylate translocator 
(ANT). Impairment of ATP-ADP exchange by VDAC closure should inhibit F1F0-ATPase 
activity, resulting in an inhibition of H+ re-entry to the matrix, and should thereby contribute 
to the hyperpolarization of the inner mitochondrial membrane. Such an increase of the 
mitochondrial transmembrane potential (Dym) is predicted to promote an osmotic matrix 
swelling (Vander Heiden et al., 1999b). However, these hypothetical mechanisms conflict 
with a second model that implicates a mitochondrial megachannel called the “permeability 
transition pore” or PTP (Figure 5b) (Desagher and Martinou, 2000). 
The PTP is a high-conductance unselective channel whose opening can be triggered by 
several physiological effectors such as Ca2+, reduced concentrations of adenine nucleotides, 
inorganic phosphate, reactive oxygen species (ROS), changes in pH or low Dym (Crompton, 
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1999) and possibly Bax (Marzo et al., 1998a). PTP opening causes a sudden increase in the 
permeability of the inner mitochondrial membrane to molecules of mass < 1.5 kDa. This 
event, the “permeability transition”, results in the immediate dissipation of the proton-
dependent Dym and chemical equilibration between the cytoplasm and mitochondrial matrix 
(Crompton, 1999). This causes a progressive osmotic swelling of the matrix owing to its high 
solute concentration and can ultimately lead to disruption of the outer membrane (Desagher 
and Martinou, 2000). 
 
 
Figure 5 : Models for the cytochrome c release from mitochondria during apoptosis. 
(a,b) The outer mitochondrial membrane ruptures as a result of swelling of the 
mitochondrial matrix, allowing cytochrome c and other proteins to escape from the 
intermembrane space. Model (a) involves closure of the voltage-dependent anion channel 
(VDAC) and impairment of ATP-ADP exchange. Under normal conditions (left), the 
protons that accumulate in the intermembrane space as a result of electron transport re-
enter the mitochondrial matrix through F1F0-ATPase (complex V of the respiratory chain). 
By inhibiting F1F0-ATPase, impairment of ATP-ADP exchange results in the 
accumulation of protons in the intermembrane space and an increase in the mitochondrial 
transmembrane potential (Dym), which is predicted to promote osmotic swelling (right). 
Model (b) suggests that the permeability-transition pore (PTP) opens and that the inner 
membrane permeability increases, causing mitochondrial–matrix swelling. Bax might 
induce this pore to open by binding to the adenine-nucleotide translocator (ANT) at the 
contact sites between the inner and outer membranes or after translocation to the inner 
membrane. (c-e) A large channel forms in the outer mitochondrial membrane, allowing 
cytochrome c release, but mitochondria are not damaged. This channel could be formed 
by Bax only (c), Bax in association with VDAC (d) or could be a lipidic channel or 
protein-lipid complex (e) formed after Bax insertion into the outer mitochondrial 
membrane (Desagher and Martinou, 2000). 
 
The rupture of the outer mitochondrial membrane is, of course, an attractive hypothesis 
because it could explain the release of many proteins from the intermembrane space such as 
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cytochrome c, Smac/DIABLO, some caspases, AIF (57 kDa), Hsp60, Hsp10, adenylate 
kinase (25.2 kDa) and sulfite oxidase (104 kDa) (Kluck et al., 1999; Samali et al., 1999; 
Susin et al., 1999b). Moreover, members of the Bcl-2 family can regulate opening of the PTP 
(Marzo et al., 1998b). Bcl-2 can prevent the PTP-mediated mitochondrial depolarization in 
intact cells and isolated mitochondria (Kroemer et al., 1997a; Shimizu et al., 1998), but Bax 
can provoke Dym loss, matrix swelling and cytochrome c release in some cell types and 
isolated mitochondria in a cyclosporin A-inhibitable fashion (Marzo et al., 1998; Narita et al., 
1998; Pastorino et al., 1998; Pastorino et al., 1999). Bax could trigger PTP opening through 
binding to ANT, as suggested by co-immunoprecipitation and yeast two-hybrid studies 
(Marzo et al., 1998). However, such a physical rupture has rarely been described and many 
data suggest that it is more likely to be a consequence than a cause of cytochrome c release. 
Moreover it has been shown that recombinant Bid and Bax cause complete cytochrome c loss 
from isolated mitochondria in vitro, but preserve the ultrastructure and protein import 
function of mitochondria, which depend on inner membrane polarization (Von Ahsen et al., 
2000). This argues for the existence of other mechanisms responsible for the initial 
cytochrome c leakage (Desagher and Martinou, 2000). 
 
The formation of cytochrome c-conducting channels 
 
According to the second theory, channels are formed that are large enough for the passage of 
soluble proteins (Figure 5c-e). One clue to how Bcl-2 family proteins exert their 
mitochondrial activity has come from the three-dimensional structure of Bcl-xL (Muchmore 
et al., 1996). Bcl-xL consists of two central, predominantly hydrophobic, a helices (a5 and 
a6, Figure 4) surrounded by five amphipathic helices (Muchmore et al., 1996). A similar 
structure can be predicted for other Bcl-2 family members such as Bcl-2 and Bax, which have 
a high degree of sequence homology with Bcl-xL (Schendel et al., 1998). Surprisingly, 
however, the structure of Bid is also similar to that of Bcl-xL, even though the amino acid 
sequence identity between Bid and Bcl-xL is limited to the 16-residue BH3 domain (Chou et 
al., 1999; McDonnell et al., 1999; Desagher and Martinou, 2000). 
Importantly, the structure of Bcl-xL and Bid resembles that of the pore-forming domains of 
diphteria toxin and some bacterial colicins (Muchmore et al., 1996), which can form channels 
for ions and proteins. Bcl-xL, Bcl-2, Bax (Schendel et al., 1998) and the truncated form of 
Bid (Schendel et al., 1999) have been shown to form functional ion channels in synthetic lipid 
vesicles and planar lipid bilayers. In a similar way to bacterial toxin pores, these channels 
have multiple conductance states, are pH and voltage-sensitive, and show a low ion 
selectivity. The  intrinsic channel properties of pro- and anti-apoptotic proteins differ 
significantly, which might account for their opposite influences on cytochrome c release 
(Schlesinger et al., 1997). More interestingly, Bcl-2 is able to prevent Bax-channel formation 
in liposomes (Antonsson et al., 1997; Desagher and Martinou, 2000). 
These data, taken together with the fact that the addition of Bax or Bak directly to 
mitochondria triggers cytochrome c release, suggest that these pro-apoptotic members of the 
Bcl-2 family could form mitochondrial channels. Could these channels be responsible for the 
outer mitochondrial membrane permeabilization that occurs during apoptosis ? Bcl-2-related 
proteins have only two helices long enough to span a membrane bilayer, which is insufficient 
to form an aqueous channel. However, Bax can oligomerize under some conditions, allowing 
it to form very high-conductance channels in liposomes and to trigger cytochrome c release 
from mitochondria (Antonsson et al., 2000). Oligomerization, a process so far described only 
for Bax, might represent the mechanism by which pro-apoptotic proteins form megachannels 
(Figure 5c). 
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Alternatively, it has been found that Bax and the truncated form of Bid (tBid), but not Bcl-xL, 
can decrease the stability of planar phospholipid bilayers, suggesting that pro-apoptotic 
proteins might act directly by destabilizing the outer mitochondrial membrane (Basanez et al., 
1999; Kudla et al., 2000). By reducing the linear tension of the membrane, Bax and tBid 
could promote the formation of a lipidic pore or a protein- lipid complex large enough to allow 
intermembrane proteins to diffuse into the cytosol (Figure 5e) (Desagher and Martinou, 
2000). 
A third possibility is that Bax cooperates with VDAC to form a large cytochrome c-
conducting channel (Figure 5d). When VDAC is reconstituted in liposomes, Bak and Bax 
promote opening of the channel, whereas Bcl-xL facilitates its closure. Furthermore, 
monitoring the movement of fluorescein- labelled cytochrome c indicates that Bax and Bak 
allow cytochrome c to pass through VDAC, possibly by inducing a conformational change or 
by cooperating with VDAC to form a megapore. However, none of Bax, Bak or VDAC is 
able by itself to form channels permeable to cytochrome c in liposomes (Shimizu et al., 
1999). 
In summary, the channel theory offers the advantage of maintaining functional mitochondria 
during the time necessary for the activation of caspases, because the latter process requires 
ATP. Nevertheless, we have thus far no evidence that Bcl-2 family proteins do form channels 
in vivo. Whether the lumen diameter of these pores would be sufficient to allow the passage 
of cytochrome c and other proteins is even less certain (Desagher and Martinou, 2000). 
 
Regulation of mitochondrial homeostasis by anti-apoptotic Bcl-2 family proteins  
 
As already described, mitochondria play a vital role in the cell, providing most of the cell’s 
energy and participating in the Ca2+, redox and pH homeostasis. This means that a major 
mitochondrial dysfunction is likely to cause cell death. For instance, disruption of electron 
transport might be responsible for the increased production of reactive oxygen species (ROS) 
and the cytoplasmic acidification that are observed early during apoptosis. In such 
circumstances, the electrons that escape in large amounts from the respiratory chain can 
reduce molecular oxygen to produce superoxide anions, and the reduced ATP synthesis 
promotes the accumulation of lactate by stimulating glycolysis (Desagher and Martinou, 
2000). 
Consistent with the idea that mitochondrial status can influence the life-death decision, anti-
apoptotic Bcl-2 proteins have also been implicated in the protection of mitochondrial 
integrity. One of the first anti-apoptotic functions attributed to Bcl-2 was the reduction of 
ROS levels (Vander Heiden et al., 1999b). Since then, Bcl-2 has been shown to stabilize Dym, 
to affect mitochondrial proton influx and to modulate mitochondrial Ca2+ homeostasis 
(Kroemer et al., 1997a; Shimizu et al., 1998; Zhu et al., 1999); similarly, Bcl-xL has been 
implicated in the regulation of mitochondrial metabolism and matrix volume (Vander Heiden 
et al., 1997; Vander Heiden et al., 1999a). Some of these effects can be ascribed to the 
blockade of cytochrome c release by Bcl-2 and Bcl-xL because the depletion of cytochrome c 
from mitochondria can impair electron transport and be responsible for some types of 
mitochondrial dysfunction (Desagher and Martinou, 2000). 
Alternatively, the control of cytochrome c release by anti-apoptotic proteins might be the 
indirect result of their effects on mitochondrial homeostasis. For example, Bcl-2 can maintain 
Dym in response to various agents such as Ca2+ and ROS by enhancing proton efflux (Shimizu 
et al., 1998). By offsetting ion imbalances that would otherwise result in a lowered Dym and 
an increased probability of PTP opening, Bcl-2 could prevent cytochrome c redistribution. 
Similarly, Bcl-xL appears to inhibit cytochrome c release by maintaining mitochondrial ADP-
ATP exchange and by preventing mitochondrial swelling (Vander Heiden et al., 1997; Vander 
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Heiden et al., 1999a). Therefore, Bcl-2 and Bcl-xL seem to regulate an aspect of 
mitochondrial physiology more general than the simple redistribution of cytochrome c 
(Desagher and Martinou, 2000). 
 
The release of mitochondrial apoptogenic factors activates downstream events 
 
With a few exceptions (e.g. Fas or TNF-triggered apoptosis in certain cells), mitochondria 
represent an essential component of many apoptotic pathways by releasing cytochrome c and 
pro-caspases into the cytosol. Once released, cytochrome c interacts with the adaptor protein 
Apaf-1 (Figures 2 and 6) (Green and Reed, 1998). Apaf-1 contains at least three functional 
domains: (i) an N-terminal caspase-activation recruitment domain (CARD), which binds the 
pro-domain of caspase-9; (ii) a CED-4 domain required for Apaf-1 self-oligomerization; and 
(iii) a series of C-terminal WD-40 repeats thought to mediate protein-protein interactions 
(Zou et al., 1997). Apaf-1, when bound to cytochrome c, apparently hydrolyzes dATP/ATP 
and undergoes oligomerization via its CED-4 domains (Hu et al., 1998a, 1999; Srinivasula et 
al., 1998). Simultaneously, the CARD domain recruits and facilitates processing of pro-
caspase-9 (Li et al., 1997; Srinivasula et al., 1998; Qin et al., 1999). This complex of 
cytochrome c, Apaf-1 and caspase-9 is commonly referred to as the apoptosome. 
Reconstitution experiments using purified recombinant proteins indicate that the apoptosome 
is ~1.4 kDa in size (Saleh et al., 1999; Zou et al., 1999), whereas in native cell lysates, Apaf-1 
oligomerizes into an ~700 kDa complex and, in addition to processed caspase-9, contains 
fully processed caspases-3 and –7 (Cain et al., 1999, 2000). Thus, the initial processing of 
downstream caspases by caspase-9 and their subsequent autocatalytic processing appears to 
take place within the apoptosome. The specific mechanisms that govern these processes 
remain unclear (Bratton et al., 2001). 
 
 
Figure 6 : Apaf-1 promotes caspase-9 activation by oligomerization. 
Cytochrome c and dATP/ATP regulate the ability of Apaf-1 to recruit caspase-9 and form 
multimers. 
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The physiological importance of cytochrome c release and the subsequent activation of 
caspase-9 has been shown by Apaf-1 or caspase-9 knockout mice, which die perinatally with 
brain overgrowth and reduced apoptosis in the central nervous system (Vaux et al., 1999). 
More recently, these observations have been confirmed by the generation of cytochrome c-
deficient mice (Susin et al., 1999b). These mice die earlier during embryonic development, 
but this is presumably due to defective mitochondrial oxidative phosphorylation. 
Nevertheless, cells derived from the cytochrome c knockout embryos (as well as cells lacking 
Apaf-1 or caspase-9) are resistant to a wide range of apoptotic stimuli, even though they 
undergo apoptosis normally after Fas or TNF-receptor activation (Susin et al., 1999b; Vaux et 
al., 1999; Desagher and Martinou, 2000). Moreover, it has been proposed that Bcl-xL might 
interact with Apaf-1 and prevent it from activating caspase-9 (Hu et al., 1998b; Pan et al., 
1998a). However, this assumption is very controversial and requires further investigation. 
 
In addition of and together with cytochrome c, other proteins, such as apoptosis-inducing 
factor (AIF), are released during apoptosis. Cloning of the full- length cDNAs corresponding 
to mouse AIF (612 amino acids) and human AIF (613 a.a.) (Susin et al., 1999b) revealed that 
AIF is strongly conserved between the two mammalian species (92% a.a. identity in the 
whole protein). The mouse AIF cDNA codes for a protein which is organized in three 
domains  : (1) an amino-terminal mitochondrial localization sequence (MLS) of 100 amino 
acids; (2) a spacer sequence of 27 amino acids; and (3) a carboxy-terminal 485 amino acid 
oxidoreductase domain. AIF is encoded by one single gene located on the X chromosome, 
and ubiquitously expressed, both in normal tissues and in a variety of cancer cell lines. The 
AIF precursor is synthesized in the cytosol and is imported into mitochondria. The mature 
protein, a flavoprotein (prothestic group: flavine adenine dinucleotide) with significant 
homology to plant ascorbate reductase and bacterial NADH (nicotinamide adenine 
dinucleotide, reduced form) oxidase, is normally confined to the mitochondrial 
intermembrane space. When released, AIF translocates through the outer mitochondrial 
membrane to the cytosol and to the nucleus. If microinjected into the cytoplasm of normal 
cells, recombinant AIF suffices to cause three hallmarks of apoptosis, namely (1) the 
dissipation of the mitochondrial transmembrane potential and the release of cytochrome c, (2) 
the condensation of nuclear chromatin, (3) and the exposure of phosphatidylserine on the 
plasma membrane surface (Susin et al., 1999b; Ferri et al., 2000; Vieira and Kroemer, 2000). 
These alterations are rapid (30-120 min.) and are not prevented by addition of the general 
caspase inhibitor Z-VAD-fmk (Susin et al., 1999b; Ferri et al., 2000). Moreover, they are not 
affected by overexpression of the anti-apoptotic protein Bcl-2 (Susin et al., 1999b). Similar in 
vivo effects have been obtained by transfection-enforced overexpression of a truncated AIF-
GFP construct lacking the N-terminal MLS (AIF-GFPD1-100) and that is misdirected to the 
extramitochondrial compartment (Vieira and Kroemer, 2000). These data confirm that ectopic 
(extramitochondrial) AIF is a caspase- independent effector of apoptosis that acts beyond the 
Bcl-2-controlled checkpoint of cell death (Daugas et al., 2000a). 
The apoptogenic effects of AIF, as revealed in intact cells, have been recapitulated in cell- free 
systems. Addition of recombinant AIF to purified nuclei causes chromatin condensation 
(Susin et al., 1999b). This is accompanied by a large-scale DNA fragmentation, but not by 
oligonucleosomal DNA fragmentation. In intact cells, Z-VAD-fmk prevents 
oligonucleosomal DNA degradation, yet frequently has no effect on the large-scale 
fragmentation pattern (Daugas et al., 2000b). These results are compatible with the hypothesis 
that AIF is (one of) the mediator(s) responsible for large-scale chromatin degradation. But 
how AIF mediates this apoptogenic function remains entirely elusive. Thus, the functional 
relationship between AIF and other factors involved in chromatin condensation and 
degradation (caspases, CAD, acinus, cyclophilin etc.) remains unknown (Zamzami and 
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Kroemer, 1999). Moreover, the AIF- interacting protein(s) in the cytosol (which are required 
for its membrane permeabilizing effects) and the nuclear AIF target(s) have not yet been 
identified. Based on our knowledge of other mitochondrial proteins and their pro-apoptotic 
effects, it may be speculated that endogenous AIF inhibitors exist. Such inhibitors would 
prevent accidental cell death induction by partial AIF release and set the threshold at which 
AIF levels suffice to drive the full cell death program (Daugas et al., 2000a). 
In conclusion, similar to cytochrome c, AIF is a phylogenetically old, bifunctional protein 
with an electron acceptor/donor (oxidoreductase) function and a second apoptogenic function. 
In contrast to cytochrome c, however, AIF acts in a caspase-independent fashion (Daugas et 
al., 2000a). Moreover, very recently, Joza et al. provide genetic evidence that the AIF-
dependent, caspase-independent PCD pathway is crucial for cell death following growth 
factor deprivation and early mammalian development (Joza et al., 2001). In fact, they show 
that AIF inactivation abolishes all signs of cell death in early morphogenesis, including the 
mitochondrial release of cytochrome c. In addition, they show that AIF is a rate- limiting 
factor of embryonic stem cell death induced by serum withdrawal (independently of caspases 
inhibition), indicating a stimulus-dependent contribution of AIF to the apoptotic cascade. 
Therefore, they postulate the coexistence of two separate pathways linking the mitochondria 
to apoptosis, one that requires AIF (which is thought to predate to the caspase pathway) and 
the other that relies on caspase activation. 
  
Activation of caspases 
 
Upon activation of caspase-8/–10 by death receptors or caspase-9 by Apaf-1, these caspases 
can then propagate the death signal by activating other caspases (see Figure 2). The study of 
this phase of the death program has been greatly facilitated by the observation that 
cytochrome c (in conjunction with dATP/ATP) can trigger apoptosis in cell- free extracts, an 
unusual property that is not displayed by the vast majority of agents that can promote 
apoptosis in intact cells (Liu et al., 1996a; Li et al., 1997; Slee et al., 1999b). Studies using 
cell- free systems have revealed that cytochrome c activates caspase-9 (via Apaf-1) and that 
caspase-9 then initiates a series of other caspase activation events that represent a bona fide 
caspase cascade, since removal, mutation of certain members of the cascade or the use of 
small pharmacological inhibitors will slow down or even prevent apoptosis (Earnshaw et al., 
1999; Slee et al., 1999b). 
Most of the morphological changes that were observed by Kerr et al. are caused by a set of 
cysteine proteases that are activated specifically in apoptotic cells and can be thought of as the 
central executioners of the apoptotic pathway. These death proteases are homologous to each 
other, and are part of a large protein family known as the caspases (Alnemri et al., 1996). 
Caspases are highly conserved through evolution, and can be found from humans all the way 
down to insects, nematodes, and hydra (Budihardjo et al., 1999; Cikala et al., 1999; Earnshaw 
et al., 1999). Over a dozen caspases (currently 14 are known) have been identified in humans; 
about two-thirds of these have been suggested to function in apoptosis (Thornberry and 
Lazebnik, 1998; Earnshaw et al., 1999; Hengartner, 2000). The others appear to play a 
primary role in cytokine maturation and inflammation. 
Given the great importance of caspases in the apoptotic process, it is reasonable to propose 
that a proper understanding of apoptosis will require us to understand how caspases are 
activated. 
As is true of most proteases, caspases are synthesized as enzymatically inert zymogens. These 
zymogens are composed of three domains: an N-terminal pro-domain, a large subunit with the 
catalytic site “QACXG” (also called the p20 domain) and a small subunit (also called the p10 
domain) (Figure 7a), which are found in the mature enzyme. Therefore, caspases can be 
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divided into two types: those with large pro-domains (like caspase-2, -8, -9, and -10) that 
function upstream as initiators of the death cascade and those with a small pro-domain (like 
caspase-3, -6 and –7) that act downstream as effectors (Fesik, 2000). In all cases examined so 
far, the mature enzyme is a heterotetramer containing two p20/p10 heterodimers and two 
active sites (Figure 7b) (Earnshaw et al., 1999). Although, much has been made about the fact 
that active caspases are dimers containing two active sites, there is no obvious  structural 
reason why this should be so, and it seems quite possible that caspases could exist as active 
monomers under the right conditions (Hengartner, 2000). 
 
 
 
 
Figure 7 : Schematic representation of caspase structure and their activation. 
 
 
Three general mechanisms of caspases activation have been described so far: (1) processing 
by an upstream caspase, (2) induced proximity, and (3) association with a regulatory subunit. 
 
(1) Processing by an upstream caspase 
 
Most caspases are activated by proteolytic cleavage of the zymogen between the p20 and p10 
domains, and usually also between the pro-domain and the p20 domain. Interestingly, all 
these cleavage sites occur at Asp-X sites- candidate caspase substrate sites- suggesting the 
possibility of autocatalytic activation (Figure 7b) (Thornberry et al., 1997). Indeed, the 
simplest way to activate a pro-caspase is to expose it to another, previously activated caspase 
molecule. This “caspase cascade” strategy of caspase activation is used extensively by cells 
for the activation of the three short pro-domain caspases, caspase-3, -6 and –7. These three 
downstream effector caspases are considered the workhorses of the caspase family, and are 
usually more abundant and active than their long pro-domains cousins (Hengartner, 2000). 
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The caspase cascade is a useful method to amplify and integrate pro-apoptotic signals, but it 
cannot explain how the first, most upstream caspase gets activated. At least two other 
approaches are used to get the ball rolling (Hengartner, 2000). 
 
(2) Induced proximity 
 
Caspase-8 and –10 are the key initiator caspases in the death-receptor pathway. Upon ligand 
binding, death receptors such as CD95 (Apo-1/Fas) aggregate and form membrane-bound 
signaling complexes (Figures 2 and 3). These complexes then recruit, through adapter 
proteins, several molecules of pro-caspase-8 or –10, resulting in a high local concentration of 
zymogens. The induced proximity model posits that under these crowded conditions, the low 
intrinsic protease activity of pro-caspase-8 or –10 (Muzio et al., 1998) is sufficient to allow 
the various pro-enzyme molecules to mutually cleave and activate each other. A similar 
mechanism of action has been proposed to mediate the activation of several other caspases, 
including caspase-2 and the nematode caspase CED-3 (Yang et al., 1998b).  
Although forced crowding of zymogens clearly is sufficient in many cases to activate 
caspases (Salvesen and Dixit, 1999), it is a rather crude a way to control the fate of a cell. 
Whereas the basic concept is probably correct, additional levels of regulation surely must 
exist in vivo to modulate the process (Hengartner, 2000). 
 
(3) Association with a regulatory subunit 
 
The most complex activation mechanism described so far is the one used by caspase-9. 
Unlike other caspases, proteolytic processing of pro-caspase-9 has only a minor effect of the 
enzyme’s catalytic activity (Rodriguez and Lazebnik, 1999; Stennicke et al., 1999). Rather, 
the key requirement for caspase-9 activation is its association with a dedicated protein co-
factor, Apaf-1 (Hengartner, 2000). Apaf-1 was identified through a biochemical approach as 
one of two proteins that are required for caspase-9 activation (the other being cytochrome c) 
(Li et al., 1997; Zou et al., 1997). Initially believed to be required only transiently, for 
caspase-9 activation, the Apaf-1/caspase-9 complex is now thought to actually represent the 
true active form of caspase-9 (Rodriguez and Lazebnik, 1999). Thus, we must view Apaf-1 
not simply as a caspase-9 activator, but rather as an essential regulatory subunit of a caspase-9 
holoenzyme (Cain et al., 1999; Beere et al., 2000; Cain et al., 2000).  
In addition, all caspases have a distinct substrate specificity that requires cleavage after an 
aspartic acid at the P1 position N-terminal to the cleavage site. The preference of amino acids 
further to the N-terminus of peptide substrates at the P2-P4 positions differs among caspases 
family members and defines their substrates specificity (Thornberry et al., 1997). The initiator 
caspases such as caspase-8 and caspase-9 prefer (V,L)EXD-containing substrates like those 
found in the cleavage sites used to process caspase-zymogens into active enzymes. In 
contrast, the effector caspases such as caspase-3 and caspase-7 cleave DEXD-containing 
substrates such as those found in structural proteins that are cleaved during apoptosis, 
resulting in the typical morphological changes in the cell (Fesik, 2000). 
In summary, effector caspases are usually activated proteolytically by an upstream caspase, 
whereas initiator caspases are activated through regulated protein-protein interactions. In fact, 
each of the long pro-domain caspases contains in its pro-domain a protein-protein interaction 
module, which allows it to bind to and associate with its upstream regulators. Caspase-8 and –
10 contain a death-effector domain (DED), whereas caspase-2 and –9 contain a caspase 
activation and recruitment domain (CARD). These two domains share little sequence identity, 
but fold into very similar three dimensional structures, consisting of six anti-parallel a-helices 
arranged in a Greek key configuration (Hofmann, 1999). The same fold is also found in the 
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death domain, a third protein interaction module present in several upstream regulators of 
apoptosis, such as CD95 and the adapter molecule FADD (Huang et al., 1996). The structure 
of the death domain, DED and CARD perfectly suits their function. The anti-parallel helices 
bundle into a tight core, leaving exposed large surfaces onto which evolution has carved 
extended protein-protein interaction domains. The particular face of the module that is used 
for interaction varies greatly from one protein to the next (Huang et al., 1996; Eberstadt et al., 
1998; Zhou et al., 1999). Work so far suggests that the death adaptor modules usually mediate 
intra- family interactions that is, death domain/death domain (DD/DD), DED/DED and 
CARD/CARD. However, structural analyses show that there is enough surface area left on 
DDs, DEDs and CARDs to also interact with other proteins. Indeed, death adaptor modules 
might well act as integration platforms, binding to several different proteins, which could 
modulate their dimerization and hence caspase activation (Hengartner, 2000). 
 
Ordering caspase activation in apoptosis 
 
As we know how caspases are activated and which are their possible targets, it is reasonable 
to try to establish the activation ordering of the different caspases from the initiator caspases 
to the final effector caspases.  
As already described, following stimuli implicating either death receptors or mitochondria, 
initiator caspase such as caspase-8, -10 or –9 can be processed, inducing the activation of 
downstream caspases. In fact, when caspase-8 or –10 is activated efficiently, it can directly 
activate caspase-3, thus bypassing an unnecessary mitochondrial step. In contrast, when only 
a small amount of caspase-8 is activated after a death-receptor- induced stimulus, 
mitochondria in these cells may function as amplifiers via the BID cleavage, release of 
cytochrome c, and caspase-9 activation (Scaffidi et al., 1998).  
The caspase activation events driven by caspase-9 appear to be the simultaneous activation of 
caspase-3 and –7 (Pan et al., 1998d; Srinivasula et al., 1998; Slee et al., 1999b). Caspase-3, 
then drives the activation of caspase-2 and –6, followed by the activation of caspase-8 and –
10 (Slee et al., 1999b). In the absence of caspase-3, caspase-7 and –9 are still activated but 
activation of other caspases downstream of this point (Figure 2) is arrested (Slee et al., 
1999b). Removal of caspase-6 blocked the activation of caspase-8 and –10 in this context, 
suggesting that these activation events are, somewhat surprisingly, driven by caspase-6 (Slee 
et al., 1999b). The activation of long pro-domain caspases late in this cascade may be 
unexpected, but these observations are bolstered by similar observations in other systems. In 
addition, it seems quite plausible that caspases that are apical (initiator) caspases in the 
context of certain pro-apoptotic stimuli may participate in an amplification role in other 
contexts. This phase of the death program may serve as an amplification step that activates the 
full complement of caspases that are required to dismantle the cell in the appropriate manner 
(Slee et al., 1999a). 
These two emerging pathways (death receptors- and mitochondria- induced) represent linear 
and simplified schemes that ignore an extraordinary complex network of interactions 
involving the caspases themselves as well as other regulatory molecules. For example, 
caspase-3 can activate pro-caspase-9 (Srinivasula et al., 1996). Likewise, caspase-6 can 
activate pro-caspase-3 (Liu et al., 1996b; Slee et al., 1999b). Furthermore, pro-caspase-8 has 
also been shown to be a substrate for caspase-3 (Sun et al., 1999). Finally, although BID is 
most likely to be activated by even low concentrations of caspase-8, it can also be cleaved by 
higher concentrations of caspase-3 (Li et al., 1998a). 
It is important to note that not all of the caspases that are activated during this phase may be 
necessary for the cell to die per se. However, they are likely to be required for the cell to 
adopt the typical apoptotic phenotype. For example, cells deficient in caspase-3 (either from 
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CASP-3 null mice, or due to a frame-shift mutation, i.e. MCF-7 cells) clearly die in response 
to many apoptotic stimuli (Kuida, et al., 1996; Jänicke et al., 1998a; Jänicke et al., 1998b). 
However, caspase-3-deficient cells undergo an aberrant form of apoptosis (restricted 
blebbing, delayed DNA fragmentation), suggesting that the downstream amplification events 
and non-caspase cleavage events that are mediated by caspase-3 cannot be carried out by 
caspases activated earlier in the pathway. In a similar but more dramatic way, if all caspases 
activity is blocked using broad spectrum caspase inhibitors (like Z-VAD-fmk), cells that 
progress beyond the mitochondrial commitment point typically exhibit features of necrosis 
rather than apoptosis (McCarthy et al., 1997; Amarante-Mendes et al., 1998). 
 
Regulation of caspases 
 
Once activated, the caspases cleave a small subset of the proteins in the cell, and it is the 
cumulative effect of these cleavage events that accounts for the physical characteristics of 
apoptosis (Nicholson, 1999). By definition, then, the caspases are potentially dangerous 
molecules, and an elaborate system of checks and balances exists to regulate these harbingers 
of cellular mortality (Nicholson, 2001). 
Caspases can be controlled in two ways: the processing and activation of a caspase can be 
regulated by molecules such as Bcl-2 family members and inhibitor-of-apoptosis proteins 
(IAPs), or active caspases can be controlled by a variety of inhibitors that directly interact 
with the protease. 
 
Molecules as regulators 
 
While the regulation of caspases by Bcl-2 family members, which sequestering caspase-
activating adaptor proteins, has been largely discussed, we would like to present a more 
recently finding. Srinivasula et al. (2001) reveal another regulatory mechanism by showing 
that a key catalyst in the apoptotic pathway, caspase-9, uses a peptide from the end of one of 
its own subunits as bait to attract a molecule from the IAP family. In doing so, caspase-9 
remains catalytically dormant even though the initial steps in committing it to its active state 
have taken place. This mechanism may work to eliminate the untoward effects that small 
amounts of activated caspase-9 would have on a cell that is not fully committed to apoptotic 
death (Nicholson, 2001). 
Once launched, the caspase-9/caspase-3 apoptotic pathway does not necessarily proceed 
unopposed: it is regulated further by proteins of the IAP family. These proteins were initially 
discovered in baculoviruses where they were found to inhibit apoptosis in host cells during 
viral infection (Crook et al., 1993). Subsequently, IAPs have been found in other viruses, 
yeast, flies, worms, and mammals (Uren et al., 1998). They contain one to three baculovirus 
IAP repeat (BIR) domains which are composed of about 70 amino acids and have a 
characteristic signature sequence (CX2CX16HX6C). Some of the IAPs also contain a C-
terminal ring finger. Several functions have been attributed to the IAPs. In Drosophila, IAPs 
have been shown to interact with the pro-apoptotic proteins REAPER, HID, and GRIM 
(Vucic et al., 1998; Goyal et al., 2000). The mammalian IAPs, cIAP-1 (MIHB) and cIAP-2 
(MIHC), bind to TNF-receptor associated factors (TRAFs) –1 and –2, while survivin 
(Ambrosini et al., 1997) has been implicated in the cell cycle (Li et al., 1998b). Some IAPs 
have also been shown to potently inhibit caspases. For example, human X-linked IAP (XIAP) 
inhibits caspase-3 and caspase-7 (Deveraux et al., 1997) and also inhibits caspase-9 
(Deveraux et al., 1999a). The portion of XIAP responsible for inhibiting caspase-3 was found 
to contain the BIR2 domain (Takahashi et al., 1998) whereas the BIR3 domain of XIAP was 
shown to inhibit caspase-9 (Deveraux et al., 1999a; Fesik, 2000; Sun et al., 2000). So the 
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presence of XIAP slows down and often (although not always) blocks the apoptotic pathway 
(Nicholson, 2001). 
The caspase- inhibiting effects of XIAP are antagonized by another apoptosis-promoting 
mitochondrial protein, called Smac/DIABLO (Du et al., 2000; Verhagen et al., 2000). This 
recently found protein promotes cytochrome c/Apaf-1-dependent caspase activation. Like 
cytochrome c, Smac/DIABLO is normally located in mitochondria and released, together with 
cytochrome c, into the cytosol when cells undergo apoptosis. The amino terminus of 
Smac/DIABLO binds to a surface groove in the BIR3 domain of XIAP, activating this latter 
for a ubiquitin/proteasome degradation and preventing the inhibition of caspases and of 
apoptosis (Chai et al., 2000; Liu et al., 2000; Wu et al., 2000). The ability of caspase-9 and 
caspase-3 to commit a cell to apoptotic death appears to depend on the dynamics and 
stoichiometry of XIAP and its antagonist, Smac/DIABLO. Other regulatory polypeptides, 
such as XIAP-associated factor-1 (Liston et al., 2001), may also contribute to these dynamics 
(Nicholson, 2001). 
There is no doubt some leakage in this finely tuned regulatory system. But the consequence of 
even low levels of an unregulated initiator caspase could be devastating to a cell. So it appears 
that caspase-9 has a back-up strategy: it actually recruits its own inhibitor. Srinivasula et al. 
(2001) show that the amino terminus of the small subunit of mature caspase-9 contains a four-
amino-acid peptide that is remarkably similar to the key amino terminus of mammalian 
Smac/DIABLO and the apoptosis-promoting fruitfly proteins Reaper, Hid and Grim. 
However, unlike the peptide in Smac/DIABLO, the peptide in mature caspase-9 does not 
block the caspase- inhibiting effects of XIAP. Instead, this peptide helps XIAP to bind and 
inhibit caspase-9. The relatively dormant caspase-9 pro-enzyme (in which this peptide is 
masked) does not bind XIAP. But once caspase-9 takes on its small subunit is liberated, it 
uses the exposed peptide as bait to recruit XIAP (Nicholson, 2001). 
But does this make sense in a cell that may need to fully activate its “mitochondrial” 
apoptosis pathway? As it turns out, all else holds true. Smac/DIABLO competes with the 
small subunit of mature caspase-9 for XIAP, and can tear XIAP away. The following scenario 
may thus play out (Figure 8). During the normal stresses of cellular existence within a 
multicellular organism, small amounts of caspase-9 may become activated by self-catalytic or 
other mechanisms. This rogue protease is inherently dangerous, so the newly exposed amino 
terminus of its small subunit binds to the BIR3 domain of XIAP; the BIR3 domain in turn 
inhibits caspase-9. However, under certain circumstances in which cell death should take 
place, signals emanating from mitochondria help to reverse or overcome this process. In other 
words, Smac/DIABLO competes for binding to XIAP and relieves the inhibition of mature 
caspase-9, while cytochrome c stimulates Apaf-1-mediated activation of the broader pool of 
caspase-9 pro-enzymes (Nicholson, 2001). 
Although it was not demonstrated by Srinivasula et al. (2001), the XIAP bound to the small 
subunit of caspase-9 may also be liberated by further proteolytic clipping of the small subunit. 
Nicholson et al. show that caspase-3 cleaves this subunit at a position downstream of the 
XIAP-binding peptide, releasing the peptide and, presumably, the bound XIAP too. In support 
of the idea that XIAP remains bound to this peptide even when it is cleaved from the small 
subunit, Srinivasula et al. showed that a synthetic form of the peptide antagonizes the 
interaction between XIAP and caspase-9, in much the same way that equivalent 
Smac/DIABLO peptides can block the interaction between XIAP and Smac/DIABLO (Chai 
et al., 2000; Liu et al., 2000; Nicholson, 2001). 
In addition to binding active caspase-9 and –3, XIAP also associates with oligomerized Apaf-
1. Thus, by associating with the apoptosome, XIAP appears not only to influence the 
activation of caspase-3 by caspase-9, but also to inhibit the release of active caspase-3 from 
the complex (Bratton et al., 2001). 
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Figure 8 : The apoptosis pathway that includes caspase-9 and its regulators. 
(a) In response to death stimuli (not shown), a molecule called Apaf-1, together with 
cytochrome c, which is released from mitochondria, induces the aggregation and 
processing of caspase-9 pro-enzymes. The processing includes the removal of the 
“CARD” domain, and separation of the large subunit from the linker peptide that connects 
it to the small subunit. This exposes the linker peptide. (b) One end of the linker peptide 
mimics the XIAP-binding peptide of Smac/DIABLO, allowing XIAP (an inhibitor of 
apoptosis) to bind to mature caspase-9. This keeps caspase-9 in a catalytically dormant 
state. (c)-(d) This suppression of caspase-9 might be counteracted by two mechanisms: 
competition for XIAP by the apoptosis-promoting protein Smac/DIABLO and a proteaso- 
mal degradation of XIAP (c), or caspase-3-mediated removal of the XIAP-binding peptide 
from caspase-9 and also a proteasomal degradation of XIAP (d) (Nicholson, 2001).  
 
Inhibitors as regulators  
 
This type of caspases regulators can be separated into two different classes : the viral/cellular 
inhibitors and the synthetic inhibitors. 
 
Viral and cellular inhibitors: 
 
Viruses must co-opt a cell’s synthetic machinery in order to reproduce. Therefore a most 
effective way of preventing viral replication is for an infected cell to kill itself. However, just 
as apoptosis is used to defend against viruses, viruses carry cell death inhibitors to block this 
response of their host cells. Several viral cell death inhibitors act by binding to activated 
caspases. The first caspase inhibitor to be identified was the Cowpox virus product Cytokine 
Response Modifier A (CrmA), which was found to inhibit mainly caspase-1 and caspase-8. In 
this way, CrmA can prevent apoptosis triggered by TNF receptor family members (Los et al., 
1995; Tewari and Dixit, 1995; Varfolomeev et al., 1998). Structurally, CrmA belongs to the 
serine protease inhibitor (serpin) group, but unlike other serpins, it inhibits caspases, which 
are cysteine proteases (Ray et al., 1992; Komiyama et al., 1994). However, like conventional 
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serpins, CrmA acts as a pseudo-substrate that binds to the active proteases. The pseudo-
substrate region of CrmA has the residue LVAD (designated P4-P1). A second, important viral 
inhibitor is p35. p35 is a baculoviral protein that can block the defensive apoptotic response of 
insect cells to viral infection (Clem et al., 1991). As well as being able to inhibit several 
caspases, p35 can inhibit C. elegans CED-3 and mammalian caspase-1, -3, -6, -7, -8 and –10, 
but does not inhibit non-caspase cysteine proteases or serine proteases important for the 
caspase- independent apoptosis. In addition, p35 is able to inhibit caspases in vivo (Ekert et al., 
1999). Cellular inhibitors for caspases are members of the IAP family as discussed above. 
 
Synthetic inhibitors: 
 
As inappropriate apoptosis has been implicated in many diseases, there has been a tremendous 
effort to develop caspase inhibitors for pharmacological use. Such synthetic caspase inhibitors 
are of course also useful for analysis of caspase activity in experimental models. Therefore, a 
number of specific or general caspase inhibitors have been developed based upon the 
substrate cleavage sites of the caspases. These peptides act as pseudo-substrates for active 
caspases and are competitive inhibitors. The chemical mechanism of action of the synthetic 
inhibitors is determined by the chemical groups which the peptides are linked. Linking the 
appropriate peptide to fluoro- or chloro-methyl ketones (-FMK, -CMK respectively) groups 
produces irreversible, competitive inhibitors. Peptides linked to aldehyde groups (-CHO) (or 
nitriles or ketones) act as reversible inhibitors. In addition, the -FMK adducts are much more 
permeable than the aldehyde based inhibitors, which enter cells poorly, and do not inhibit any 
caspases in intact cells at concentrations less than 1 mM. Thus, the best known caspase 
inhibitors are Z-VAD-FMK, which inhibits all known caspases except perhaps the caspase-2, 
Ac-YVAD-CHO, which inhibits mainly caspase-1, and Z-DEVD-FMK or Ac-DEVD-CHO, 
which inhibits caspase-1, -3, -6, -7, -8, -9 and –10 (Ekert et al., 1999).    
 
1.4.4 The demolition phase 
 
When the full complement of caspases that are necessary for the proper execution of the death 
program have become activated, the final demolition phase can begin. The distinction 
between the commitment/amplification and demolition phase is obviously an artificial one, 
since it is presumed that substrates will become cleaved as soon as the caspases responsible 
for particular cleavage events are activated. However, it should be noted that whereas many of 
the caspases have a cytosolic localization, many of their known substrates are contained 
within the nucleus or other compartments. Thus, there is likely to be some delay between 
activation of a caspase and the subsequent proteolytic attack of substrate(s) (Slee et al., 
1999a).  
Activation of caspases does not result in the wholesale degradation of cellular proteins. 
Rather, caspases selectively cleave a restricted set of target proteins, usually at one, or at most 
a few positions in the primary sequence (always after an aspartate residue). In most cases, 
caspase-mediated “protein surgery” results in inactivation of the target protein. But caspases 
can also activate proteins, either directly, by cleaving off a negative regulatory domain, or 
indirectly, by inactivating a regulatory subunit (Hengartner, 2000). 
Several important caspase substrates have been identified in recent years. One of the more 
exciting discoveries has been the elucidation of the mechanism of activation of the nuclease 
responsible for the famous nucleosomal ladder. First described by Wyllie (1980), this 
nuclease cuts the genomic DNA between nucleosomes, to generate DNA fragments with 
lengths corresponding to multiple integers of approximately 180 base pairs. The presence of 
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this DNA ladder has been used extensively as a marker for apoptotic cell death (Hengartner, 
2000). 
In an elegant series of experiments, the group of Wang and Nagata showed that the DNA 
ladder nuclease (now known as caspase-activated DNase, or CAD) pre-exists in living cells as 
an inactive complex with an inhibitory subunit, dubbed ICAD (Nagata, 2000). Activation of 
CAD occurs by means of caspase-3-mediated cleavage of the inhibitory subunit, resulting in 
the release and activation of the catalytic subunit (Liu et al., 1997; Enari et al., 1998; Sakahira 
et al., 1998). 
Caspase-mediated cleavage of specific substrates also explains several of the other 
characteristic features of apoptosis. For example, cleavage of the nuclear lamins is required 
for nuclear shrinking and budding (Rao et al., 1996; Buendia et al., 1999). Loss of overall cell 
shape is probably caused by the cleavage of cytoskeletal proteins such as fodrin and gelsolin 
(Kothakota et al., 1997). Finally, caspase-mediated cleavage of PAK2, a member of the p21-
activated kinase family, seems to mediate the active blebbing observed in apoptotic cells. 
Interestingly, in this last case, caspase cleavage occurs between the negative regulatory 
subunit and the catalytic subunit, and results in a constitutive activation of PAK2 (Rudel and 
Bokoch, 1997; Hengartner, 2000). 
Close to 100 additional caspase substrates have been reported over the years, and there will 
certainly be many more (Earnshaw et al., 1999; Nicholson, 1999). Why are there so many 
substrates ? Perhaps apoptosis is just more complicated that we currently believe. Indeed, 
several of the key apoptotic sub-programs, such as cell shrinking and the emission of pro-
engulfment signals, are still poorly understood. Alternatively, it is possible that many of the 
described caspase substrates are not relevant substrates, but simply “innocent bystanders” that 
get caught in the action. According to this line of reasoning, there might be little selection 
against the presence of fortuitous caspase cleavage sites on irrelevant proteins, as the cell is 
about to stop functioning anyway. Further experimentation will allow this issue to be resolved 
(Hengartner, 2000). 
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2. RESULTS 
 
2.1 ARTICLE : Bcl-2 is a monomeric protein: prevention of homodi-
merization by structural constraints 
 
Conus, S., Kaufmann, T., Fellay, I., Otter, I., Rossé, T. and Borner, C. (2000) Embo 19(7), 
1534-1544. 
 
Bcl-2 and related cytoplasmic proteins are key regulators of apoptosis, the cell suicide 
program critical for development, tissue homeostasis, and protection against pathogens 
(Adams and Corry, 1998). Therefore, it has become widely accepted that the sensitivity of a 
cell for apoptosis is determined by the kind and degree of physical interaction between anti-  
and pro-apoptotic members of the Bcl-2 family (rheostat model). While Bax-Bax homodimers 
seem to favor apoptosis, Bcl-2-Bcl-2 homodimers are supposed to confer death protection. It 
was reported that Bax-Bax homodimers form in vitro as well as in intact cells and that these 
homodimers are required for the apoptotic action of Bax in most situations (Simonen et al., 
1997; Zha and Reed, 1997; Kelekar and Thompson, 1998). Moreover, mutagenesis analyses 
and stable or transient co-overexpression studies have validated the concept that Bcl-2-Bax 
heterodimers neutralize the pro-apoptotic activity of Bax and the anti-apoptotic activity of 
Bcl-2 (Zha et al., 1996). However, it is unknown whether Bcl-2 has to homodimerize to 
protect cells from apoptosis as proposed by the rheostat model.  
We decided to challenge this hypothesis because it is crucial to know how Bcl-2 really acts 
inside cells. We showed by co- immunoprecipitation and FPLC purification of recombinant 
proteins that whereas Bax readily forms homodimers and heterodimers with Bcl-2 that can be 
disrupted by an interacting BH3-Bax peptide, we did not find any evidence for Bcl-2 
homodimer formation even under conditions when Bcl-2 protects cells from apoptosis. 
Moreover, we showed by immunofluorescence (an analysis without detergent, because the 
immunoprecipitation technique, which uses detergent to solubilize membrane proteins, is 
controversial to study interactions between proteins) that membrane-bound Bcl-2 is incapable 
of dislocating soluble Bcl-2. However, when we changed the structure of Bcl-2 by mutations 
or deletions in the BH1 and the BH2 domains, the mutated Bcl-2 is now capable to form 
homodimers with wild-type Bcl-2. This indicated that the naturally occurring Bcl-2 acts as a 
monomer to protect cells from apoptosis, a notion that is in agreement with the published 
monomeric structure of the Bcl-2 homologue Bcl-xL (Muchmore et al., 1996). But our 
findings were inconsistent with previously published data indicating that Bcl-2 interacts with 
another Bcl-2 molecule in a head-to-tail fashion in the yeast two-hybrid system (Hanada et 
al., 1995) and in co- immunoprecipitates (Yin et al., 1994). A possible explanation of this 
discrepancy may be that in such previous studies tagged (GST, HA, LexA, etc.) versions of 
Bcl-2 were used where the native structure of Bcl-2 may have been disrupted.  
Taken together, our results showed that Bcl-2 stays monomeric inside cells to protect cells 
from apoptosis and is therefore probably not capable of forming a channel as suggested by 
Schendel et al. (1998) with recombinant Bcl-2 on artificial membranes. 
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The pro-apoptotic activity of the Bcl-2 family member
Bax has been shown to be facilitated by homodimeriza-
tion. However, it is unknown whether Bcl-2 or Bcl-xL
have to homodimerize to protect cells from apoptosis.
Here we show by co-immunoprecipitation and FPLC
analyses that while Bax multimerizes and forms hetero-
dimers with Bcl-2, there is no evidence for Bcl-2
homodimerization, even in conditions under which
Bcl-2 protects cells from apoptosis. Immunofluores-
cence studies confirmed that Bax can attract active,
soluble Bcl-2 to mitochondrial membranes, but that
nuclear/ER membrane-bound Bcl-2 was incapable of
dislocating soluble Bcl-2. The failure of Bcl-2 to homo-
dimerize is due to structural constraints as versions of
Bcl-2 deleted or mutated in the BH1 and BH2 domains
effectively dimerized with wild-type Bcl-2 and were
dislocated by Bcl-2 inside cells. These data indicate
that naturally occurring Bcl-2 does not expose protein
domains that mediate homodimerization and therefore
most likely acts as a monomer to protect cells from
apoptosis.
Keywords: apoptosis/Bax/Bcl-2/BH3 domain/
dimerization
Introduction
Apoptosis is a tightly controlled, physiological mechanism
to eliminate superfluous and damaged cells from a multi-
cellular organism. At the center stage of this process
are caspases, a family of cysteine-dependent, aspartate-
directed proteases, which dismantle cells by cleaving
survival factors, cytoskeletal and nuclear scaffold proteins
and components of the replication, transcription, splicing
or repair machineries (Earnshaw et al., 1999). Inhibition
of caspases and hence interference with apoptosis occurs
either directly through a pseudosubstrate strategy (p35,
IAPs) (Clem et al., 1996) or indirectly by sequestering and
inactivating caspase-activating adaptor proteins (Thome
et al., 1997). Some members of the Bcl-2 family have
emerged as prototypes for the latter mechanism (Reed,
1997).
1534 © European Molecular Biology Organization
Bcl-2 family members can be grouped into anti-
apoptotic survival factors such as Bcl-2 or Bcl-xL, which
block caspase activation, and pro-apoptotic killer proteins
such as Bax and Bak, which facilitate apoptosis via
caspase-dependent and -independent mechanisms (Reed,
1997). Sequence analysis has not provided any clue as to
how these proteins may work. However, they share one
to four α-helical Bcl-2 homology domains, called the BH
domains, whose subtle differences in primary sequence
and spatial arrangements may determine pro- and anti-
apoptotic functions (Muchmore et al., 1996; Aritomi
et al., 1997).
The anti-apoptotic proteins Bcl-2 and Bcl-xL possess
four BH domains (BH1–4), which are all required for
death protection (Adams and Cory, 1998). Based on the
crystal structure of Bcl-xL, these domains cooperate to
form a hydrophobic face on one side of the molecule to
which numerous proteins, including caspase activators,
may bind (Muchmore et al., 1996; Aritomi et al., 1997).
An additional, amphipathic C-terminus allows the proteins
to be tail-anchored to intracellular membranes (mainly
mitochondria and nuclear/ER) (Nguyen et al., 1993;
Lithgow et al., 1994) and thus to sequester apoptosis
regulatory molecules from the cytoplasm to specific
membrane sites. This ‘docking effect’ may, however, not
be the only activity of Bcl-2 or Bcl-xL (Reed, 1997).
Structurally, Bcl-xL resembles the bacterial, pore-forming
toxins colicin or diphtheria toxin, especially in an α-helical
region that mediates the membrane insertion of the toxins
(Muchmore et al., 1996). This region corresponds to BH1
and part of the BH2 domains of Bcl-2 and Bcl-xL, and is
called the α5/α6 region. As recombinant Bcl-2 and Bcl-xL
can form ion channels on artificial membranes, it was
proposed that, like the bacterial toxins, these proteins use
their α5/α6 region for membrane insertion and/or channel
formation (Schendel et al., 1998).
Apart from lacking an N-terminal BH4 domain, the
pro-apoptotic family members Bax and Bak contain BH3,
BH1 and BH2 domains that are highly homologous and
similarly spaced as in Bcl-2 or Bcl-xL (Adams and Cory,
1998). Studies on the structure of the pro-apoptotic family
member Bid (Chou et al., 1999; McDonnell et al., 1999)
as well as molecular modeling of Bax (Aritomi et al.,
1997; Schendel et al., 1998) suggest that the overall
structure of Bax or Bak may be very similar to that of
Bcl-xL. In addition, like Bcl-xL and Bcl-2, Bax can form
ion channels on artificial membranes, and this also depends
on the α5/α6 membrane spanning region encompassing
the BH1/BH2 domains (Schendel et al., 1998). However,
a major difference between Bax/Bak and Bcl-2/Bcl-xL is
that the former undergo conformational changes inside
cells. While Bcl-2 and Bcl-xL are mostly membrane bound,
Bax and Bak are often found in the cytoplasm of normal
cells. In response to apoptotic stimuli, the pro-apoptotic
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proteins change their conformation, expose an N-terminal
epitope and translocate to mitochondria where they per-
form their cytotoxic action (Wolter et al., 1997; Goping
et al., 1998; Griffiths et al., 1999). Part of this action
involves the release of cytochrome c into the cytoplasm
(Ju¨rgensmeier et al., 1998; Rosse´ et al., 1998) where it
binds to the adapter protein Apaf-1 to activate caspases-9
and -3 (Green and Reed, 1998). Bax may itself form a
channel through which cytochrome c can pass or regulate
an outer mitochondrial channel, such as the voltage-
dependent anion channel (VDAC), to make it more
permeable for cytochrome c (Shimizu et al., 1999).
In addition to the α5/α6 membrane spanning regions,
Bax and Bak depend on the BH3 domain for cytotoxicity
(Kelekar and Thompson, 1998). Two modes of action
have been proposed for this domain. First, it can interact
with Bcl-2 and Bcl-xL and inhibit their death protective
activities (Chittenden et al., 1995; Zha et al., 1996;
Holinger et al., 1999). Structural analysis revealed that
the BH3 domain of Bak nestles into a shallow groove in
the hydrophobic face of Bcl-xL because it changes from
a random coil to an α-helical structure and rotates outward
to expose its hydrophobic surface (Sattler et al., 1997).
Secondly, the BH3 domain is used for Bax or Bak
homodimerizations (Simonen et al., 1997; Zha and Reed,
1997; Kelekar and Thompson, 1998). While there is still
some disagreement whether such homodimerizations are
required for pro-apoptotic activities (Simonian et al.,
1996), enforced dimerization of Bax was shown to facili-
tate mitochondrial translocation, mitochondrial dysfunc-
tion and apoptosis induction (Gross et al., 1998). Moreover,
purified Bax can form heptamers in solution (Lewis
et al., 1998).
It has remained even more controversial whether Bcl-2
and Bcl-xL require homodi- or multimerization for their
survival activity. This is an important issue if one wants
to know whether these proteins form channels within
cells. Although the crystal structure of soluble, anchorless
Bcl-xL is a monomer (Muchmore et al., 1996), it could
still form dimers after conformational changes and/or
insertion into membranes. Bcl-2 was shown to interact
with another Bcl-2 molecule in a head-to-tail fashion in
the yeast two-hybrid system (Hanada et al., 1995) and in
co-immunoprecipitates (Yin et al., 1994). However,
these analyses were often done with tagged [glutathione
S-transferase (GST), LexA, hemagglutinin (HA), etc.]
versions of Bcl-2 where the native structure of Bcl-2 may
have been disrupted. Here we show that while Bax
dimerizes in a BH3-dependent manner, Bcl-2 does not
readily form homodimers both in vitro and within cells.
This is not because the BH3 domain cannot participate at
dimerization reactions, but because this domain is not
accessible and/or recruitable in the wild-type Bcl-2
molecule.
Results
Bax homodimerizes and heterodimerizes with
Bcl-2 in a BH3-dependent manner
We previously showed homodimerization between ex-
ogenous and endogenous Bax and heterodimerization
between exogenous Bax and Bcl-2 in anti-Bax immuno-
precipitates from rat 6 (R6) embryo fibroblasts stably
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Fig. 1. BH3-dependent interaction between Bax and Bax/Bcl-2 in R6
cell extracts. (A) α-hBax immunoprecipitates (IP) from radiolabeled
R6 cell extracts co-overexpressing hBax and mBcl-2 (R6-Bcl-2/
Bax#9), performed in the absence (lane a) or presence of a wild-type
(lane b) or a mutant (D68A) (lane c) Bax–BH3 peptide. The location
of the immunoprecipitated overexpressed hBax (exo hBax) [24 kDa;
see Otter et al., (1998)], the co-precipitating endogenous rBax (endo
rBax) (21 kDa) and overexpressed mBcl-2 (exo mBcl-2) (26 kDa) are
indicated. (B) α-mBcl-2/27-6 immunoprecipitates from R6 cell
extracts overexpressing mBcl-2 (R6-Bcl-2#9), performed in the
absence (lane a) or presence of the wild-type Bax–BH3 peptide
(lane b). (C) α-h/mBax/UBI Western blot of α-mBax immuno-
precipitates from R6-Bcl-2/Bax#9 cell extracts before (lane a) and
after (lane b) three rounds of mBcl-2 immunodepletion using the
α-mBcl-2/10C4 antibody. We also show α-h/mBax/UBI and
α-mBcl-2/10C4 Western blots of the cell extracts before (lanes c and
e) and after (lanes d and f) mBcl-2 immunodepletion to prove the total
disappearance of Bcl-2 (compare lanes e and f) and the partial
disappearance of exo hBax and endo rBax (compare lanes c and d).
co-overexpressing Bax and Bcl-2 (R6-Bcl-2/Bax#9) (Otter
et al., 1998). As these interactions are thought to be
mediated via the BH3 domain of Bax, we performed
competition experiments using a 19 amino acid Bax–BH3
peptide either in its wild-type (56TKKLSECLKRIGDEL-
DSNM74) or mutant (D68A) configuration. When mixed
at a concentration of 100 µM into a [35S]methionine/
cysteine-labeled R6-Bcl-2/Bax#9 cell lysate, the wild-
type, but not the mutant Bax–BH3 peptide prevented the
co-immunoprecipitation of endogenous rat Bax (rBax)
with exogenous human Bax (hBax) (Figure 1A). The same
peptide also interfered with the co-immunoprecipitation
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Fig. 2. No interaction between Bcl-2 molecules in HEK cell extracts.
α-hBcl-2/100 Western blot of unlabeled α-hBcl-2/100 (lane a) and
α-mBcl-2/27-6 (lanes b and c) immunoprecipitates from extracts of
HEK cells transfected with hBcl-2 alone or co-transfected with hBcl-2
and mBcl-2. Lane d shows an α-mBcl-2/27-6 Western blot of an
α-mBcl-2/27-6 immunoprecipitate from extracts of co-transfected
cells. Note that there is not more hBcl-2 in lane b than in lane c,
indicating that hBcl-2 does not co-precipitate with mBcl-2.
of endogenous rat Bax with exogenous mouse Bcl-2
(mBcl-2) from an R6-Bcl-2#9 cell lysate (Figure 1B). To
rule out the possibility that Bax formed homodimers
via Bcl-2, we immunodepleted the R6-Bcl-2/Bax#9 cell
extract of Bcl-2 prior to anti-Bax immunoprecipitations.
Although this procedure also diminished the levels of Bax
(due to its binding to Bcl-2) (Figure 1C, lanes c and
d), we could still detect the co-immunoprecipitation of
exogenous hBax with endogenous rBax (lane b) in the
absence of any detectable Bcl-2 (lane f). Thus, Bax can
form either Bcl-2-independent homodimers or hetero-
dimers with Bcl-2 in a BH3-dependent manner.
No evidence for Bcl-2 homodimers in anti-Bcl-2
and anti-Flag immunoprecipitates
Next, we wanted to know whether Bcl-2 formed homo-
dimers under the same extraction/immunoprecipitation
conditions. For that purpose we transiently co-overex-
pressed hBcl-2 and mBcl-2 in HEK cells. Following an
immunoprecipitation with a Bcl-2 antibody against one
species, the immunoprecipitate was immunoblotted and
probed with a Bcl-2 antibody against the other species.
As shown in Figure 2, the mouse Bcl-2-specific antibodyα-
mBcl-2/27-6 immunoprecipitated high amounts of mBcl-2
from an HEK-hBcl-2/mBcl-2 cell extract (lane d). This
antibody slightly crossreacted with hBcl-2 as seen in
an α-mBcl-2/27-6 immunoprecipitate from HEK-hBcl-2
lysates (Figure 2, lane c). The amount of crossreactive
hBcl-2 was, however, far below that immunoprecipitated
with the human Bcl-2-specific antibody α-hBcl-2/100
(Figure 2, compare lanes a and c). Moreover, an α-mBcl-
2/27-6 immunoprecipitate from an HEK-hBcl-2/mBcl-2
lysate did not contain more hBcl-2 than an α-mBcl-2/27-6
immunoprecipitate from an HEK-hBcl-2 lysate (Figure 2,
compare lanes b and c), indicating that the two Bcl-2
species did not interact.
To confirm the absence of Bcl-2 dimers in vitro, we
investigated the interaction of mBcl-2 with an
N-terminally Flag-tagged version of mBcl-2 (Flag–
mBcl-2) in lysates from R6 cells stably overexpressing
the two proteins individually (R6-Bcl-2#9, R6-Flag–
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Fig. 3. No interaction between Bcl-2 and Flag-tagged Bcl-2 in R6
extracts. (A) α-Flag/M5 (lanes a–c) or α-mBcl-2/27-6 (lane d)
immunoprecipitates from radiolabeled R6 cell extracts harboring either
the transfer vector (pMV12) (lane a), Flag–mBcl-2 (R6-Flag–
Bcl-2mix) (lane b), mBcl-2 (R6-Bcl-2#9) (lane d) or both (R6-Bcl-2/
Flag–Bcl-2#7) (lane c). Note the absence of a band at 26 kDa in
lane c, indicating that 26 kDa mBcl-2 does not co-precipitate with
27 kDa Flag–mBcl-2. (B) α-mBcl-2/10C4 Western blot of α-Flag/M5
immunoprecipitates from unlabeled extracts of R6 cells overexpressing
Flag–mBcl-2 (R6-Flag–Bcl-2mix) (lanes a and e) or mBcl-2
(R6-Bcl-2#9) (lanes c and g) or both (R6-Bcl-2/Flag–Bcl-2#7)
(lanes b, f and i) before (– stress) and after treatment with 1 µM
MG132 ( MG132) or depletion of serum for 48 h (– serum). Total
extracts from R6-Bcl-2/Flag–Bcl-2#7 cells in the presence or absence
of serum are shown in lanes d and h, respectively. Note that neither
lane b nor lanes f and i contain co-precipitating 26 kDa exo mBcl-2
although it is clearly present in the total extracts (lanes d and h).
(C) α-hBcl-2/100 Western blot of an extract (lane a) or an α-Flag/M5
immunoprecipitate of this extract (lane b) prepared from HEK cells
co-transfected with Flag–hBcl-2 and hBcl-2. Note that the human
forms of Bcl-2 also do not interact.
Bcl-2mix) or in combination (R6-Bcl-2/Flag–Bcl-2#7).
Flag–mBcl-2 was as efficient in protecting cells from
apoptosis as mBcl-2 (Otter et al., 1998; also see
Supplementary material available in The EMBO Journal
Online). Thus, if dimer formation was crucial for Bcl-2
function it should also occur between Flag–mBcl-2 and
mBcl-2. When we compared α-Flag immunoprecipitates
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from extracts of [35S]methionine/cysteine-labeled R6-
Bcl-2/Flag–Bcl-2#7 and R6-Flag–Bcl-2mix cells, we
found in both cases a 27 kDa protein corresponding to
Flag–mBcl-2 as well as a 21 kDa protein corresponding
to co-precipitated endogenous rBax (Figure 3A, lanes b
and c). However, there was no additional 26 kDa
mBcl-2 that co-immuno-precipitated from the R6-Bcl-2/
Flag–Bcl-2#7 cell extract (Figure 3A, lane c), indicating
that Flag–mBcl-2 and mBcl-2 did not interact.
To increase the sensitivity of immunodetection, we
probed the α-Flag immunoprecipitates from unlabeled
R6-Bcl-2/Flag–Bcl-2#7 and R6-Flag–Bcl-2mix lysates on
an α-mBcl-2/10C4 Western blot. In addition, we consid-
ered the possibility that Bcl-2 homodimers would only
form when the cells were exposed to apoptotic stimuli,
i.e. when Flag–mBcl-2 and mBcl-2 acted as survival
factors. For that purpose, we treated the cells with 1 µM
MG132 or removed the serum for 48 h. Under these
conditions most of the R6 cells underwent apoptosis while
the Bcl-2 overexpressing counterparts were effectively
protected (Otter et al., 1998; our unpublished data). α-Flag
immunoprecipitates from both unstressed and stressed
R6-Bcl-2/Flag–Bcl-2#7 lysates still contained only the
27 kDa Flag–mBcl-2 and no co-precipitated 26 kDa
mBcl-2 when tested on an α-mBcl-2/10C4 Western blot
(Figure 3B, lanes b, f and i). This was not due to the
degradation or lack of expression of the 26 kDa mBcl-2
as this protein was clearly immunodetected in a total
extract of unstressed (Figure 3B, lane d) or stressed
(lane h) R6-Bcl-2/Flag–Bcl-2#7 cells. In addition, the lack
of Bcl-2 homodimerization was not species specific since
the human forms of Flag–Bcl-2 and Bcl-2 also did not
interact in α-Flag immunoprecipitates (Figure 3C, lane b).
Taken together, our data show that even under apoptotic
stress conditions when Bcl-2 effectively acts as a survival
factor, it does not form homodimers.
Purified recombinant Bax multimerizes, while Bcl-2
stays monomeric
We embarked on yet another approach to study di- or
multimer formation of Bcl-2 and Bax in vitro. Both
proteins were generated as GST fusions in bacteria,
attached to a glutathione–Sepharose column and cleaved
on the column by thrombin to release the recombinant
mBcl-2 or hBax proteins. Since we worked with the full-
length molecules, detergent had to be included at all
steps of the purification. However, to minimize micelle
formations on the FPLC column, elutions of mBcl-2 and
hBax from the glutathione column were performed in the
presence of 0.05% N,N-dimethyldodecylamine-N-oxide
(LDAO) instead of 1% Triton X-100. After passing through
an FPLC Superose 12 sizing column and comparing with
the elution of standard proteins (see figure legends), the
two recombinant proteins exhibited a strikingly different
elution profile. While hBax eluted in several peaks that
were multiples of ~21 kDa (Figure 4A), mBcl-2 eluted in
a single peak of ~26 kDa (Figure 4B). These peaks all
contained the respective hBax or mBcl-2 proteins as tested
by Western blotting of the eluted fractions (our unpublished
data). Moreover, when Flag–mBcl-2 was affinity purified
from an R6-Flag–Bcl-2mix extract and applied to the
Superose column, it also eluted as a single peak at ~27 kDa
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Fig. 4. Recombinant Bax, but not Bcl-2 or Flag–Bcl-2, forms
multimers in vitro. On-line 280 nm measurements of glutathione
affinity-purified, thrombin-cleaved GST–hBax (A), GST–mBcl-2 (B)
or α-Flag/M2-purified Flag–mBcl-2 (C) eluting from an FPLC
Superose 12 column. The time of sample application (Start) and the
void volume of the column (Vo) are indicated. While hBax elutes in
multiple peaks corresponding to the molecular masses of its multimers
(21, 42, 63, 84 kDa and higher), mBcl-2 and Flag–mBcl-2 are
recovered in one single peak each (monomeric 26 or 27 kDa forms,
respectively). The molecular masses were calculated according to the
elutions of the standard proteins carbonic anhydrase (29 kDa),
ovalbumin (45 kDa), bovine serum albumin (66 kDa) and
β-galactosidase (115 kDa).
(Figure 4C). These data show that Bax, but not Bcl-2, can
multimerize in vitro.
Bax, but not Bcl-2, dislocates a soluble form of
Bcl-2 inside cells
It has been reported that detergent can either promote or
disrupt Bcl-2 family protein interactions (Hsu and Youle,
1997; Otter et al., 1998). We therefore needed to confirm
our Bcl-2–Bax interaction studies in an experimental
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system that does not require detergent extraction. We
chose an immunofluorescence analysis on fixed, perme-
abilized R6 cells and investigated how Bax and Bcl-2
molecules recruit each other to different subcellular com-
partments. Our previous data showed that while Bax was
mainly associated with mitochondria, a high portion of
Bcl-2 was bound to the nuclear envelope and the associated
ER membrane (Borner et al., 1994a; Rosse´ et al., 1998).
Upon co-overexpression, Bax could attract Bcl-2 to the
mitochondrial membrane, indicating that the two proteins
interacted inside cells (Otter et al., 1998; Rosse´ et al.,
1998); however, it was difficult to monitor Bcl-2–Bcl-2
interactions as mBcl-2, hBcl-2 and Flag–mBcl-2 all local-
ized to the same nuclear/ER site (our unpublished data).
We therefore took advantage of a Bcl-2 mutant that was
devoid of its C-terminal membrane anchor and thus
localized to the cytoplasm (mBcl-2∆TM). This mutant
was previously shown to retain its function to protect
neurons from NGF-deprived apoptosis (Borner et al.,
1994a). We first validated our strategy by testing whether
Bax could attract mBcl-2∆TM similarly to the way in
which it attracted wild-type mBcl-2. As expected, while
wild-type Bcl-2 was detected on nuclear/ER membranes,
mBcl-2∆TM exhibited a diffuse cytoplasmic and intra-
nuclear staining after transfection into R6 cells (Figure 5A).
The reason for a presumed nuclear staining of mBcl-2∆TM
is unknown but the lack of its membrane anchor and its
low molecular mass (24 kDa) may allow a free passage
into the nucleus. In contrast, transfected hBax showed a
punctated, mitochondrial pattern as previously reported
(Rosse´ et al., 1998), and triggered nuclear fragmentation
(Figure 5A). Upon co-transfection with Bax, mBcl-2∆TM
lost most of its cytoplasmic/nuclear association, became
co-localized with Bax in punctated mitochondria and inhib-
ited Bax-induced nuclear fragmentation (Figure 5A). Thus,
cytosolic mBcl-2∆TM behaved like wild-type membrane-
bound Bcl-2 in that it was attracted by Bax to mitochondria
and inhibited the pro-apoptotic activity of the latter. This
set the stage to investigate whether mBcl-2∆TM inter-
acted similarly with wild-type Bcl-2. To distinguish
between the two proteins, we co-transfected R6 cells with
mBcl-2∆TM and a human form of wild-type Bcl-2 and
used species-specific antibodies for immunofluorescence.
As shown in Figure 5B, while hBcl-2 was mainly detected
on the nuclear envelope/ER network, mBcl-2∆TM
remained diffuse, cytoplasmic and intranuclear after co-
transfection into R6 cells. This was also the case when
the cells were exposed to the apoptotic stimulus MG132
(our unpublished data). Thus, unlike Bax, hBcl-2 cannot
significantly recruit mBcl-2∆TM to the ER/nuclear mem-
brane, suggesting that Bcl-2 homodimers do not readily
form within cells.
Bcl-2 lacking BH1/BH2 domains dimerizes with
wild-type Bcl-2 in a BH3-dependent manner
Our data so far indicate that despite a high sequence
homology, Bcl-2 and Bax may be structurally different.
An attractive possibility is that Bax can form di- or
multimers because its BH3 domain is exposed or at least
easily recruitable. In Bcl-2 this domain would be hidden
inside the molecule. Indeed, based on the crystal structure
of Bcl-xL, the BH3 domain of Bcl-2 is in close contact
with the BH1/BH2 domains (Muchmore et al., 1996;
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Aritomi et al., 1997). Thus, by breaking this intramolecular
interaction, we may obtain a Bcl-2 molecule that now has
its BH3 domain exposed for dimerizations. We therefore
generated two Bcl-2 deletion mutants: an mBcl-2 lacking
BH1/BH2 (mBcl-2∆BH1/2) and an mBcl-2 lacking
BH1/BH2 and BH3 (mBcl-2∆BH1/2/3). The purpose of
the latter mutant was to test whether an eventual interaction
between mBcl-2∆BH1/2 and Bcl-2 was BH3 mediated.
Both mBcl-2∆BH1/2 and mBcl-2∆BH1/2/3 were stable
proteins of 19 and 17 kDa, respectively, which could be
highly expressed in HEK, R6 and other cell types (Figure 6,
lanes g–j; our unpublished data). To see whether mBcl-
2BH∆1/2, but not mBcl-2∆BH1/2/3, was capable of
dimerizing with hBcl-2, we first performed the above
described Western blot/immunoprecipitation analysis on
HEK cells transiently transfected with hBcl-2, each of
the mutants, or in combinations. As shown in Figure 6,
the α-hBcl-2/100 antibody detected similar amounts of
26 kDa hBcl-2 in HEK-hBcl-2 (lane a), HEK-hBcl-2/
mBcl-2∆BH1/2 (lane c) and HEK-hBcl-2/mBcl-2∆BH1/
2/3 lysates (lane e). Also, the α-mBcl-2/10C4 antibody
detected similar amounts of 19 kDa mBcl-2∆BH1/2
or 17 kDa mBcl-2∆BH1/2/3 in HEK-mBcl-2∆BH1/2
(lane h), HEK-mBcl-2∆BH1/2/3 (lane j), HEK-hBcl-2/
mBcl2∆BH1/2 (lane g) and HEK-hBcl-2/mBcl-2∆BH1/
2/3 lysates (lane i). This showed that the respective
proteins were similarly expressed in single and double
transfectants. As previously seen with α-mBcl-2/27-6
(Figure 2, lane c), the α-mBcl-2/10C4 antibody slightly
crossreacted with hBcl-2 and immunoprecipitated a low
amount of the protein from an HEK-hBcl-2 extract
(Figure 6, lane b). The amount of hBcl-2 was, however, 5–
10 times higher in an α-mBcl-2/10C4 immmunoprecipitate
from HEK-hBcl-2/mBcl-2∆BH1/2 cells (Figure 6, lane d).
This was not the case when the immunoprecipitation was
performed on an HEK-hBcl-2/mBcl-2∆BH1/2/3 extract
(Figure 6, lane f), indicating that hBcl-2 and mBcl-
2∆BH1/2 interacted in a BH3-dependent fashion.
Bcl-2 dislocates mitochondrial Bcl-2∆BH1/2 to the
ER/nuclear membrane
To substantiate our in vitro findings, we used immuno-
fluorescence to see whether Bcl-2 could dislocate
mBcl-2∆BH1/2, but not mBcl-2∆BH1/2/3, inside cells.
Strikingly, when mBcl-2∆BH1/2 was transiently expressed
in R6 cells, it displayed a ‘spaghetti-like’ immunodetection
pattern that co-localized with the mitochondrial marker
Tom20 (Figure 7A). This was detected with both the
α-mBcl-2/10C4 (Figure 7A) and α-mBcl-2/27-6 (our
unpublished data) antibodies. In contrast, as shown in
Figure 5B, hBcl-2 was mainly associated with ER/nuclear
membrane structures (Figure 7B). Upon co-transfection
with hBcl-2, mitochondrial mBcl-2∆BH1/2 dislocated to
the nuclear/ER membrane, indicating that the two proteins
could interact within cells (Figure 7B). This was not the
case with the mBcl-2∆BH1/2/3 mutant as it did not show
co-localization with Bcl-2 on the nuclear envelope after
co-transfection with Bcl-2 (Figure 7B). Thus, our data
show that the deletion of the BH1/BH2 domains converts
Bcl-2 into a molecule that can interact with wild-type
Bcl-2 in a BH3-dependent manner, both in vitro and
within cells.
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Fig. 5. Membrane recruitment of cytoplasmic Bcl-2∆TM by Bax, but not by Bcl-2. (A) α-mBcl-2/10C4 (fluorescein), α-h/mBax/UBI (Texas Red)
and Hoechst 33342 (UV, nuclei) fluorescence analysis on R6 cells transfected with the C-terminally deleted mBcl-2∆TM mutant, hBax or both at
24 h post-transfection. For comparison a wild-type mBcl-2 transfectant is shown. (B) α-mBcl-2/27-6 (fluorescein) and α-hBcl-2/100 (Texas Red)
fluorescence analysis on R6 cells co-transfected with mBcl-2∆TM and hBcl-2 at 24 h post-transfection. Note that hBax attracts mBcl-2∆TM from a
diffuse to a punctated (mitochondrial) staining, accompanied by a block in nuclear condensation/fragmentation. Both hBcl-2 and mBcl-2 localize to
the ER/nuclear membrane and do not attract mBcl-2∆TM.
A Bcl-2 mutated in BH2 can attract wild-type Bcl-2
to mitochondria
It is known that blatant deletions in proteins can produce
structural changes that may be artefactual. Although the
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mBcl-2∆BH1/2 mutant is a perfect homolog of the
naturally occurring Bcl-xs splice variant (the variant of
Bcl-xL that lacks BH1 and BH2 domains) (Boise et al.,
1993), we were still worried that it might not fold correctly
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Fig. 6. BH3-dependent interaction between Bcl-2 and Bcl-2∆BH1/2 in
HEK extracts. α-hBcl-2/100 Western blot of α-hBcl-2/100 (lanes a, c
and e) or α-mBcl-2/10C4 immunoprecipitates (lanes b, d and f) from
unlabeled extracts of HEK cells transfected with hBcl-2 alone
(lanes a and b) or together with mBcl-2∆BH1/2 (lanes c and d) or
mBcl-2∆BH1/2/3 (lanes e and f). Note that there is more 26 kDa
hBcl-2 in lane d than b or f, indicating that hBcl-2 co-precipitates with
mBcl-2∆BH1/2, but not with mBcl-2∆BH1/2/3. As a control for equal
expression/immunoprecipitation of the mutant proteins, we show an
α-mBcl-2/10C4 Western blot of α-mBcl-2/10C4 immunoprecipitates
from extracts of HEK cells transfected with mBcl-2∆BH1/2 (lane h)
or mBcl-2∆BH1/2/3 (lane j) alone or together with hBcl-2 (lanes g
and i).
inside cells and promote an aberrant interaction with wild-
type Bcl-2. We therefore created a Bcl-2 variant that had
retained a BH2 domain but in a mutated form. To avoid
the introduction of unnatural mutations, we exchanged the
BH2 domain and C-terminus of Bcl-2 with the correspond-
ing regions of Bax. The resulting hBcl-2(BH2C-Bax)
construct was expressed as a stable 25 kDa protein in
HEK cells (our unpublished data) and exhibited a pre-
dominantly mitochondrial immunolocalization after trans-
fection into R6 cells (Figure 8A). Like mBcl-2∆BH1/2,
this mutant Bcl-2 seemed to interact with wild-type Bcl-2
but at another intracellular site. Instead of being passively
attracted by hBcl-2 to the ER/nuclear membrane
(Figure 7B), the hBcl-2(BH2C-Bax) variant actively
dislodged Bcl-2 from the ER/nuclear membrane to mito-
chondria (Figure 8B). This dislocation again depended on
the BH3 domain, as an hBcl-2(BH2C-Bax) deleted in
BH3 did not recruit Bcl-2 (our unpublished data). Thus,
our findings indicate that not only blatant deletions but
also subtle mutations in the BH2 region convert Bcl-2
into a molecule that can now interact with Bcl-2 in a
BH3-dependent fashion.
1540
Discussion
It has been proposed that Bcl-2 family members regulate
apoptosis like a rheostat (Oltvai et al., 1993). If
pro-apoptotic factors such as Bax prevail, they form
homodimers and cell death ensues. If anti-apoptotic factors
such as Bcl-2 are more abundant, it is their turn to form
homodimers and cells are protected from apoptotic insults.
In between these two extremes is the formation of Bax–
Bcl-2 heterodimers that keep additional cytotoxic and
survival activities in check. Although various mutagenesis
and expression studies have confirmed the existence and
role of Bax–Bax and Bax–Bcl-2 dimerizations (Adams
and Cory, 1998; Reed, 1998), those of Bcl-2 homodimers
have remained hypothetical. In this study we challenge
this issue and show by several methods that Bcl-2 does
not form homodimers when it sets the rheostat to ‘survival’.
The crystal structure of Bcl-xL in the absence or presence
of the Bak–BH3 peptide shows that Bcl-2 family members
with several BH domains can be in two conformational
states (Muchmore et al., 1996; Aritomi et al., 1997; Sattler
et al., 1997): a ‘receptor state’, where all BH domains
join to form a hydrophobic face to which other proteins
can bind, and a ‘ligand state’, where the BH3 domain of
this hydrophobic face can turn outwards to interact with
the hydrophobic face of another Bcl-2-like molecule. This
nicely explains the formation of heterodimers between
anti-apoptotic and pro-apoptotic partners, especially when
the pro-apoptotic partner is a so-called ‘BH3-only’ protein.
Such proteins have the BH3 domain as their only Bcl-2
homology domain and use non-homologous regions to
localize to different subcellular compartments (Kelekar
and Thompson, 1998). This has been elegantly demon-
strated with the protein Bim, which usually binds to the
microtubule-associated dynein motor complex via regions
outside of BH3 but uses the BH3 domain to translocate
to mitochondrial Bcl-2 in apoptotic cells (Puthalakath
et al., 1999).
An unresolved issue is whether Bax or Bcl-2 homodi-
or multimers form via the same mechanism as Bax–
Bcl-2 heterodimers. In favor of such a model is that
homodimerization of Bax depends on both the BH3 and
BH1 domains (Simonian et al., 1996; Simonen et al.,
1997; Zha and Reed, 1997; Kelekar and Thompson, 1998),
so that one Bax molecule would use its BH3 domain as
a ‘ligand’, the other as part of the hydrophobic face
‘receptor’. However, a previous study (Lewis et al., 1998)
and our study here show that Bax forms high-order
structures (up to heptamers) that are inconsistent with
such a dimerization scheme. Alternatively, Bax may not
be able to maintain a hydrophobic face ‘receptor’ structure,
but exposes its BH3 domain for homotypic interactions.
There is, however, no reported evidence that BH3 peptides,
either in their isolated form or when present in ‘BH3-
only’ proteins have the tendency to dimerize or even
multimerize. It therefore remains unknown how Bax
multimers form.
Part of the reason for our lack of insight into the Bax
structure is that this molecule undergoes a conformational
change when it moves from an inactive state in the
cytoplasm to an active state on the mitochondrial mem-
brane (Wolter et al., 1997; Goping et al., 1998; Griffiths
et al., 1999). Analogous to diphtheria toxin or colicin,
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Fig. 7. Dislocation of mitochondria-associated Bcl-2∆BH1/2, but not Bcl-2∆BH1/2/3, to the ER/nuclear membrane by Bcl-2 in R6 cells.
(A) α-mBcl-2/10C4 (fluorescein) and α-Tom20 (Texas Red) fluorescence analysis on R6 cells transfected with mBcl-2∆BH1/2 or mBcl-2∆BH1/2/3
at 24 h post-transfection. (B) α-mBcl-2/27-6 (fluorescein) and α-hBcl-2/100 (Texas Red) fluorescence analysis on R6 cells co-transfected with
mBcl-2∆BH1/2 and hBcl-2 or mBcl-2∆BH1/2/3 and hBcl-2 at 24 h post-transfection. In this co-localization experiment α-mBcl-2/10C4 cannot be
used because it is a monoclonal mouse antibody like α-hBcl-2/100. However, α-mBcl-2/27-6 and α-mBcl-2/10C4 exhibit the same immunostaining
of mBcl-2∆BH1/2 and mBcl-2∆BH1/2/3 (our unpublished data). Note that mBcl-2∆BH1/2 dislocates from its original mitochondrial to a nuclear
envelope/ER pattern upon co-transfection with hBcl-2. In contrast, mBcl-2∆BH1/2/3 does not co-localize with hBcl-2 on the nuclear envelope. The
vacuoles are due to the transient transfection with Superfect.
Fig. 8. Attraction of ER-localized Bcl-2 to mitochondria by Bcl-2(BH2C-Bax). (A) α-hBcl-2/100 (fluorescein) and α-Tom20 (Texas Red)
fluorescence analysis on R6 cells transfected with hBcl-2(BH2C-Bax) at 24 h post-transfection. (B) α-hBcl-2/100 (fluorescein) and α-mBcl-2/27-6
(Texas Red) fluorescence analysis on R6 cells co-transfected with hBcl-2(BH2C-Bax) and mBcl-2 at 24 h post-transfection. Note that mBcl-2, which
usually associates with nuclear/ER structures (Figure 5A), localizes to ‘spaghetti-like’ mitochondria upon co-expression with hBcl-2(BH2C-Bax).
this change may disrupt the hydrophobic face of Bax and
expose its pore-forming BH1/BH2 (α5/α6) regions for
membrane insertion. As a consequence, the Bax structure
would open up like an umbrella (as proposed for the
bacterial toxins) to allow other protein regions, such as
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the BH3 domain, to bind other proteins or to participate
in multimerization reactions (Schendel et al., 1998). In this
way, Bax could form a multimerized ion- or cytochrome
c-releasing channel on the mitochondrial membrane.
Although our data do not prove such a mechanism, they
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show that Bax can form homodimers in immunoprecip-
itates of membrane extracts and even multimers as
full-length recombinant protein in vitro. These Bax–Bax
interactions are clearly mediated by the BH3 domain and
not by regions that are artificially exposed due to the
presence of detergent (NP-40 or LDAO), as recently
suggested (Hsu and Youle, 1997).
The novel and quite surprising finding of this study is
that Bcl-2 behaves differently from Bax under the same
experimental conditions. Despite the fact that immuno-
precipitations and FPLC analysis were also performed in
detergent, neither cell-based, cell-extracted nor recombin-
ant Bcl-2 homodi- or multimerized. Even in response to
apoptotic stimuli such as MG132 or serum removal Bcl-2
remained in a monomeric form. These findings strongly
indicate that Bcl-2 is structurally different from Bax and
does not require homodimerization for its survival activity.
Indeed, when Aritomi et al. built a homology model of
Bax from the Bcl-xL structure, they noted that Bax
exhibited more hydrophobic patches and a better exposure
of its α5/α6 helices than Bcl-xL (Aritomi et al., 1997).
They suggested that Bax has a greater potential for
membrane insertion and is more likely to form membrane
pores than either Bcl-2 or Bcl-xL. Moreover, there is
no reported evidence that Bcl-2, like Bax, changes its
conformation and translocates from the cytoplasm to
membranes in response to apoptotic stimuli. Bcl-2 is
rarely cytoplasmic, but if it is due to the removal of its
hydrophobic C-terminus (e.g. mBcl-2∆TM), it is still
partially active (Borner et al., 1994a) and looks like
the known structure of C-terminally deleted Bcl-xL. We
therefore propose that Bcl-2 retains its hydrophobic face
structure to bind crucial death-regulatory proteins (includ-
ing BH3-containing proteins) both in the cytoplasm and
on membranes. In this respect the C-terminal sequence
would serve to anchor Bcl-2 to various different mem-
branes to increase its access to crucial binding proteins
(the ‘docking activity’ model) (Reed, 1997).
However, this model implies, as previously suggested
(Aritomi et al., 1997), that Bcl-2 would not necessarily
form multimeric channels like Bax within cells. How can
this be reconciled with the reported in vitro channel
activity of Bcl-2 (Schendel et al., 1998)? First, there is
currently no proof that any member of the Bcl-2 family
forms channels under physiological conditions. In fact,
one report shows that Bcl-2 blocks the channel activity
of Bax rather than being a channel itself (Antonsson et al.,
1997). Secondly, the non-physiological amounts of pure,
recombinant Bcl-2 protein and phospholipid vesicles could
force Bcl-2 into a conformation that facilitates membrane
insertion and dimerizations like Bax. Thirdly, most of the
recombinant Bcl-2 proteins used to measure channel
activities in vitro were C-terminally deleted and/or tagged
at their N-termini (His, GST, etc.) (Minn et al., 1997;
Schendel et al., 1997). Although some fusion proteins
such as Flag–Bcl-2 are active and stay in a monomeric
form as shown here, others such as GST–Bcl-2 lose their
capacity to protect cells from apoptosis and tend to
dimerize (our unpublished data). Similarly, homodimeriza-
tion of Bcl-2 in the yeast two-hybrid system may have
been due to the presence of the LexA protein at the
N-terminus of the Bcl-2 bait (Hanada et al., 1995). By
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using untagged, full-length Bcl-2 proteins, we studied this
molecule in its most natural form.
Our mutagenesis analyses indeed show that Bcl-2 needs
to be in a correct conformation to perform its survival
action. If the BH1 and BH2 regions of Bcl-2 are deleted,
or the BH2 region is replaced by that of Bax, the
hydrophobic face most likely changes its conformation in
a way that Bcl-2 now homodimerizes in a BH3-dependent
manner. That the dimerizations between the Bcl-2 mutants
and Bcl-2 are not an artefact due to detergents can be
shown by immunofluorescence analysis where the proteins
are mutually attracted to mitochondria or ER/nuclear
membrane sites. Why the Bcl-2 mutants are predominantly
localized to mitochondria, as compared with the ER/
nuclear association of wild-type Bcl-2, is not yet known.
Perhaps there are exposed regions that now have a higher
affinity for mitochondria than for other membranes, just
as seen with Bax (Rosse´ et al., 1998). Strikingly, both the
Bcl-2∆BH1/2 and Bcl-2(BH2C-Bax) mutants have lost
their death-protective activity (Borner et al., 1994a),
indicating that the BH1/BH2 regions of Bcl-2 are indeed
crucial for its function. Moreover, these mutants, but not
the Bcl-2∆BH1/2/3 version, can block the survival activity
of Bcl-2 in a dominant-negative fashion (see Supplemen-
tary material available in The EMBO Journal Online),
suggesting that their BH3 domains bind to the hydrophobic
face of Bcl-2 like the BH3 domain of Bax. This reinforces
the notion that the hydrophobic face of Bcl-2 is different
from that of Bcl-2(BH2C-Bax) because only the former
is maintained in a death-protective state while the latter
is disrupted to expose its BH3 domain. It remains to be
seen which region of Bcl-2 confers the stability of the
hydrophobic face, and by what mechanism pro-apoptotic
molecules such as Bax, Bak or the Bcl-2(BH2C-Bax)
mutant change their conformation to di- or multimerize.
A candidate region for regulation is the BH2 domain, in
particular at its C-terminal half where it differs in sequence
between Bcl-2 and Bax. This region, which we have called
domain X, is absolutely crucial for the survival activity
of Bcl-2 (Borner etal., 1994b) but its role in homodimeriza-
tion and cytotoxic activity of Bax is not yet known.
Additional mutagenesis and crystallographic analysis will
provide further insights into the structural differences
between Bcl-2 and Bax and why they regulate apoptosis
in an opposing fashion.
Materials and methods
Antibodies and cDNAs
The anti-Bcl-2 and anti-Bax antibodies used for immunoprecipitations
and Western blots are described in the Supplementary material available
in The EMBO Journal Online. The cDNAs for human Bax (hBax),
human Bcl-2 (hBcl-2), mouse Bcl-2 (mBcl-2), mBcl-2 devoid of its
C-terminus (mBcl-2∆TM, formerly T3) and mBcl-2 devoid of the
BH1/BH2 domains (mBcl-2∆BH1/2, formerly DEL2) were generated
and/or subcloned into the pcDNA3 or pcDNAamp vectors (Invitrogen)
as previously described (Borner et al., 1994a). The cDNAs for Flag-
tagged hBcl-2, the mBcl-2 mutant lacking the BH1, BH2 and BH3
domains (mBcl-2∆BH1/2/3) and the hBcl-2 mutant in which the BH2
and C-terminus were replaced by those of Bax [hBcl-2(BH2C-Bax)]
were generated by PCR as described in the Supplementary material
available in The EMBO Journal Online.
Cells
Human embryonic kidney 293 cells (HEK) and rat 6 (R6) embryo
fibroblasts overexpressing Bcl-2, Flag–Bcl-2 and/or Bax were generated
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and cultured as described in the Supplementary material available in
The EMBO Journal Online.
Immunoprecipitations
HEK or R6 cell derivatives (3 106) were either non-labeled or
radiolabeled with [35S]methionine/cysteine (Tran35S-label, Hartmann
Analytic) and lysed for immunoprecipitations as previously described
(Otter et al., 1998). To disrupt Bax–Bax and Bax–Bcl-2 interactions,
the cell lysate was supplemented with 100 µM wild-type (56TKKLSE-
CLKRIGDELDSNM74) or mutant (56TKKLSECLKRIGAELDSNM74)
Bax–BH3 peptide (kindly provided by Markus Wartmann and Carlos
Garcia-Echeverria, Novartis Pharma Ltd, Basle, Switzerland). The lysates
were then subjected to immunoprecipitation using 5 µl of α-mBcl-2/
27-6, 3 µl of α-hBcl-2/100, 3 µl of α-mBcl-2/10C4, 6 µl of α-mBax or
2.5 µl of α-Flag/M5. Following antibody incubation for 2 h at 4°C,
50 µl of 50% (v/v) protein A–Sepharose (Sigma) or protein G–Sepharose
(Amersham Pharmacia) were added, and the immunocomplexes were
captured on an end-over-end wheel at 4°C for 1 h. Immunocomplexes
were applied to 15% SDS–polyacrylamide gels and either blotted to a
polyvinylidene difluoride membrane (PVDF) (Immobilon-P, Millipore)
for Western blotting (unlabeled extracts) or analyzed by fluorography as
described (Otter et al., 1998). For Bcl-2 immunodepletion, cell extracts
were subjected to three rounds of immunoprecipitations using 5 µl of
α-mBcl-2/10C4 and 50 µl of protein G–Sepharose for each round.
Western blotting
Western blot analysis of immunoprecipitates from unlabeled cell extracts
was performed as described previously (Olivier et al., 1997), using either
α-hBcl-2/100 at a titer of 1:200, α-mBcl-2/10C4 at 1:500, α-mBcl-2/
27-6 at 1:5000 or α-h/mBax/UBI at 1:10000. Secondary antibodies were
Fcγ-specific, peroxidase-coupled goat anti-rabbit or anti-mouse antibodies
(Jackson ImmunoResearch Laboratories).
Transient transfections
HEK cells were grown on 100 mm plates until ~80% confluence and
transfected with 5 µg of one cDNA plus 5 µg of the pcDNA3 vector
(single transfections) or 5 µg of each of two cDNAs (double transfections)
using 25 µl of Superfect (Qiagen) as described by the manufacturer.
After 3 h the Superfect–DNA complex was removed, and the cells
were cultured for another 21 h in fresh medium before lysis for
immunoprecipitation analysis.
Immunofluorescence analysis
Cells grown on 12 mm glass coverslips were transfected with 0.8 µg of
one cDNA in 2.4 µl Superfect (single transfections) or 0.8 µg of each
of two cDNAs in 4.8 µl Superfect as described above. At 24 h post-
transfection, cells were washed twice in phosphate-buffered saline (PBS),
fixed in 4% paraformaldehyde, and permeabilized with 0.05% saponin
and acetone. The cells were treated with α-mBcl-2/27-6 (1:100),
α-h/mBax/UBI (1:100), α-mBcl-2/10C4 (1:100) or α-hBcl-2/100 (1:100)
in the absence or presence of the mitochondria marker antibody α-
Tom20 (1:300) for 1 h followed by incubation with Texas Red-
and fluorescein-conjugated goat anti-rabbit or anti-mouse secondary
antibodies (Jackson ImmunoResearch Laboratories). After another fixa-
tion in 4% paraformaldehyde containing 2 µg/ml Hoechst 33342 dye
(Molecular Probes), the anti-fading agent Slowfade (Molecular Probes)
was added, and the cells were viewed under a Zeiss Axiovert fluorescence
microscope at a magnification of 1000. Pictures were taken with a
Contax 167 MT camera.
FPLC analysis of Bcl-2/Bax multimers
mBcl-2 and hBax were expressed as GST fusion proteins in DH5α
bacteria using the pGEX-based expression vectors as previously described
(Olivier et al., 1997). After protein induction with 100 µM isopropyl-β-
D-thiogalactopyranoside (IPTG; Life Technologies) at 30°C for 4 h,
bacterial extracts were prepared and applied to glutathione–Sepharose
beads according to the manufacturer’s protocol (Amersham Pharmacia).
After washing in PBS plus 1% Triton X-100, the attached GST–mBcl-2
and GST–hBax were cleaved by 0.6 U of thrombin at 25°C for 1 h to
release the mBcl-2 and hBax proteins into the supernatant. One hundred
microliters (100 µg) of the cleaved proteins were applied to FPLC
Superose 12 chromatography using 0.05% LDAO (Sigma) as detergent.
Eluted protein was measured at OD280 on-line. For the analysis of Flag–
mBcl-2, a cell extract of R6-Flag–Bcl-2mix cells was prepared in
buffer A plus 0.2% NP-40 as described above for immunoprecipitations.
The extract was applied to an anti-Flag M2 affinity column (Sigma), the
column washed in buffer A and Flag–mBcl-2 eluted with 0.1 M glycine
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at pH 3.5. The eluted sample was immediately neutralized with NaOH
and 100 µl (100 µg) subjected to FPLC chromatography as described
for GST–mBcl-2.
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2.2 ARTICLE : Failure of Bcl-2 family members to interact with Apaf-
1 in normal and apoptotic cells 
 
Conus, S., Rossé, T. and Borner, C. (2000) Cell Death Differ. 7, 947-954. 
 
The molecular characterization of the Caenorhabditis elegans (C. elegans) cell death genes 
has been crucial in revealing some of the biochemical mechanisms underlying apoptosis in all 
animals. Four C. elegans genes, egl-1, ced-9, ced-4, and ced-3 are required for all somatic 
programmed cell death to occur. This genetic network is highly conserved during evolution. 
The pro-death gene egl-1 and the anti-death gene ced-9 have structural and functional 
similarities to the vertebrate Bcl-2 gene family. The killer gene ced-3 encodes a cysteine-
aspartate protease (caspase), which is the archetype of a family of conserved proteins known 
as effectors of apoptosis in mammals. Zou et al. (1997) reported the biochemical 
identification of an apoptotic protease activating factor (Apaf-1), a human homologue of C. 
elegans CED-4, providing important clues to how CED-4 and its potential relatives could 
work. A number of proteins have been shown to interact with Apaf-1 or to be determinant for 
its activity as an apoptotic adapter (Cecconi, 1999). But it has remained controversial whether 
the CED-4 homologue Apaf-1 is a target and mediator of the death-protective activities of 
Bcl-2 and Bcl-xL. Two groups have reported a physical interaction between Bcl-xL and Apaf-
1 in co-immunoprecipitates of HEK293 and MCF-7 cell lysates highly overexpressing the two 
proteins (Hu et al., 1998; Pan et al., 1998a). However another group could not find such 
Apaf-1 interactions when analyzing ten different Bcl-2 family members in their endogenous 
and overexpressed forms using cell lysates from normal and apoptotic cells (Moriishi et al., 
1999). All three studies used the same in vitro immunoprecipitation protocol where Apaf-
1/Bcl-2 protein complexes may be disrupted during cell lysis.  
With our results, we confirmed the failure of Bcl-2, Bcl-xL or Bax to co-immunoprecipitate 
with Apaf-1. In addition, we showed by immunofluorescence and subcellular fractionation 
analyses that while Flag-Apaf-1 and Apaf-1 are both cytoplasmic proteins, Bcl-2, Bcl-xL and 
Bax are predominantly bound to nuclear/ER and mitochondrial membranes. This pattern of 
localization is maintained when the proteins were co-overexpressed in normal or apoptotic 
cells in various combinations. Thus, neither Bcl-2, Bcl-xL nor Bax can sequester cytoplasmic 
Apaf-1 to intracellular membranes inside cells raising doubts that Apaf-1 is a direct 
physiological target of Bcl-2 family members. 
While our paper was under review, Hausmann et al. (2000) published that Apaf-1 does not 
co-localize with Bcl-2 or Bcl-xL when analyzed by immunofluorescence and immunogold 
electron microscopy. Moreover, Newmeyer et al. (2000) and Haraguchi et al. (2000) used in 
vitro assays and cells deficient in Apaf-1 to show that Bcl-2 and Bcl-xL do not require Apaf-1 
for their caspase- inhibiting and death protective function. These three papers confirmed our 
results showing that Bcl-2 family members does not directly interact with Apaf-1. 
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Abstract
CED-9 blocks programmed cell death (apoptosis) in the
nematode C. elegans by binding to and neutralizing CED-4, an
essential activator of the aspartate-directed cysteine protease
(caspase) CED-3. In mammals, the CED-9 homologs Bcl-2 and
Bcl-xLalsoblockapoptosisby interferingwith theactivationof
CED-3-like caspases. However, it is unknown whether this
occurs by binding to the CED-4 homolog Apaf-1. Whilst two
groups previously detected an interaction between Bcl-xL and
Apaf-1 in immunoprecipitates,1,2 another group found no
interaction between Apaf-1 and any of ten individual members
of the Bcl-2 family using the same experimental approach.3 In
this study, we aimed toresolve this discrepancy by monitoring
the binding of Apaf-1 to three Bcl-2 family members within
cells. Using immunofluorescence and Western blot analysis,
we show that whilst Apaf-1 is a predominantly cytoplasmic
protein, Bcl-2, Bcl-xL and Bax mostly reside on nuclear/ER and
mitochondrial membranes. This pattern of localization is
maintainedwhentheproteins areco-expressed in bothnormal
and apoptotic cells, suggesting that Bcl-2, Bcl-xL or Bax do not
significantly sequester cytoplasmic Apaf-1 to intracellular
membranes. In addition, we confirm that Apaf-1 does not
interact with Bcl-2 and Bcl-xL in immunoprecipitates. Based
on these data, we propose that Apaf-1 is not a direct,
physiological target of Bcl-2, Bcl-xL or Bax. Cell Death and
Differentiation (2000) 7, 947 – 954.
Keywords: Apaf-1; apoptosis; Bax; Bcl-2; Bcl-xL; CED-4
Abbreviations: HEK, human embryonic kidney; R6, rat 6 embryo
fibroblasts; CED, product of cell-death-abnormal gene; caspase,
cysteinyl aspartate-specific proteinase; Apaf-1, apoptotic protease
activating factor-1;BH,Bcl-2homologydomain;COX,cytochromec
oxidase; NP-40, Nonidet P-40; CHAPS, 3-[(3-cholamidopro-
pyl)dimethylammonio]-1-propane-sulfonate; ER, endoplasmic re-
ticulum; IP, immunoprecipitation
Introduction
Programmed cell death, or apoptosis, is the physiological
process that removes superfluous and damaged cells from a
multicellular organism.4 Genetic studies in the nematode C.
elegans revealed that programmed cell death during
development is executed by the aspartate-directed cysteine
protease (caspase) CED-3.5 Activation of this protease
occurs by binding an adaptor molecule CED-46,7 which
oligomerizes and brings into proximity the inactive pro-
form of CED-3 enabling it to autoprocess to the active
protease.8 – 10 Another protein, CED-9, blocks cell death by
forming a complex with CED-4 and attenuating its ability to
oligomerize and activate CED-3.6,7,9,10, The ability of CED-9,
CED-4 and CED-3 to exist in a multiprotein complex has led to
the ‘apoptosome’ model of cell-death regulation.11
Several counterparts of this genetic network have been
identified in higher eukaryotes. Up to 14 mammalian CED-
3-like caspases are known. Caspases-3 and -7 (and
probably also caspase-6) function as executioner or
effector caspases because they are activated in all types
of apoptosis, their inhibition or chromosomal deletion
interfere with apoptosis and/or they cleave most of the
cellular substrates implicated in apoptosis.12,13 The other
caspases are so called initiator caspases which form a
proteolytic cascade on selected signaling pathways (Fas/
CD95, cytokine removal, etc.) to cleave and activate the
inactive pro-forms of effector caspases.12 – 14 The need for
CED-4 homologs in caspase activation was not appreciated
until the isolation of the first mammalian homolog Apaf-1.15
Peculiarly, Apaf-1 does not directly activate effector
caspases but forms oligomers to facilitate the activation of
the initiator caspase-9 which in turn cleaves and activates
effector caspases-3 and -7.16 – 19 In addition, activation of
Apaf-1 requires the binding of the mitochondrial component
cytochrome c15,20 which is released into the cytoplasm in
response to many apoptotic stimuli.21 Thus, like CED-4,
Apaf-1 activates a CED-3-like caspase, but its function
depends on mitochondria.
The mammalian homologs of CED-9 are a family of
proteins that consists of anti-apoptotic (e.g. Bcl-2) and pro-
apoptotic (e.g. Bax) members.22 – 24 In analogy with C.
elegans, anti-apoptotic proteins such as Bcl-2 and Bcl-xL
might function by binding to CED-4 homologs such as
Apaf-1 to prohibit the activation of CED-3-like effector
caspases. In support of this notion, Bcl-2 and Bcl-xL have
been shown to interfere with the activation of effector
caspases,25 – 27 and Bcl-xL has been reported to form a
complex with CED-4 upon co-overexpression in mamma-
lian cells.6,28 Moreover, two recent studies have shown that
Bcl-xL interacts with Apaf-1 in immunoprecipitates from
lysates of cells overexpressing both proteins.1,2 This
interaction prevented caspase-9 activation either within a
ternary caspase-9/Apaf-1/Bcl-xL complex
2 or by disrupting
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the binding of Apaf-1 to caspase-9.1 Although this finding is
in agreement with the nematodal ‘apoptosome’ model, it is
inconsistent with the modes of action that have so far been
described for Bcl-2 and Bcl-xL. In contrast to CED-9, Bcl-2
and Bcl-xL act by blocking the release of cytochrome c, i.e.
at a step occurring before Apaf-1 activation.29 – 31 Although
the exact mechanism of this effect is yet unknown, it has
been proposed that Bcl-2 and Bcl-xL directly regulate the
permeability of the mitochondrial membrane due to their
association with this organelle23 and/or their presumed pore
forming activity.32,33 Alternatively, they may sequester a
cytoplasmic, cytochrome c-release factor such as the Bcl-2
family member BID.34,35 Based on these propositions,
Moriishi et al have recently challenged the idea that Apaf-
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1 and Bcl-xL interact by showing that Bcl-xL or nine other
Bcl-2 family members do not co-immunoprecipitate with
Apaf-1 from lysates of mammalian cells.3
As Bcl-2 and Bcl-xL are both integral membrane
proteins, they have to be solubilized by detergents for
immunoprecipitation studies. It has however been reported
that detergents can either promote or disrupt interactions
between Bcl-2 family members.36,37 We therefore needed
to investigate the interaction between Apaf-1 and Bcl-2
family members in an experimental system that does not
require detergent extraction. We chose an immunofluores-
cence analysis on fixed, permeabilized rat embryo
fibroblasts overexpressing the proteins and show that
three Bcl-2 family members Bcl-2, Bcl-xL, or Bax cannot
attract cytoplasmic Apaf-1 to membranes in normal and
apoptotic cells. These data raise doubts that Apaf-1 is a
direct target of Bcl-2, Bcl-xL or Bax in mammalian cells.
Results
We first studied interactions between Apaf-1 and two anti-
apoptotic (Bcl-2 and Bcl-xL) and one pro-apoptotic (Bax) Bcl-2
family members using the previously reported immunopreci-
pitation approach.1 – 3 For that purpose, N-terminally, Flag-
tagged Apaf-1 was transiently co-transfected with either Bcl-2,
Bcl-xL or Bax into human embryonic kidney 293 (HEK293)
cells. In some cases, the cells were treated for different time
periods with apoptotic agents such as the proteasomal
inhibitor MG132 to determine whether interactions between
Flag-Apaf-1 and Bcl-2 or Flag-Apaf-1 and Bcl-xL are only
Figure 1 Flag-Apaf-1 or Apaf-1 do not interact with Bcl-2 or Bcl-xL in immunoprecipitates. Anti-Flag (a,e), anti-Bcl-2 (b,d), anti-Bcl-xL (c,d), or anti-Apaf-1 (d)
Western blots of anti-Flag, anti-Bcl-2, anti-Bcl-xL or anti-Apaf-1 immunoprecipitates (IP) from 0.2% NP-40 (a – d), 0.2% CHAPS (e) or 0.5% digitonin (e) lysates of
HEK293 cells transfected with Flag-Apaf-1 alone or co-transfected with Flag-Apaf-1 and human Bcl-2 (hBcl-2), Flag-Apaf-1 and mouse Bcl-2 (mBcl-2), Flag-Apaf-1
and human Bcl-xL (hBcl-xL), Apaf-1 and human Bcl-2, or Apaf-1 and human Bcl-xL, treated (+stress) or not (7stress) with 1 mM of the proteasome inhibitor MG132
for 24 h. Note that exogenous Flag-Apaf-1 is present in anti-Flag (a, lanes 1 and 3, e, lanes 1) but not in anti-Bcl-2 (a, lanes 2, e, lanes 3) or anti-Bcl-xL (a, lanes 4, e,
lanes 2) IPs from co-transfected cells. Similarly, Apaf-1 is present in anti-Apaf-1 (d, lanes 1 and 3, left panel), but not in anti-Bcl-2 (d, lane 2, left panel) or anti-Bcl-
xL (d, lane 4, left panel) IPs. By contrast, exogenous Bcl-2 is present in anti-Bcl-2 (b, lanes 1, d, lane 2, middle panel) but not in anti-Flag (b, lanes 2) or anti-Apaf-1
(d, lane 1, middle panel) IPs and exogenous Bcl-xL is present in anti-Bcl-xL (c, lanes 1, d, lane 4, right panel) but not in anti-Flag (c, lanes 2) or anti-Apaf-1 (d, lane
3, right panel) IPs from co-transfected cells. The two bands at 32 and 38 kDa detected in anti-Flag IPs (c, lanes 2) correspond to cross-reactive proteins as they are
not detected in anti-Apaf-1 IPs (d, lane 3, right panel). Sometimes the secondary antibody reacted with the heavy IgG (ca. 50 kDa) of the primary antibody
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formed when the latter two proteins act as death suppres-
sors.37 Cell lysates prepared in the presence of the detergent
Nonidet P-40 (NP-40) were subjected to anti-Flag, anti-Bcl-2
or anti-Bcl-xL immunoprecipitations, and the immunoprecipi-
tates were Western-blotted for the detection of co-precipitat-
ing proteins. As shown in Figures 1 and 3, the proteins were
similarly co-expressed so that interactions should have been
seen in immunoprecipitates if they indeed occurred. An anti-
Flag Western blot showed that Flag-Apaf-1 was present in
anti-Flag (Figure 1a, lanes 1 and 3) but not in anti-Bcl-2
(Figure 1a, lane 2) or anti-Bcl-xL (Figure 1a, lane 4)
immunoprecipitates of HEK293 cell lysates co-overexpres-
sing Flag-Apaf-1 and Bcl-2 or Flag-Apaf-1 and Bcl-xL,
respectively. Similarly, whilst Bcl-2 or Bcl-xL could be
Figure 2 Bcl-2, Bcl-xL or Bax cannot attract cytoplasmic Flag-Apaf-1 to intracellular membranes in both normal and apoptotically stressed cells. (a) Anti-Flag or
anti-Apaf-1 (fluorescein), and anti-Bcl-2, anti-Bcl-xL or anti-Bax (all Texas Red) immunofluorescence analysis on rat embryo fibroblasts (R6) transfected with Flag-
Apaf-1, hBcl-2, hBcl-xL or hBax for 15 h, respectively. (b) Anti-Apaf-1 (fluorescein) and anti-Bcl-2, anti-Bcl-xL or anti-Bax (all Texas Red) immunofluorescence
analysis on R6 cells co-transfected with Flag-Apaf-1 and hBcl-2 or Flag-Apaf-1 and hBcl-xL or Flag-Apaf-1 and hBax for 15 h, respectively. (c) Immunofluorescence
analysis of co-transfected R6 cells as in (b) but after treating the cells with 1 mM MG132 for 1 h (out of 15 h total transfection time). Note that Flag-Apaf-1 and Apaf-1
show a diffuse, cytoplasmic/nuclear staining irrespective of whether it is co-transfected with Bcl-2 (nuclear envelope/endoplasmic reticulum), Bcl-xL (mitochondria,
elongated) or Bax (mitochondria, punctuated) and/or whether the cells are stressed with the apoptotic agent MG132. The cells expressing Bax undergo apoptosis
(nuclear fragmentation) (data not shown)
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specifically immunoprecipitated with anti-Bcl-2 or anti-Bcl-xL
antibodies, respectively (Figure 1b, c, lanes 1), they did not
co-immunoprecipitate with anti-Flag antibodies from the same
cell extracts (Figure 1b, c, lanes 2). This was also the case for
extracts prepared from cells exposed to MG132 for 0 – 24 h
(Figure 1, compare7stress and +stress, 24 h). The anti-Flag
antibody seemed to co-immunoprecipitate two proteins at 32
and 38 kDa which were detected by the anti-Bcl-xL antibody
(Figure 1c). However, upon close examination, the same
proteins were also detected by anti-Flag and anti-Bcl-2
antibodies (Figure 1a, lanes 1 and 3 and Figure 1b, lane 2).
By contrast, a highly specific anti-Apaf-1 antibody did not co-
immunoprecipitate these proteins (Figure 1d, lane 3 in the
anti-Bcl-xL panel). This indicates that the 32 and 38 kDa
proteins are most likely degradation products of IgG heavy
chains of the anti-Flag antibody rather than modified (i.e.
phosphorylated) forms of Bcl-xL. The lack of interaction
between Flag-Apaf-1 and Bcl-2 or Bcl-xL was not due to the
Flag-tag, as the same results were obtained by transfecting
non-tagged Apaf-1 and using an anti-Apaf-1 specific antibody
(Figure 1d). The latter experiment was also instructive
because it did not reveal any interaction between Bcl-2 or
Bcl-xL and endogenous Apaf-1 (Figure 1d, lanes 2 and 4 in
anti-Apaf-1 panel). Moreover, the failure of these molecules to
form complexes was not due to the experimental conditions
as anti-Bcl-2 effectively co-immunoprecipitated endogenous
Bax, a known physiological partner of Bcl-2.37,38 It was also
highly unlikely that the putative Apaf-1/Bcl-2 complex was
disrupted by the immunoprecipitation antibodies, because we
used both polyclonal (data not shown) and monoclonal
(Figure 1) antibodies to Bcl-xL and Bcl-2. We also used two
other detergents (digitonin, CHAPS) for cell lysis and
immunoprecipitation and still did not find interactions
between Apaf-1 and Bcl-2 or Apaf-1 and Bcl-xL (Figure 1e).
Unfortunately, we were unable to monitor the interaction
between Apaf-1 and Bax as this combination killed most of the
co-expressing cells before they could be lysed. Thus, our data
confirm the recent report by Moriishi et al 3 that Apaf-1 does
not form a stable complex with Bcl-2 or Bcl-xL under the
conditions used for immunoprecipitations.
Although we tested different detergents (NP-40, CHAPS,
digitonin) for our in vitro experiments, it was still possible that
Bcl-2 and Bcl-xL interacted with Apaf-1 in cells, but that this
interaction was disrupted during cell lysis and/or immuno-
precipitation. To resolve this issue, we performed an
immunofluorescence analysis on rat embryo fibroblasts
(R6), Hela, HEK293 and SW480 human colon carcinoma
cell lines which had previously been co-transfected with Flag-
Figure 3 Apaf-1 is predominantly cytoplasmic while Bcl-2 and Bcl-xL are mainly found in nuclear and membrane fractions. (a) Anti-Flag, anti-Bcl-2 or anti-Bcl-xL
Western blots of cytosolic, nuclear and membrane fractions of HEK293 cells transfected with Flag-Apaf-1 or co-transfected with Flag-Apaf-1 and hBcl-2 or Flag-
Apaf-1 and hBcl-xL. (b) Anti-Apaf-1, anti-Bcl-2 or anti-Bcl-xL Western blots of cytosolic, nuclear and membrane fractions of HEK293 cells transfected with Apaf-1,
hBcl-2 or hBcl-xL or co-transfected with Apaf-1 and hBcl-2 or Apaf-1 and hBcl-xL
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Apaf-1 and Bcl-2, Flag-Apaf-1 and Bcl-xL or Flag-Apaf-1 and
Bax. Here we show the results in R6 cells but similar results
were obtained in the other cell lines. After transient
transfection, Flag-Apaf-1 displayed a diffuse immunostain-
ing in the cytoplasm with both anti-Flag and anti-Apaf-1
antibodies (Figure 2a, Flag-Apaf-1). This staining was
specific as non-transfected cells revealed only a low
background staining with both antibodies (see neighboring
cell in Figure 2a, anti-Apaf-1). The nuclear staining of Flag-
Apaf-1 was probably due to the non-confocal type of
immunofluorescence method used here as no Flag-Apaf-1
was detected in nuclear fractions isolated from Flag-Apaf-1-
transfected cells (Figure 3a, nuclei). In contrast to the diffuse
immunostaining of Apaf-1, Bcl-xL was observed on elon-
gated, ‘spaghetti-like’ structures that co-localized with the
mitochondrial marker cytochrome c oxidase (COX) (Figure
2a, Bcl-xL, and data not shown). Bax was also clearly
mitochondrial, but in a punctated pattern, and the cells
containing high levels of Bax were dying by apoptosis (Figure
2a, Bax, and ref39). Finally, Bcl-2 showed a broad subcellular
localization pattern that included the nuclear envelope and
the endoplasmic reticulum as previously reported (Figure 2a,
Bcl-2).40 Thus, if Flag-Apaf-1 interacted with Bcl-2 or Bcl-xL
upon co-overexpression, it should migrate to their sites of
localization. However, despite effective and equal co-
overexpression with Bcl-2, Bcl-xL or Bax, Flag-Apaf-1
continued to display a predominantly cytoplasmic localiza-
tion (Figure 2b). The same result was seen when the cells
were stressed with MG132 or other apoptotic stimuli for
different time periods (Figure 2c, 1 mM MG132 for 1 h is
shown here). Thus, Apaf-1 does not seem to be attracted to
intracellular sites where Bcl-2, Bcl-xL or Bax reside.
To confirm that Apaf-1 was mostly cytoplasmic and Bcl-2
or Bcl-xL were mostly membrane-bound even in co-
transfected cells, we performed Western blots of cytoso-
lic, membrane and nuclear fractions of HEK293 cells either
transfected with Flag-Apaf-1, Apaf-1, Bcl-2 or Bcl-xL alone
or co-transfected with Flag-Apaf-1 (or Apaf-1) and Bcl-2 or
Flag-Apaf-1 (or Apaf-1) and Bcl-xL. Although some Flag-
Apaf-1 and Apaf-1 were detected in the membrane fraction,
most of these proteins resided in the cytosol, irrespective of
the co-presence of overexpressed Bcl-2 or Bcl-xL (Figure
3a, b). By contrast, both Bcl-2 and Bcl-xL localized to
membranes or nuclei, and this distribution did not change in
the presence of overexpressed Flag-Apaf-1 (Figure 3a) or
Apaf-1 (Figure 3b). Thus, Apaf-1 has a cytoplasmic
localization distinct from Bcl-2 or Bcl-xL.
Discussion
Despite intensive research, it has remained unknown how
anti-apoptotic Bcl-2 family members prevent caspase
activation. Two modes of action have been proposed, one
which indirectly and another which directly affects Apaf-1
function. The indirect model suggests that Bcl-2 and/or Bcl-xL
act on the outer mitochondrial membrane to prevent the
release of cytochrome c,29 – 31 a necessary co-factor for Apaf-
1 oligomerization and the subsequent activation of caspase-9
and -3.15 – 17,20 The direct model suggests a physical
interaction between Bcl-2 and Apaf-1 or Bcl-xL and Apaf-1.
Heterologous overexpressions of the C. elegans death
regulators in mammalian cells have shown that CED-9,
CED-4 and CED-3 exist in a multiprotein complex, dubbed
the apoptosome, in which CED-9 inhibits apoptosis by binding
to CED-4, thereby preventing it from activating CED-3.6,7,9 – 11
Interestingly, such interactions have not only been detected
by co-immunoprecipitation but also using immunofluores-
cence analysis where soluble CED-4 was sequestered to the
perinuclear region by CED-9.28 The latter study showed that it
should be possible to detect a similar attraction between Apaf-
1 and Bcl-2 or Bcl-xL if the analogous mammalian
apoptosome indeed consisted of these factors.
Our data disfavor the notion that Apaf-1 forms a
mammalian apoptosome with Bcl-2 or Bcl-xL. Why are our
results in conflict with two previous studies that have
reported direct interactions between Bcl-xL and Apaf-1?
1,2
Both studies used immunoprecipitation approaches to
determine protein-protein interactions. Although Moriishi et
al 3 and we have used immunoprecipitation protocols that
closely replicated those reported1,2 it may be difficult to
reach the exact same experimental conditions for reprodu-
cing the results. For example, we noticed that, when in
abundance, Apaf-1, Bcl-2 and Bcl-xL all bind non-
specifically to Sepharose beads (data not shown), and
thus part of the presumed Apaf-1/Bcl-2 or Apaf-1/Bcl-xL
complexes may originate from such artefacts. In addition,
there remains the possibility that the quality of the
detergents influences complex formations during cell lysis
and immunoprecipitation. Our use of immunofluorescence
to study the interaction between Apaf-1 and Bcl-2 family
members within cells circumvents these in vitro problems.
In several different cell types co-transfected with Flag-Apaf-
1, Apaf-1, Bcl-2, Bcl-xL or Bax and exposed to different
apoptotic stimuli for various time periods, we have not seen
any evidence that the diffusely stained, cytoplasmic Apaf-1
is sequestered to nuclear or mitochondrial membranes in a
similar fashion that CED-9 sequesters CED-4.28 Is it
possible that Apaf-1 was recruited to Bcl-2 or Bcl-xL at
levels undetectable by immunofluorescence? Although
such a possibility cannot be entirely excluded, we think
that we should have seen a major sequestration by this
technique as the apoptosome model in C. elegans
accounts for a tight complex formation between CED-9
and CED-4 in healthy cells.28,41 In addition, Western blot
analysis of subcellular fractions of HEK293 cells co-
transfected with Flag-Apaf-1/Bcl-2 or Flag-Apaf-1/Bcl-xL
revealed that both Apaf-1 and Flag-Apaf-1 were predomi-
nantly present in the cytosol rather than in membrane
fractions. Thus, instead of being sequestered to membrane-
associated Bcl-2 or Bcl-xL, Apaf-1 seems to constitutively
reside in the cytoplasm to await the release of cytochrome
c for the activation of caspase-9. A novel CED-4 homolog,
named Nod1/CARD442,43 has recently been identified, and
it will be interesting to determine whether it fulfills the
criteria to form an apoptosome with Bcl-2 or Bcl-xL. Based
on the findings that Bcl-2 and Bcl-xL prevent the release of
cytochrome c, it is expected that these proteins bind to and
inhibit a CED-4 homolog that functions upstream of
mitochondria to initiate the release of cytochrome c and
other apoptogenic factors.
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Materials and Methods
Subcellular fractionation, immunoprecipitations
and Western blot analysis
HEK293 cells were co-transfected with 5 mg of each human Flag-Apaf-
1/pcDNA3 (kindly provided by V Dixit), human Apaf-1/pcDNA3.1(7)
(kindly provided by X Wang), human Bcl-2/pcDNA3, mouse Bcl-2/
pcDNA3 or human Bcl-xL/pcDNA3 (kindly provided by G Nun˜ez) using
25 ml of Superfect (Qiagen) as described by the manufacturer. In some
cases, the cells were treated with 1 mM of MG132 (Alexis) for 0 – 24 h.
The cells were lysed in 0.2% NP-40, 0.2% CHAPS or 0.5% digitonin
and subjected to immunoprecipitation using 3 ml of mouse monoclonal
anti-hBcl-2/100 (Neomarker), 5 ml of rabbit polyclonal anti-m/rBcl-2/27-
6,37 3 ml of mouse monoclonal anti-Bcl-xL/2H12 (Zymed), 2.5 ml of
mouse monoclonal anti-Flag/M5 (Sigma) or 5 ml of rabbit polyclona
anti-Apaf-1/IP14 (Zymed) and 50 ml of 50% (v/v) protein G-Sepharose
(PharmaciaAmersham) or protein A-Sepharose (Sigma) as previously
described.37 Immunocomplexes were subjected to Western blot
analysis using either anti-hBcl-2/100 at a titer of 1 : 200, anti-Bcl-xL/
2H12 at a titer of 1 : 1000, anti-Flag/M5 at a titer of 1 : 1000 or anti-
Apaf-I/IP14 at a titer of 1 : 1000. Secondary antibodies were Fcg-
specific, peroxidase-coupled goat anti-rabbit or anti-mouse antibodies
(Jackson ImmunoResearch Laboratories), and the detection system
was enhanced chemiluminescence (ECL, AmershamPharmacia). For
subcellular fractionation analysis, the co-transfected HEK293 cells
were lysed in buffer A/sucrose (20 mM HEPES, pH 7.5, 10 mM KCl,
1.5 mM MgCl2, 1 mM EGTA, 1 mM EDTA, 1 mM DTT, 0.25 M
sucrose, 10 mg/ml leupeptin, 2 mg/ml aprotinin, 0.4 mM Pefabloc,
1 mg/ml pepstatin) using a tight fitting Dounce homogenizer. The
lysates were centrifuged at 7506g to obtain a nuclear pellet. The
postnuclear supernatant was further centrifuged at 100 0006g to
obtain a membrane pellet and the cytosol. Thirty mg of each fraction
was loaded on polyacrylamide gels for Western blot analysis.
Immunofluorescence analysis
R6 cells were transfected with 0.8 mg of each Flag-hApaf-1/pcDNA3,
hBcl-2/pcDNA3, hBcl-xL/pcDNA3 or hBax/pcDNA3 in 2.4 ml (single
transfections) or 4.8 ml (double transfections) Superfect as described
by the manufacturer (Qiagen). The cells were fixed in 4%
paraformaldehyde, and permeabilized with 0.05% saponin and
acetone as previously described.39 The cells were treated with
mouse monoclonal anti-Flag (1 : 100), rabbit polyclonal anti-Apaf-1/
IP14 (1 : 50), mouse monoclonal anti-hBcl-2/100 (1 : 100), mouse
monoclonal anti-Bcl-xL/2H12 (1 : 100) or mouse monoclonal anti-hBax/
2D2 (1 : 100) (Zymed) for 1 h followed by incubations with fluorescein-
and Texas Red-conjugated goat anti-rabbit and anti-mouse secondary
antibodies (Jackson ImmunoResearch Laboratories). After postfixa-
tion in 4% paraformaldehyde, the antifading agent Slowfade
(Molecular Probes) was added, and the cells were viewed under a
regular Zeiss Axiovert fluorescence microscope at a magnification of
10006. Pictures were taken with a Contax 167 MT camera.
Note added in proof
While this paper was under review, Hausmann et al 44 published that
Apaf-1 does not colocalize with Bcl-2 or Bcl-xL when analyzed by
immunofluorescence and immunogold electron microscopy. Moreover,
Newmeyer et al 45 and Haraguchi et al 46 used in vitro assays and cells
deficient in Apaf-1, respectively, to show that Bcl-2 and Bcl-xL do not
require Apaf-1 for their caspase-inhibiting and death protective
function.
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2.2.1 Additional results 
 
The goal was to complete Figure 1 of the paper, specially the panel e, by performing some 
additional experiments and controls to confirm that Bcl-2 family members cannot directly 
interact with Apaf-1. For that purpose, we used exactly the same reagents, cells and 
previously reported immunoprecipitation approach (see “Materials and Methods” in the 
article). 
 
Flag-Apaf-1 does not interact with human Bcl-2 in immunoprecipitates and Bcl-2/Bcl-xL 
are readily extracted from membranes using CHAPS or Digitonin as detergent. 
 
To address the small possibility that Flag-hApaf-1 interacted with human Bcl-2 in a species-
specific manner (we showed only the results obtained with mouse Bcl-2 in the paper) and to 
make sure that Bcl-2 and Bcl-xL could be extracted from ER/nuclear and mitochondrial 
membranes (it was a missing control), we transiently co-transfected N-terminally, Flag-tagged 
human Apaf-1 (Flag-Apaf-1) with either human Bcl-2 (hBcl-2) or human Bcl-xL (hBcl-xL) 
into human embryonic kidney 293 (HEK293) cells. Cell lysates were prepared in the presence 
of CHAPS or Digitonin as detergent and subjected to anti-human Bcl-2 (anti-Bcl-2) or anti-
human Bcl-xL (anti-Bcl-xL) immunoprecipitations (IP). The immunoprecipitates were 
analyzed on a Western blot for the detection of the Bcl-2 and Bcl-xL proteins or the co-
precipitating protein Flag-Apaf-1 (Figure 9). 
 
 
Figure 9 : Flag-Apaf-1 does not interact with Bcl-2 and Bcl-2/Bcl-xL are pulled out of 
their target membranes. 
 Anti-Bcl-2 (lanes a and d), anti-Flag (lanes b and c), and anti-Bcl-xL (lane e) Western 
blots of anti-Bcl-2 or anti-Bcl-xL immunoprecipitates (IP) from 0.2% CHAPS (lanes a 
and b) or 0.5% Digitonin (lanes c, d and e) lysates of HEK 293 cells co-transfected with 
Flag-Apaf-1 and human Bcl-2 (hBcl-2) or Flag-Apaf-1 and human Bcl-xL (hBcl-xL). 
Note that exogenous Bcl-2 is present in anti-Bcl-2 (lanes a and d) IPs from co-transfected 
cells. Similarly exogenous Bcl-xL is present in anti-Bcl-xL (lane e) IP. However, Flag-
Apaf-1 is not present in anti-Bcl-2 (lanes b and c) IPs from co-transfected cells, because 
the detected band corresponds to a non-specific protein (compare lane c with Figure 1, 
panel a, lanes 3 in the article). 
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As shown in Figure 9, Bcl-2 and Bcl-xL were specifically immunoprecipitated with anti-Bcl-
2 (lanes a and d) or anti-Bcl-xL (lane e) antibodies in the presence of CHAPS or Digitonin as 
detergent. Moreover, we previously demonstrated that Flag-Apaf-1 immunoprecipitated with 
anti-Flag antibody in the presence of the same detergents (paper, Figure 1, panel e, lanes 1).  
These results indicated that if there was an interaction between Flag-Apaf-1 and Bcl-2 or Bcl-
xL, we should be able to detect it. But even under these conditions, Flag-Apaf-1 did not 
interact with hBcl-2 (Figure 9, lanes b and c), mBcl-2 (paper, Figure 1, panel e, lanes 3) or 
hBcl-xL (paper, Figure 1, panel e, lanes 2). Although we tested different detergents (NP-40, 
CHAPS, Digitonin) for our in vitro experiments, it was still possible that an eventual cellular 
interaction between Bcl-2/Bcl-xL and Apaf-1 was disrupted upon cell lysis and/or 
immunoprecipitation. To solve this issue, we confirmed our results by immunofluorescence 
(paper, Figure 2) and subcellular fractionation (paper, Figure 3) analyses. 
 
Apaf-1 does not interact with Bcl-2 or Bcl-xL, even in the presence of dATP. 
 
It has been reported that dATP (25 times more active than ATP, Genini et al., 2000) is an 
important factor for the in vitro binding of pro-caspase-9, cytochrome c (cyt. c) and Apaf-1 
which in turn leads to caspase-9 activation (Li et al., 1997).  
To test the possibility that the interaction between Apaf-1 and Bcl-2/Bcl-xL could only occur 
in the presence of sufficient levels of dATP in the extract, we performed an anti-Flag Western 
blot of anti-Bcl-xL, anti-Flag or anti-Bcl-2 immunoprecipitates (IP) from 0.2% NP-40 and 1 
mM dATP lysates of HEK293 cells transiently co-transfected with Flag-Apaf-1 and hBcl-xL 
or with Flag-Apaf-1 and hBcl-2 for the detection of the co-precipitating protein Flag-Apaf-1 
(Figure 10). 
 
Figure 10 : No interaction between Flag-Apaf-1 and Bcl-2 or Bcl-xL in the presence of dATP. 
 Anti-Flag Western Blot of anti-Bcl-xL, anti-Bcl-2 or anti-Flag immunoprecipitates (IP) 
from 0.2% NP-40 and 1 mM dATP lysates of HEK 293 cells co-transfected with Flag-
Apaf-1 and human Bcl-2 or Flag-Apaf-1 and hBcl-xL. Note that exogenous Flag-Apaf-1 
is present in anti-Flag (lane a) but not in anti-Bcl-xL (lane b) or anti-Bcl-2 (lane c) IPs 
from co-transfected cells. Moreover, the non-specific band is still detected at about 85 kD 
(lanes a, b and c). 
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As seen from the absence of co-immunoprecipitated Flag-Apaf-1 in anti-Bcl-xL (Figure 10, 
lane b) or anti-Bcl-2 (Figure 10, lane c) IPs from co-transfected cells, Flag-Apaf-1 is not able 
to interact with Bcl-2 or Bcl-xL under the conditions used. This is not due to the degradation 
of the different proteins because we could detect them as full- length, entire proteins as seen in 
anti-Flag IPs (Figure 10, lane a), in anti-Bcl-2 IPs (paper, Figure 1, panel b, lanes 1) or in 
anti-Bcl-xL IPs (paper, Figure 1, panel c, lanes 1). Even, when we stressed the cells to force 
Bcl-2 and Bcl-xL to act as survival factors we could not detect any interaction with Apaf-1. 
This was also the case when we added dATP or cytochrome c to the extraction buffer (data 
not shown, but exactly the same as in Figure 10). 
Taken together, our additional data confirm that Apaf-1 is not a direct, physiological target of 
Bcl-2, Bcl-xL or Bax.  
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2.3 ARTICLE : The binding properties and biological activities of 
Bcl-2 and Bax in cells exposed to apoptotic stimuli 
 
Otter, I., Conus, S., Ravn, U., Rager, M., Olivier, R., Monney, L., Fabbro, D. and Borner, C. 
(1998) J. Biol. Chem. 273(11), 6110-6120. 
 
 
Notice : 
 
My contribution to this work was the co-immunoprecipitation analyses to show that Bax is the 
only protein that specifically co- immunoprecipitates with Bcl-2 and that Bcl-2 is the only 
protein that associates stably with Bax in non-stressed mammalian cells (Figure 1A, middle 
panel, Figures 1C and 1D, Figures 2A and 2B). Moreover, I participated in the experiments 
showing that cell death protection by Bcl-2 does not require Bax and is most effective when 
Bcl-2 is in excess of Bax by performing again co-immunoprecipitation analyses (Figures 7B 
and 8B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Binding Properties and Biological Activities of Bcl-2
and Bax in Cells Exposed to Apoptotic Stimuli*
(Received for publication, June 6, 1997, and in revised form, December 30, 1997)
Isabelle Otter, Se´bastien Conus, Ulla Ravn, Monika Rager, Reynald Olivier, Laurent Monney,
Doriano Fabbro‡, and Christoph Borner§
From the Institute of Biochemistry, University of Fribourg, Rue du Muse´e 5, CH-1700 Fribourg, Switzerland,
and the ‡Department of Oncology, Novartis Ltd., Klybeckstrasse 141, CH-4002 Basel, Switzerland
The oncogene product Bcl-2 protects cells from apo-
ptosis whereas its homolog Bax functions to kill cells.
Several binding partners of Bcl-2 and Bax have been
isolated, but none of them has yet provided clues as to
exactly how Bcl-2 and Bax work. According to one view,
Bcl-2 and Bax interact with survival and death effector
molecules, respectively, and neutralize each other
through heterodimerization. Alternatively, Bcl-2 re-
quires Bax for death protection, and additional proteins
bind to the heterodimer to regulate its activity. Here we
used a co-immunoprecipitation strategy to distinguish
between these two possibilities. We show that the Bcl-2-
Bax heterodimer is maintained, and no other protein
associates stably in detectable amounts with Bcl-2, Bax,
or the heterodimer in anti-Bcl-2 and anti-Bax immuno-
precipitates from normal cells and cells exposed to apo-
ptotic stimuli. Analysis of cells expressing various levels
of Bcl-2 and Bax, however, revealed that the degree of
protection against apoptosis does not correlate with the
number of Bcl-2-Bax heterodimers but the amount of
Bcl-2 that is free of Bax. In addition, the survival activity
of Bcl-2 is unaffected when Bax expression is ablated by
an antisense strategy. Our findings suggest that the Bcl-
2-Bax heterodimer is a negative regulator of death pro-
tection, and that Bcl-2 requires neither Bax nor major,
stable interactions with other cellular proteins to exert
its survival function. We therefore propose that Bcl-2
acts as an enzyme (capturing substrates in a transient
way), as a homodi- or multimer, or through the interac-
tion with non-proteaceous targets (lipids, ions).
Bcl-2 is an oncogene product originally isolated from human
follicular lymphomas harboring a t(14;18) chromosomal trans-
location (1). Compared with other transforming genes it has the
unusual property of increasing cell numbers by preventing
programmed cell death (apoptosis) rather than stimulating cell
multiplication (2). The death-protective activity of wild-type
Bcl-2 seems to be proportional to its expression level (3). No
natural activating mutant of Bcl-2 has yet been found in nor-
mal or transformed cells. Thus, to study the molecular action of
Bcl-2, the protein has been overexpressed in many mammalian
cells and shown to counteract programmed cell death induced
by various stimuli (2). Both endogenous and exogenous Bcl-2
are anchored via their carboxyl-terminal hydrophobic tails to
the outer membranes of mitochondria, nuclei, and the endo-
plasmic reticulum with the bulk of the protein facing the cyto-
plasm (4–7). Whereas a cytosolic Bcl-2 mutant remains par-
tially active, membrane localization is required for full activity
(8–10).
The mechanisms underlying the survival activity of Bcl-2 are
still defined vaguely. It has been shown that Bcl-2 acts as an
antioxidant (8, 11), preserves the potential of mitochondrial
membranes (12, 13), and blocks the release of calcium from
internal stores into the cytoplasm (14–16). It also interferes
with the apoptotic effect of cell-permeable analogs of ceramide
(17, 18), retards cell proliferation by prolonging the G1 phase of
the cell cycle (19–21), enhances gene amplification and recom-
bination (22), and prevents activation of a subclass of cysteine
proteases called caspases (formely ced-3/ICE (interleukin-1b-
converting enzyme)-like proteases) which have become largely
implicated in the execution phase of apoptosis (23–25). More-
over, the Bcl-2 homolog Bcl-xL has recently been shown to be
structurally related to bacterial, pore-forming proteins (26) and
to form ion channels in synthetic phospholipid bilayers (27).
Thus, Bcl-xL, and by analogy Bcl-2, may directly or indirectly
affect the permeability and/or transport capacity of organelles
and regulate their homeostasis during apoptotic processes. In-
deed, very recently Bcl-2 was shown to inhibit the release of
holocytochrome c and an apoptogenic protease from the inter-
membrane space of mitochondria into the cytoplasm (28–30).
Both proteins were shown to contribute to nuclear fragmenta-
tion and apoptosis via the activation of cytoplasmic caspases.
To understand better the molecular function of Bcl-2, it is
necessary to identify the molecules with which Bcl-2 interacts.
So far, such molecules have been searched only under non-
apoptotic situations. Using interaction cloning, yeast two-hy-
brid and recombinant baculovirus systems, various Bcl-2-bind-
ing proteins have been discovered. Among them are R-Ras, a
Ras-related protein implicated in cell adhesion and apoptosis
(31–33); c-Raf-1, a transducer of growth factor-elicited signals
via the mitogen-activated protein kinase pathway (34–36);
BAG-1, a ubiquitin-like protein enhancing the survival action
of Bcl-2 (37); Nip1–3, three proteins of unknown function also
interacting with the survival factor E1B (38); a p53-binding
protein called 53BP2 (39); the cellular prion protein PrP (40);
the mitochondrial carnitine palmitoyltransferase (41); and
more recently, calcineurin (42) and the Caenorhabditis elegans
death gene product ced-4 (43). Although all of these proteins
could be forced to interact with Bcl-2 when mixed in recombi-
nant forms in vitro or co-overexpressed at high levels in intact
cells, there has been no conclusive evidence that they are
partners and/or regulators of Bcl-2 under physiological concen-
trations/conditions. We have shown recently that, in contrast to
previous reports (34–36), Bcl-2 does not co-immunoprecipitate
with Raf from normal cellular extracts and extracts of cells
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exposed to apoptotic agents (44). Moreover, using various ap-
proaches to down-regulate Raf activity, we demonstrated that
Bcl-2 does not use a Raf/mitogen-activated protein kinase sig-
naling pathway to confer cell survival (44).
Bcl-2 belongs to a family of related proteins. Whereas some
members such as Bcl-2, Bcl-xL, Bcl-w, Bfl-1, Mcl-1, A1, and
BHRF act as death repressors (anti-apoptotic subfamily) (45,
46; for review, see Ref. 47), others such as Bax, Bad, Bak, Bik,
and Bid exert the opposite function, e.g. induce apoptosis when
overexpressed in a variety of eukaroytic cells (pro-apoptotic
subfamily) (48; for review, see Ref. 47). Selective pairs of anti-
apoptotic and pro-apoptotic proteins, such as for example Bcl-2
and Bax, dimerize via highly homologous regions (BH1 regions)
present in all family members (49, 50). Mutagenesis analyses
have shown that the BH1 and BH2 regions of Bcl-2 interact
with the BH3 region of Bax (51–54). The same BH regions are
also required for the anti-apoptotic and pro-apoptotic activities
of Bcl-2 and Bax, respectively, as if survival/death activity and
heterodimerization capacity were non-separable functions (51–
54). These findings suggest two models for the regulation of
apoptosis by Bcl-2 and Bax. (i) Bcl-2 binds unknown factors
crucial for its survival activity via the BH1/BH2 regions, and
Bax binds unknown factors crucial for its killing activity via the
BH3 region. The Bcl-2-Bax heterodimer disrupts these inter-
actions and serves a negative regulatory role for both Bcl-2 and
Bax. (ii) Alternatively, the Bcl-2-Bax heterodimer is the active
component for death protection (in analogy to the Myc-Max
complex that stimulates transcription; see Ref. 55), and addi-
tional proteins bind to it to regulate its survival function.
To distinguish between the two possibilities, we embarked
on a co-immunoprecipitation strategy to detect the proteins
that bind to Bcl-2, Bax, or the heterodimer in response to
various apoptotic stresses. We show that Bcl-2 and Bax co-
localize in intact cells and are firm partners during four differ-
ent apoptotic stresses. However, no additional proteins associ-
ate stably in significant amounts with Bcl-2, Bax, or the
heterodimer under these conditions.
EXPERIMENTAL PROCEDURES
Reagents—Tumor necrosis factor a, hygromycin B, and protein G-
agarose were purchased from Juro Supply/Calbiochem, Lucerne, Swit-
zerland. Lipofectin was from Life Technologies, Basel, Switzerland.
Dithiothreitol (DTT), protein A-Sepharose, and peroxidase-labeled goat
anti-rabbit antibodies were from Sigma Chemical Co., St. Louis, MO.
Rhodamine-conjugated goat anti-mouse and fluorescein-conjugated
goat anti-rabbit IgG were from Jackson ImmunoResearch Laboratories,
Inc., West Grove, PA. Polyvinylidene difluoride membranes (Immo-
bilon-P) were from Millipore, Volketswil, Switzerland. Enhance was
from DuPont-Nemours, Geneva, Switzerland. [35S]Methionine/cysteine
(Tran35S-label) was bought from ICN, Zu¨rich, Switzerland, and the
enhanced chemiluminescence (ECL) detection system was from Amer-
sham, Buckinghamshire, U. K. Brefeldin A (BFA) (dissolved in metha-
nol) was from Alexis Corp., La¨ufelfingen, Switzerland, and dithio-
bis(succinimidylpropionate) was from Pierce, Rockford, IL. MG132
(dissolved in Me2SO) was a gift from Proscript Inc., Boston (formerly
known as Myogenics Inc.). Staurosporine (dissolved in Me2SO), okadaic
acid (dissolved in Me2SO), and the antisense phosphorothioate oligonu-
cleotide against Bax were kindly provided by Novartis Ltd. The mono-
clonal anti-human Bcl-2 antibody clone 100 was generously given by
D. Y. Mason, John Radcliffe Hospital, Oxford, Great Britain.
cDNAs—The Flag-Bcl-2 cDNA was constructed by inserting the
mouse Bcl-2 cDNA into the EcoRI site of the Flag-P1 plasmid (Kodak).
For stable and transient expressions in rat fibroblasts, the human Bax,
human Bcl-2, and Flag-Bcl-2 cDNAs were inserted into the EcoRI site of
the pcDNA3 plasmid.
Antibodies—Rabbit polyclonal antisera against amino acids 41–54
(27-6) and against amino acids 95–111 (28-5) of murine Bcl-2 were used
in this study (9). To detect Bax the following antibodies were available:
Ab 06-499, a rabbit polyclonal antibody against the NH2-terminal
amino acids 1–21 of human Bax cross-reacting with mouse and rat Bax,
kindly provided by Upstate Biotechnology, Inc., Lake Placid, NY; Ab
13666E, a rabbit polyclonal antibody against amino acids 43–61 of
human Bax, non-reactive with rat/mouse Bax, purchased from Pharm-
ingen, Hamburg, Germany; and Ab 13686E, a rabbit polyclonal anti-
body against amino acids 43–61 of mouse Bax, cross-reactive with rat,
but not human Bax, purchased from Pharmingen. The mouse mono-
clonal anti-Flag antibody M5 was bought from Kodak/Integra
Biosciences.
Cells—Vector control and Bcl-2-overexpressing rat 6 embryo fibro-
blasts (R6) and murine L929 fibroblasts were generated by retroviral
transduction of the pMV12hygro plasmid lacking or containing the
murine Bcl-2 cDNA as described previously (9, 19). Cell lines expressing
intermediate (R6-Bcl-2#5) and high amounts of Bcl-2 (R6-Bcl-2#9) were
used for further studies. R6 cells overexpressing Flag-Bcl-2 were pro-
duced by transfecting the Flag-Bcl-2/pcDNA3 construct using Lipofec-
tin. Following selection in 400 mg/ml G418, clones were picked, ex-
panded into cell lines, and analyzed for Flag-Bcl-2 expression by anti-
Flag immunoblotting. For further studies, a cell line expressing low
amounts of Flag-Bcl-2 (R6-Flag-Bcl-2#15) and a mixed cell population
expressing high amounts of Flag-Bcl-2 (R6-Flag-Bcl-2mix) were used.
In addition, the Flag-Bcl-2/pcDNA3 vector was transfected into R6-Bcl-
2#9 cells to yield a cell line (R6-Bcl-2/Flag-Bcl-2#7) that overexpressed
both Bcl-2 and Flag-Bcl-2. R6 cells co-overexpressing mouse Bcl-2 and
human Bax were generated by transfecting the Bax/pcDNA3 construct
into the R6-Bcl-2#9 cell line. Following selection in 400 mg/ml G418, two
cell lines were isolated which expressed high amounts of Bcl-2 together
with low (R6-Bcl-2-Bax#1) or high amounts of human Bax (R6-Bcl-2-
Bax#9). All R6 cell derivatives were grown in Dulbecco’s modified Ea-
gle’s medium containing 5% fetal calf serum and low amounts (50
mg/ml) of hygromycin (to maintain Bcl-2 expression) or G418 (to main-
tain Flag-Bcl-2 or Bax expression). Vector control and Bcl-2-overex-
pressing JILY B lymphoblasts were generated as described previously
(19). These were mixed cell populations carrying the episomal pMEPhy-
gro vector (Invitrogen Corp., NV Leek, The Netherlands) lacking or
containing the murine Bcl-2 cDNA. They were cultured in RPMI 1640
containing 10% fetal calf serum and 50 mg/ml hygromycin (to maintain
Bcl-2 expression) at 5% CO2 and 37 °C.
Drug Treatments and Cell Viability Assay—Cells were seeded at 2 3
105 in triplicate into 35-mm wells. The next day, the cells were treated
with the solvent Me2SO (0.1%), 1 mM staurosporine, or 1 mM MG132 to
induce apoptosis. After 24–96 h, viable cells were counted on triplicate
plates using either the trypan blue exclusion assay or the LIVE/DEAD
fluorometric assay as described by the manufacturer (Molecular Probes,
Eugene, OR). The results are the means of six to eight independent
experiments.
Protein Extraction and Immunoblotting—Total protein extraction
and immunoblotting were performed as described previously (24). To
detect the co-immunoprecipitation of Bcl-2 and Bax, anti-Bcl-2 (27-6)
immunoprecipitates from unlabeled cell extracts of R6-Bcl-2#9 were
analyzed by anti-Bax Ab 06-499 immunoblotting at a titer of 1:10,000.
Mouse Bcl-2 was immunodetected by the rabbit polyclonal 27-6 anti-
body at a titer of 1:5,000. Secondary antibodies were peroxidase-coupled
goat anti-rabbit antibodies. The detection system was ECL.
Immunoprecipitations—3 3 106 cells were labeled with 50 mCi/ml
[35S]methionine/cysteine in 5 ml of methionine/cysteine-free RPMI me-
dium overnight. 10 min to 72 h before extraction, cells were treated with
0.1% solvent (Me2SO or methanol), 1 mM staurosporine, 1 mM okadaic
acid, 1 mM MG132, or 5 mg/ml BFA. All cells (viable and dead) were
harvested by centrifugation, washed once in phosphate-buffered saline
and once in buffer A (10 mM Hepes, pH 7.2, 143 mM KCl, 5 mM MgCl2,
1 mM EGTA, 100 mg/ml aprotinin, 10 mg/ml leupeptin, 1 mg/ml pepsta-
tin, 0.2 mM phenylmethylsulfonyl fluoride), and lysed in buffer A plus
0.2% Nonidet P-40. After leaving on ice for 30 min, the cell lysates were
cleared by centrifugation, supplemented with 2.5 mg/ml ovalbumin,
and adjusted to the same amount of radioactivity. 600 ml of the lysates
was precleared on 50 ml of 50% protein A-Sepharose at 4 °C for 1 h and
then subjected to immunoprecipitation using 5 ml of affinity-purified
anti-mouse Bcl-2 antibody 27-6 or 28-5, 3 ml of anti-human Bax anti-
body Ab 13666E, 3 ml of anti-mouse/rat Bax antibody Ab 13686E, or 2.5
ml of the anti-FLAG antibody. Following antibody incubation for 2 h at
4 °C, 50 ml of a 50% protein A-Sepharose suspension (protein G-agarose
for anti-FLAG antibody) was added, and the immunocomplexes were
captured on an end-over-end wheel at 4 °C for 60 min. Immunocom-
plexes were pelleted by centrifugation, washed three times in buffer A,
1 The abbreviations used are: BH, Bcl-2 homology; DTT, dithiothre-
itol; BFA, brefeldin A; ECL, enhanced chemiluminescence; Me2SO,
dimethyl sulfoxide; Ab, antibody; PAGE, polyacrylamide gel
electrophoresis.
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and then boiled in SDS-sample buffer for 6 or 12% SDS-PAGE analysis.
The gels were fixed in 40% methanol and 10% acetic acid, treated with
Enhance, washed in H20, dried, and subjected to fluorography.
For mild cell disruptions, cells were washed twice in phosphate-
buffered saline and exposed to five cycles of freezing in dry ice/ethanol
and thawing at 30 °C. Subsequently, 0.2% Nonidet P-40 was added
either directly or after cross-linking in the presence of dithiobis(succin-
imidylpropionate). For certain immunoprecipitations, buffer A was
modified as follows. The pH was adjusted to 5–8, or phosphatase in-
hibitors (50 mM NaF, 100 mM Na3VO4, 25 mM b-glycerophosphate), an
ATP regeneration system (1 mM DTT, 2 mM ATP, 10 mM phosphocrea-
tine, and 50 mg/ml creatine kinase), 1 mM CaCl2 in the absence of
EGTA, or various amounts of KCl (0–500 mM) were added. To account
for disulfide-linked protein-protein interactions, immunoprecipitates
were boiled in SDS-sample buffer in the absence or presence of 30 mM
DTT. To detect high stringency interactions, RIPA buffer (buffer A plus
0.5% Nonidet P-40, 0.5% sodium deoxycholate, and 0.1% SDS) was used
for cell disruption, immunoprecipitation, and washes.
Transient Transfection and Immunocytochemistry—R6 cells were
grown on sterile 12-mm glass coverslips until 60–70% confluence. 1 mg
each of human Bax/pcDNA3 and human Bcl-2/pcDNA3 was combined
with 3 ml (3 mg) of Lipofectin in Dulbecco’s modified Eagle’s medium
(without serum and antibiotics) and transfected into the cells as de-
scribed by the manufacturer (Life Technologies). After 6 h, the Lipofec-
tin was removed, replaced by fresh Dulbecco’s modified Eagle’s medium
plus 10% fetal calf serum in the absence or presence of 5 mg/ml BFA,
and incubated at 37 °C for another 22 h. At 28 h post-transfection, cells
were washed twice in phosphate-buffered saline, fixed in 4% paraform-
aldehyde, and permeabilized with 0.05% saponin and acetone. The cells
were treated with the monoclonal anti-human Bcl-2 antiserum, clone
100 (1:10) and the polyclonal anti-human Bax antiserum Ab 06-499
(1:200) for 1 h followed by an incubation with rhodamine-conjugated
goat anti-mouse and fluorescein-conjugated goat anti-rabbit secondary
antibodies. The antifading agent SlowFadey (Molecular Probes) was
added, and the cells were viewed under a Zeiss Axiovert fluorescence
microscope at a magnification of 3 1,000.
Antisense Experiments—2 3 106 R6-Bcl-2#9 cells were transfected
with a 1 mM concentration of the antisense phosphorothioate oligonu-
cleotide 59-TGCTCCCCGGACCCGTCCAT-39 targeted against the RNA
sequence 1–20 of rat Bax using Lipofectin. As a control, a 1 mM concen-
tration of the corresponding sense oligonucleotide 59-ATGGACGGGTC-
CGGGGAGCA was transfected. After each day, a total cell extract was
prepared and analyzed for Bax expression by Ab 06-499 immunoblot-
ting. At 3 days post-transfection when endogenous Bax expression was
ablated, the cells were treated with 1 mM staurosporine or 1 mM MG132,
and viability was monitored for another 24 h by the trypan blue exclu-
sion assay. The down-regulation of Bax expression lasted at least until
day 5 post-transfection.
Quantitation of Proteins—Autoradiography of Western blots (ECL)
and immunoprecipitations were scanned with a Bio-Rad GS-700 densi-
tometer, and the protein bands were quantified by imaging densitom-
etry (Molecular Analyst® 2.1). Arbitrary integrated volume units (outer
diameter 3 area) are presented in the graphics. The values were cor-
rected against the background of the autoradiography, and the protein
amount on the polyvinylidene difluoride membrane was determined by
amido black staining.
Statistical Analysis—All quantitative measurements were per-
formed at least three times. Results are shown as means 6 S.E.
RESULTS
Bax Is the Only Protein That Specifically Co-immunoprecipi-
tates with Bcl-2 under Various Extraction and Immunoprecipi-
tation Conditions—To identify novel Bcl-2-binding proteins, we
followed exactly the protocol used for the co-immunoprecipita-
tion and isolation of Bax, i.e. direct cell lysis in an isotonic
buffer containing 0.2% Nonidet P-40 (50). This has been con-
sidered mild conditions retaining protein-protein interactions
(56). First, we used an antibody (27-6) against an epitope
shown to be irrelevant for the survival activity of Bcl-2 accord-
ing to mutagenesis data (amino acids 41–60) (26, 57). This
antibody immunoprecipitated a high amount of Bcl-2 from
[35S]methionine/cysteine-labeled extracts of the Bcl-2-overex-
pressing R6 cell line R6-Bcl-2#9 (Fig. 1A, middle panel). Com-
pared with immunoprecipitates from extracts of R6-pMV12
vector control cells, only a protein of 21 kDa was specifically
co-immunoprecipitated with Bcl-2 from R6-Bcl-2#9 cell ex-
tracts (Fig. 1A, middle panel). Similar findings were obtained
with anti-27-6 immunoprecipitates from extracts of Bcl-2-over-
expressing JILY B lymphoblasts and L929 fibroblasts (Fig. 1B)
and U937 monocytes (data not shown) as well as with immu-
noprecipitates using an anti-Bcl-2 antibody against another
epitope (28-5; amino acids 95–111) (Fig. 1A, right panel). To
resolve high molecular mass proteins better, immunoprecipi-
tates were run on 6% SDS-PAGE. However, no major protein
above 26 kDa co-precipitated with Bcl-2 (Fig. 1A, left panel).
The co-precipitating 21-kDa protein was identified as Bax on
an anti-Bax Western blot of the anti-Bcl-2 immunoprecipitates
(Fig. 1D). Because Bcl-2 and Bax contained a similar number of
radiolabeled methionine and cysteine residues (12 in mouse
Bcl-2, 10 in rat Bax) (50) and had similar protein turnover rates
(data not shown), we could estimate the stoichiometry of the
two proteins in the heterodimer. Bcl-2 was 3–10 times more
abundant than Bax in anti-Bcl-2 immunoprecipitates from
L929-Bcl-2#5, JILY-Bcl-2mix, and R6-Bcl-2#9 cell extracts
(Fig. 1, A and B). Less than 20% of the total cellular level of rat
Bax remained in the supernatant of the anti-Bcl-2 immunopre-
cipitates (Fig. 2C), indicating that Bcl-2 co-immunoprecipitated
almost all of the endogenous Bax. Thus, most of the overex-
pressed Bcl-2 appeared to be free of Bax and did not associate
stably with detectable amounts of other cellular proteins.
Because the anti-Bcl-2 antibodies 27-6 and 28-5 may have
interacted with the same sites as Bcl-2-binding proteins, we
overexpressed in R6 cells a NH2-terminally tagged (Flag) Bcl-2
that could be immunoprecipitated with an anti-tag (Flag) an-
tibody recognizing an epitope outside of the Bcl-2 molecule.
Again, Bax was the only protein that specifically co-immuno-
precipitated with Flag-Bcl-2 from extracts of cells that overex-
pressed Flag-Bcl-2 alone (R6-Flag-Bcl-2mix) or Flag-Bcl-2 to-
gether with Bcl-2 (R6-Flag-Bcl-2/Bcl-2#7) (Fig. 1C).
To account for the possibility that the experimental condi-
tions were not optimal for detecting Bcl-2-binding proteins
other than Bax, we performed anti-Bcl-2 immunoprecipitations
under variable pH (5–8) and salt (0–500 mM) conditions and
added phosphatase inhibitors, calcium, or an ATP regeneration
system to extraction, immunoprecipitation, and wash buffers.
Despite these modifications, no protein other than Bax was
specifically co-immunoprecipitated with Bcl-2 (see Fig. 4B and
data not shown). In addition, disruption of the immunocom-
plexes in the presence or absence of DTT revealed that Bcl-2
did not interact with a binding partner via disulfide bonds
(data not shown).
Bcl-2 Is the Only Protein That Associates Stably with Bax in
Non-stressed Mammalian Cells—To identify novel Bax-binding
proteins we performed anti-Bax immunoprecipitations of radio-
labeled R6-pMV12 and R6-Bcl-2#9 extracts using a polyclonal
antibody recognizing amino acids 64–78 of the mouse/rat Bax
protein (Ab 13686E). The extraction and immunoprecipitation
conditions were as described for Bcl-2 (direct lysis in 0.2%
Nonidet P-40). Anti-Bax immunoprecipitates of R6-pMV12 cell
extracts contained endogenous Bax along with other cellular
proteins (Fig. 2A, lane b). These proteins did not bind specifi-
cally to Bax because they also co-precipitated when endogenous
Bax was down-regulated by an antisense strategy (see below)
and when immunoprecipitations were performed in the pres-
ence of the Bax peptide antigen (data not shown). By contrast,
anti-Bax antibodies specifically co-immunoprecipitated overex-
pressed Bcl-2 from R6-Bcl-2#9 cell extracts (Fig. 2A, lane d).
The amount of co-precipitated Bcl-2 was similar to that of Bax
but significantly lower than the amount of Bcl-2 that can be
immunoprecipitated by anti-Bcl-2 antibodies from these ex-
tracts (Fig. 2A, compare lanes c and d). These data indicate
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that Bcl-2 and Bax form equimolar heterodimers until most of
the endogenous Bax is bound. Any excessive Bcl-2 is free of Bax
and may thus be available for the interaction with other mol-
ecules. However, as shown above for anti-Bcl-2 immunoprecipi-
tations (Fig. 1), no proteins other than Bcl-2 and Bax specifi-
cally immunoprecipitated in detectable amounts with anti-Bax
antibodies. This was true for low molecular mass (12% SDS-
PAGE, Fig. 2A) as well as high molecular mass proteins (6%
SDS-PAGE, data not shown). We also did not detect any pro-
tein that is released from endogenous Bax once Bcl-2 was
bound, indicating that Bcl-2 did not compete for proteins con-
stitutively bound to Bax (Fig. 2A). These findings were con-
firmed by another anti-Bax antibody directed against an NH2-
terminal epitope of Bax (Ab 06-499) as well as by anti-Bax
immunoprecipitations from L929 and JILY cell extracts (data
not shown).
To continue our search for novel proteins interacting with
Bcl-2 and/or Bax, we overexpressed human Bax in R6-Bcl-2#9
FIG. 1. Bax specifically co-immunoprecipitates with Bcl-2. Cells were labeled with [35S]methionine/cysteine overnight, disrupted in buffer
A containing 0.2% Nonidet P-40, and the lysate was subjected to anti-Bcl-2 or anti-Flag immunoprecipitations. Panel A, anti-Bcl-2/27-6 (left and
middle panels) or anti-Bcl-2/28-5 (right panel) immunoprecipitates from vector control R6-pMV12 and Bcl-2 overexpressing R6-Bcl-2#9 cell
extracts, analyzed on 6% (left panel) or 12% (middle and right panels) SDS-PAGE. Panel B, anti-Bcl-2/27-6 immunoprecipitates from vector control
L929-pMV12 and JILY-pMEPmix and Bcl-2 overexpressing L929-Bcl-2#5 and JILY-Bcl-2mix cell extracts. Panel C, anti-Flag/M5 immunoprecipi-
tates (a-Flag IP) from vector control R6-pMV12, Flag-Bcl-2 overexpressing R6-Flag-Bcl-2mix, and Flag-Bcl-2/Bcl-2 co-overexpressing R6-Bcl-2/
Flag-Bcl-2#7 cell extracts. For comparison an anti-Bcl-2/27-6 immunoprecipitate (a-Bcl-2 IP) from R6-Bcl-2#9 cell extracts is shown. Panel D, total
extracts (Tot Ex) and anti-Bcl-2 immunoprecipitates (27-6, a-Bcl IP) from unlabeled R6-pMV12 and R6-Bcl-2#9 cells were analyzed by anti-Bax (Ab
06-499) Western blotting as described under “Experimental Procedures.”
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cells yielding the R6-Bcl-2-Bax#9 cell line. In these cells the
molecular mass of the overexpressed Bax was 3 kDa higher (24
kDa) than that of endogenous Bax, allowing a distinction be-
tween the two protein species (Fig. 2B). The introduced 24-kDa
human Bax had the following effects on endogenous rat Bax
and overexpressed murine Bcl-2. (i) It did not disrupt the 1:1
complex between Bcl-2 and endogenous rat Bax (compare Fig.
2, panel A, lane d, with panel B, lane c), indicating that pre-
formed Bcl-2-Bax heterodimers are not disturbed by incoming
Bax. (ii) It bound to the Bcl-2 that was in excess of endogenous
Bax and therefore formed more Bcl-2-Bax heterodimers than in
the R6-Bcl-2#9 cell line (Fig. 2B, lane a). This is best illustrated
with anti-Bcl-2 immunoprecipitates from R6-Bcl-2-Bax#9 cells
(Fig. 2B, lane e) where Bcl-2 formed heterodimers with both
overexpressed human 24-kDa Bax and endogenous rat 21-kDa
Bax (compare Fig. 2, panel A, lane c, with panel B, lane e).
Again, less than 20% of the overexpressed human Bax re-
mained in the supernatant after an anti-Bcl-2 immunoprecipi-
tation, indicating that most of the human Bax was complexed
to and co-precipitated by Bcl-2 (Fig. 2C). Similarly, when com-
paring anti-human Bax (Fig. 2B, lane a) and anti-Bcl-2 (Fig.
2B, lane e) immunoprecipitates it became evident that almost
all Bcl-2 was bound to Bax in R6-Bcl-2-Bax#9 cells. This may
explain the diminished death-protection capacity of this cell
line (see below). (iii) The newly formed human Bcl-2-Bax het-
erodimers did not co-immunoprecipitate novel proteins, irre-
spective of whether anti-human Bax (Fig. 2B, compare lanes a
and b) or anti-Bcl-2 immunoprecipitates (Fig. 2B, compare
lanes e and f) were analyzed. In addition, it seemed that some
of the overexpressed human 24-kDa Bax was not bound to Bcl-2
in R6-Bcl-2-Bax#9 cells (Fig. 2B, compare lanes a and e). This
free form of Bax did not interact stably with new protein
partners either.
Taken together, our data show that Bcl-2 and Bax have a
strong affinity for each other, and neither the Bcl-2-Bax het-
erodimer nor the free Bcl-2 and Bax molecules appear to bind
stably to other cellular proteins, at least as judged from
immunoprecipitations.
Bcl-2 and Bax Co-localize in Intact Cells—To show that Bcl-2
and Bax may also be partners in intact cells, we studied the
intracellular localization of the two proteins by immunocyto-
chemistry. Equimolar amounts of human Bcl-2 and human Bax
cDNAs were transiently transfected into R6 cells. Bcl-2 was
detected with a monoclonal anti-human Bcl-2 antiserum and a
rhodamine-conjugated secondary antibody, Bax by a polyclonal
anti-human Bax antiserum and a fluorescein-conjugated sec-
ondary antibody. Bcl-2 and Bax co-localized perfectly in a punc-
tuated subcellular structure (Fig. 3A) reminiscent of mitochon-
dria (data not shown). Although this analysis does not prove
heterodimer formation of Bcl-2 and Bax in vivo, it clearly
demonstrates that the two proteins localize to the same sub-
cellular compartment.
Bcl-2-Bax Heterodimers Are Maintained, and Neither Bcl-2
nor Bax Associates Stably with New Proteins under Apoptotic
Stresses—Interactions between Bcl-2 and Bax and putative
binding proteins have so far been studied in non-apoptotic
cellular systems. It is however possible that Bcl-2 and/or Bax
acquires or loses binding partners only following cellular treat-
ments with apoptotic agents. We therefore exposed R6-pMV12
and R6-Bcl-2#9 cells to the protein kinase inhibitor staurospo-
rine (1 mM), the secretion-inhibiting drug BFA (5 mg/ml), the
proteasome inhibitor MG132 (1 mM), or the protein phosphatase
inhibitor okadaic acid (1 mM) for different time periods. Under
all of these conditions R6-pMV12 rapidly underwent apoptosis,
FIG. 2. Bcl-2 specifically co-immu-
noprecipitates with endogenous and
overexpressed Bax. Cells were labeled
with [35S]methionine/cysteine overnight,
disrupted in buffer A containing 0.2%
Nonidet P-40, and the lysate was sub-
jected to anti-Bcl-2 or anti-Bax immuno-
precipitations. Panel A, anti-Bcl-2/27-6
(a-Bcl-2 IP) or anti-mouse/rat Bax/Ab
13686E (a-Bax IP) immunoprecipitates
from R6-pMV12 (lanes a and b) and R6-
Bcl-2#9 (lanes c and d) cell extracts. Panel
B, anti-Bcl-2/27-6 (27-6 a-Bcl-2), anti-
mouse/rat Bax/Ab 13686E (a-mBax), or
anti-human Bax/Ab 13666E (a-hBax) im-
munoprecipitates from R6-pMV12 (lanes
b, d, and f) and R6-Bcl-2-Bax#9 (lanes a, c,
and e) cell extracts. Arrows indicate the
positions of the overexpressed 26-kDa
mouse Bcl-2, the overexpressed 24-kDa
human Bax, and the endogenous 21-kDa
rat Bax. The major, co-precipitating 45-
kDa protein is actin (closed circles). Panel
C, left panel, equal amounts of unlabeled
R6-Bcl-2#9 cell extracts were probed with
anti-mouse/rat Bax/Ab13868E on West-
ern blots (a-mBax) for the presence of en-
dogenous rat Bax (rBax) before and after
anti-Bcl-2/27-6 immunoprecipitation; right
panel, same experiment but using anti-
human Bax/Ab 13666E (a-hBax) to mon-
itor extracts of R6-Bcl-2-Bax#9 cells for
the presence of overexpressed human Bax
(hBax).
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whereas R6-Bcl-2#9 cells were protected efficiently for up to
48–72 h (see Figs. 7C and 8C, and data not shown).
We first investigated Bcl-2 binding properties at early time
points (10–60 min) of a cellular exposure to staurosporine. The
amounts of free and heterodimerized Bcl-2 and Bax proteins
were not altered in anti-Bcl-2 immunoprecipitates from
stressed R6-Bcl-2#9 cells, nor was any new protein partner of
Bcl-2 detected under these conditions (Fig. 4A). This was also
true for cell extracts from R6-Bcl-2#9 cells stressed for up to
48 h with staurosporine irrespective of the presence of absence
of phosphatase inhibitors in the extraction and immunoprecipi-
tation buffers (Fig. 4B). Similar results were obtained with the
apoptotic stimuli MG132, okadaic acid, or BFA (data not
shown).
Next, we tested if Bax bound a novel protein following a
treatment of cells with apoptotic agents. It has been reported
recently that Bax formed disulfide-linked homodimers in re-
sponse to the apoptotic agent camptothecin (58). We therefore
analyzed anti-Bax immunoprecipitates in the presence or ab-
sence of the reducing agent DTT. We did not detect any Bax
homodimer formation nor the interaction of new proteins with
Bax in anti-Bax immunoprecipitates from R6-pMV12 cells
stressed with staurosporine or BFA for up to 48 h (Fig. 5).
Moreover, anti-Bax immunoprecipitates from stressed R6-Bcl-
2#9 cells revealed that Bax still interacted with Bcl-2 in an
equimolar ratio (Fig. 5). Occasionally, higher levels of proteins
at 55 and 75 kDa were detected in anti-Bax immunoprecipi-
tates of staurosporine or BFA-treated compared with non-
treated cell extracts (Fig. 5, filled and open circles). This how-
ever varied between different experiments and occurred in
R6-pMV12 and R6-Bcl-2#9 cells, excluding the possibility that
these proteins were real Bax-binding proteins released in the
presence of Bcl-2. Thus, as judged from immunoprecipitations,
the only consistent and firm partner of Bax during apoptotic
stresses appeared to be Bcl-2. Indeed, immunofluorescence
analysis showed that Bcl-2 and Bax still co-localized to a punc-
tuated subcellular site in intact cells after an apoptotic stress
with 5 mg/ml BFA for 22 h (Fig. 3B).
FIG. 3. Bcl-2 and Bax co-localize in intact normal cells and
cells exposed to BFA. R6 cells on 12-mm glass coverslips were trans-
fected with human Bcl-2 and human Bax cDNAs as described under
“Experimental Procedures.” After 6 h, the cells were incubated with
fresh medium in the absence (unstressed) or presence (BFA) of 5 mg/ml
BFA and left for another 22 h. 28 h post-transfection, the cells were
fixed, permeabilized, incubated with the anti-human Bcl-2 antibody,
clone 100 (a-Bcl-2), and the anti-Bax antibody Ab 06-499 (a-Bax) and
then with secondary rhodamine-conjugated (a-Bcl-2) and fluorescein-
conjugated (a-Bax) antibodies. Photographs were taken under a Zeiss
fluorescence microscope at a magnification of 3 1,000. FIG. 4. Stable Bcl-2-Bax heterodimers in anti-Bcl-2 immuno-
precipitates from cells exposed to staurosporine. R6-pMV12 and
R6-Bcl-2#9 cells were labeled with [35S]methionine/cysteine overnight.
10–60 min (panel A) or 48 h (panel B) before extraction, the cells were
treated with 1 mM staurosporine. Cell disruption was in buffer A plus
0.2% Nonidet P-40 in the presence or absence of phosphatase inhibitors
(6PhI). Immunoprecipitations were performed with and without phos-
phatase inhibitors using the anti-Bcl-2/27-6 antibody. The positions of
endogenous Bax and overexpressed Bcl-2 are indicated by arrows. The
major 45-kDa protein that co-precipitates in the presence of the phos-
phatase inhibitors is actin (closed circle).
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Cell Death Protection by Bcl-2 Does Not Require Bax and Is
Most Effective When Bcl-2 Is in Excess of Bax—The stability of
the Bcl-2-Bax heterodimer in immunoprecipitates from cells
exposed to apoptotic stimuli suggested that Bcl-2 may require
Bax for its death-protection activity. To investigate this issue
further, we (i) down-regulated endogenous Bax expression in
R6-Bcl-2#9 cells by an antisense Bax strategy and (ii) gener-
ated R6 cell lines that expressed various levels of Bcl-2 and
Bax. All cells were monitored for their survival capacity in
response to the apoptotic agents staurosporine and MG132.
Transfection of R6-Bcl-2#9 cells with a 20-mer antisense Bax
phosphorothioate oligonucleotide encompassing the ATG start
codon of rat Bax led to a time-dependent decrease of endoge-
nous Bax expression (Fig. 6A). This was complete after 3 days
and persisted for another 2 days (Fig. 6A and data not shown).
A sense Bax oligonucleotide encompassing the same sequence
did not affect endogenous Bax expression (Fig. 6A). When
sense-transfected and antisense-transfected R6-Bcl-2#9 cells
were compared for their capacity to resist staurosporine- or
MG132-induced apoptosis, no difference was detected over a
period of 24 h when Bax was down-regulated entirely (between
day 3 and 4 post-transfection) (Fig. 6B). These results indicate
that Bcl-2 can act as a survival factor in the absence of Bax
expression.
To study whether the survival activity of Bcl-2 was directly
proportional to its expression level, we constructed R6 cell lines
that expressed the 26-kDa Bcl-2 and/or the 27-kDa Flag-Bcl-2
protein at low (R6-Flag-Bcl-2#15), intermediate (R6-Bcl-2#5),
or high levels (R6-Bcl-2#9, R6-Flag-Bcl-2mix, R6-Bcl-2/Flag-
Bcl-2#7) (Fig. 7A). Importantly, Flag-Bcl-2 protected cells
against apoptosis as efficiently as Bcl-2 when expressed at
similar levels (data not shown). In addition, human 24-kDa
Bax protein was expressed at low (R6-Bcl-2-Bax#1) and high
amounts (R6-Bcl-2-Bax#9) in the R6-Bcl-2#9 cell line to study
the effect of exogenous Bax on death protection by Bcl-2
(Fig. 8A).
Similar amounts of endogenous Bax were co-immunoprecipi-
tated with anti-Bcl-2 antibodies from the extracts of the vari-
ous Bcl-2-overexpressing cell lines (Fig. 7B), indicating that all
of these cells had the endogenous Bax complexed to Bcl-2 and
differed in the amount of the Bcl-2 protein that was free of Bax.
FIG. 5. Stable Bcl-2-Bax heterodimers in anti-Bax immunopre-
cipitates from cells exposed to staurosporine or BFA. R6-pMV12
and R6-Bcl-2#9 cells were labeled with [35S]methionine/cysteine over-
night. 48 h before extraction, the cells were treated with 1 mM stauro-
sporine or 5 mg/ml BFA. Cell disruption was in buffer A plus 0.2%
Nonidet P-40. Immunoprecipitations were performed using the anti-
mouse Bax antibody 13686E. Immunocomplexes were denatured in
SDS-sample buffer in the presence or absence of 30 mM DTT. The
positions of endogenous Bax and overexpressed Bcl-2 are indicated by
arrows. Filled and open circles mark 55- and 75-kDa proteins that
occasionally co-immunoprecipitate with Bax. This, however, varied
among different experiments and occurred in R6-pMV12 and R6-Bcl-
2#9 cells, excluding the possibility that these proteins were real Bax-
binding proteins released in the presence of Bcl-2.
FIG. 6. Bcl-2 does not require Bax expression for its death-
protective activity. R6-Bcl-2#9 cells were transfected with a 1 mM
concentration of the antisense (a-sense) or sense phosphorothioate Bax
oligonucleotide 1–20 using Lipofectin. Control cells (Ctrl) received only
Lipofectin. Panel A, every day total cell extracts were prepared and
analyzed for endogenous Bax expression by anti-Bax Western blotting
(Ab 06-499). Panel B, at day 3 post-transfection, antisense (E)- and
sense-transfected R6-Bcl-2#9 (l as well as R6-pMV12 vector control
cells (M) were treated with 1 mM staurosporine or 1 mM MG132 for 24 h.
Cell viability was monitored by counting trypan blue-excluded cells in a
Neubauer chamber. The displayed cell counts are the means of three
independent experiments.
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As judged from anti-Bcl-2 immunoprecipitates (Fig. 7B), the
level of free Bcl-2 correlated positively with the degree of death
protection against apoptosis induced by MG132 (Fig. 7C).
Whereas R6-FLAG-Bcl-2#15 cells only slightly resisted apo-
ptosis, this was enhanced in R6-Bcl-2#5 and best in R6-Bcl-2#9
and R6-Bcl-2/Flag-Bcl-2#7 cells (Fig. 7C). Conversely, the ex-
pression of exogenous human Bax resensitized R6-Bcl-2#9 cells
for MG132- or staurosporine-induced apoptosis in a dose-de-
pendent manner (Fig. 8C). This was accompanied by the ap-
pearance of more Bcl-2-Bax heterodimers in both anti-Bcl-2
and anti-Bax immunoprecipitates of R6-Bcl-2-Bax#9 compared
with R6-Bcl-2#9 cells (Fig. 8B), suggesting that the Bcl-2-Bax
heterodimer neutralized rather than favored the death-protec-
tive activity of Bcl-2. The resensitization was somehow smaller
with the R6-Bcl-2-Bax#1 cell line (Fig. 8C) because less human
Bax was overexpressed (Fig. 8A) and/or co-precipitated in anti-
Bcl-2 immunoprecipitates compared with the R6-Bcl-2-Bax#9
cell line (data not shown).
DISCUSSION
To our knowledge this is the first study describing the bind-
ing properties, subcellular localizations, and biological activi-
ties of Bcl-2 and Bax in cells exposed to apoptotic stimuli. It
shows that (i) Bcl-2 and Bax co-localize to the same subcellular
compartment and form strong, equimolar heterodimers under
both normal and apoptotic conditions; (ii) the protection
against apoptosis does not necessitate Bax expression and cor-
relates with the amount of the Bcl-2 protein that is free of Bax;
and (iii) no other cellular protein associates stably with Bcl-2,
Bax, or the Bcl-2-Bax heterodimer in anti-Bcl-2 or anti-Bax
immunoprecipitates.
The conditions used for cell fractionations and immunopre-
cipitations were as physiological as possible (143 mM KCl, pH
7.5). However, because both Bcl-2 and Bax are integral mem-
brane proteins they had to be solubilized in 0.2% Nonidet P-40.
Although such a treatment might disrupt protein-protein in-
teractions, several membrane complexes including Bcl-2-Bax
have been isolated previously in the presence of 0.2–1% non-
ionic detergent (50, 56). In addition, it has been reported re-
cently that non-ionic detergents promoted rather than dis-
rupted dimerizations among members of the Bcl-2 family (59).
Disruption of the Bcl-2-Bax complex, however, occurred when
0.5% deoxycholate and/or 0.1% SDS (RIPA buffer conditions)
were added, suggesting an intermediate binding affinity be-
tween the two proteins (Ref. 50 and data not shown). Since we
did not detect any Bcl-2-binding protein under the stringent
RIPA buffer conditions, no cellular protein seems to bind stron-
ger to Bcl-2 than Bax and vice versa.
There was no obvious reason why proteins with an affinity
similar to Bax would not have been co-immunoprecipitated
with anti-Bcl-2 antibodies, especially in cells where a high
FIG. 7. Protection against apoptosis induced by MG132 positively correlates with the amount of Bcl-2 free of Bax. Panel A,
unlabeled, total protein extracts of vector control R6-pMV12, Flag-Bcl-2 overexpressing R6-Flag-Bcl-2#15 and R6-Flag-Bcl-2mix, Bcl-2 overex-
pressing R6-Bcl-2#5 and R6-Bcl-2#9, and Bcl-2/Flag-Bcl-2 co-overexpressing R6-Bcl-2/Flag-Bcl-2#7 cells were analyzed by anti-Bcl-2/27-6 Western
blotting (WB) followed by quantifying the expression levels of the 26-kDa Bcl-2 (closed circle) and the 27-kDa Flag-Bcl-2 (open circle) by
densitometric scanning of the ECL autoradiographs (OD). Each OD value represents the sum of the intensities obtained from Bcl-2 and Flag-Bcl-2.
Panel B, [35S]methionine/cysteine-labeled buffer A and 0.2% Nonidet P-40 protein extracts of the various cell derivatives were subjected to
anti-Bcl-2/27-6 immunoprecipitations. The positions of the endogenous 21-kDa rat Bax and the overexpressed 26-kDa Bcl-2 and 27-kDa Flag-Bcl-2
are indicated. Panel C, subconfluent cell derivatives were treated with 1 mM MG132 for 4 days, and each day the cell viability was determined by
trypan blue exclusion or the LIVE/DEAD kit. The data are the means of six independent experiments. f, pMV12; , Bcl-2#5; E, Flag-Bcl-2mix;
, Flag-Bcl-2#15; l, Bcl-2#9; M, Bcl-2/Flag-Bcl-2#7.
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amount of the Bcl-2 protein was accessible, i.e. free of Bax
(R6-Bcl-2#9). Interference by the antibodies used was consid-
ered minimal as both the anti-Bcl-2 antibody 27-6 and the
anti-Flag antibody detect epitopes outside of the BH1–4 do-
mains essential for the survival activity of Bcl-2 (26, 57). In
addition, we have reported recently that Bax was the only
cellular protein that was specifically retained by a GST-Bcl-2
affinity column incubated with radiolabeled extracts from non-
stressed or apoptotically stressed cells, although this method
was antibody-independent (44).
Compared with other binding techniques (yeast two-hybrid,
interaction cloning) co-immunoprecipitation is the method of
choice if one wants to study protein-protein interactions that
may only occur in response to cellular treatments with apo-
ptotic stimuli. However, the following disadvantages should be
considered. First, proteins that bind transiently or with low
affinities are difficult to co-immmunoprecipitate. Although we
tried to optimize buffer conditions for extraction and/or immu-
noprecipitation, complexes of Bcl-2 or Bax with other cellular
proteins may not have been maintained after cell disruption.
To overcome this problem we lysed cells by repeated freeze-
thawing cycles and added the bifunctional cross-linker dithio-
bis(succinimidylpropionate) to the extract before solubilization
in detergent. However, even under these conditions no addi-
tional Bcl-2-binding proteins were found (data not shown).
Second, the binding between Bcl-2 and its partners may depend
on post-translational modifications. It has been reported pre-
viously that the binding of Bcl-2 to c-Raf-1 and/or Ras is phos-
phorylation-sensitive (35, 60). Moreover, Bax was shown to
form disulfide-linked dimers in response to chemotherapeutic
drugs (58). However, the absence or presence of phosphatase
inhibitors or DTT had only a minor effect on the protein pattern
in our immunoprecipitates, and no disulfide-linked Bax ho-
modimers were found. Third, the binding partners of Bcl-2
and/or Bax may not be sufficiently abundant to be detected by
immunoprecipitations because they exhibit a high turnover
rate. We have recently obtained evidence for the involvement of
short lived proteins in apoptosis induced by decreased ubiquiti-
nation (61). Fourth, the binding proteins may not contain
enough methionine and/or cysteine residues to be radiolabeled
and detected on autoradiographs after immunoprecipitation
(for example, heat shock protein 27; Ref. 62). This issue is
currently being addressed by labeling cellular proteins with
other amino acids or detecting them in immunoprecipitates by
silver staining.
It was surprising that none of the previously reported Bcl-2-
binding proteins was detected in our anti-Bcl-2 immunoprecipi-
tates (31–43, 60). Interestingly, with the notably exception of
Bax (50), all so far known Bcl-2-binding proteins have been
isolated by interaction cloning or yeast two hybrid techniques
(31–43) and have not yet been shown to bind to Bcl-2 at en-
dogenous expression levels. By contrast, interactions of these
proteins with Bcl-2 were detected readily when they were
mixed as recombinant proteins in vitro or immunoprecipitated
following forced co-overexpressions in mammalian, insect, or
yeast cells (31–43, 60). Although such experiments provide
FIG. 8. Overexpression of Bax resensitizes Bcl-2 overexpressing cells for apoptosis induced by MG132 or staurosporine. Panel A,
unlabeled, total protein extracts of Bcl-2 overexpressing R6-Bcl-2#9 and Bcl-2-Bax co-overexpressing R6-Bcl-2-Bax#1 and R6-Bcl-2-Bax#9 cells
were analyzed by anti-Bax/Ab 06-499 Western blotting (WB) followed by quantifying the expression levels of the endogenous 21-kDa rat Bax (closed
circle) and the overexpressed 24-kDa human Bax (open circle) by densitometric scanning of the ECL autoradiographs (OD). Each OD value
represents the sum of the intensities obtained from the two Bax species. Panel B, [35S]methionine/cysteine-labeled buffer A/0.2% Nonidet P-40
protein extracts of the various cell derivatives were subjected to anti-Bcl-2/27-6 (a-Bcl-2-IP), anti-Bax/Ab 13686E (a-mBax-IP), or anti-Bax/Ab
13666E (a-hBax-IP) immunoprecipitations. The positions of the endogenous 21-kDa rat Bax (mBax), the overexpressed 24-kDa human Bax, and
the 26-kDa mouse Bcl-2 are indicated. Panel C, subconfluent cell derivatives were treated with 1 mM MG132 or 1 mM staurosporine for 4 days, and
each day the cell viability was determined by trypan blue exclusion or the LIVE/DEAD kit. The data are the means of six independent experiments.
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first clues as to whether a given protein-protein interaction is
possible at all, they increase the chances of nonspecific inter-
actions and should therefore be accompanied by analyses under
physiological conditions. This might be especially important for
proteins that have been reported to bind to the NH2-terminal
BH4 region of Bcl-2, such as c-Raf-1, BAG-1, and calcineurin
(34–37, 42). Recent molecular modeling has shown that this
region can adopt a helical conformation that contains five hy-
drophobic amino acids clustered on one surface of the helix (63).
Thus, protein binding to the BH4 of Bcl-2 may be based on
nonspecific hydrophobic interactions that confer to Bcl-2 the
“stickiness” that has been suggested previously (64).
Based on site-directed mutagenesis studies it has remained
controversial whether Bcl-2 requires Bax for its death-protec-
tive function (51). By using an antisense Bax strategy and
increasing the amount of exogenous Bax in Bcl-2-overexpress-
ing cells, we show here that Bcl-2 exerts its survival function
independent of Bax and that higher levels of Bcl-2-Bax het-
erodimers diminish rather than enhance the death-protective
capacity of Bcl-2. The same result has been obtained recently
from studying the activities of Bcl-2 and Bax in Bax and/or
Bcl-2 knock-out mice (65). We also find that the degree of
Bcl-2-Bax heterodimer formation depends on the expression
levels of each partner in unstressed cells. This in turn dictates
the amount of Bcl-2 that will be available to protect the cell
once it is exposed to apoptotic stimuli. Thus, our data favor a
model in which putative effectors of Bcl-2 do not disrupt Bcl-
2-Bax heterodimers but bind to and/or modulate the activity of
Bcl-2 that is free of Bax.
How might Bcl-2 and Bax regulate apoptosis in the absence
of a stable interaction with other cellular proteins? Bcl-2 and/or
Bax may be enzymes that bind to proteins or other substrates
crucial for death or survival in a transient fashion. Alterna-
tively, Bcl-2 and/or Bax may interact with small peptides or
non-proteaceous molecules such as lipids that are difficult to be
detected by SDS-PAGE. In this regard it is worth noting that
Bcl-2 protects cells from apoptosis induced by membrane-per-
meable ceramide analogs (17, 18), presumably by preventing
these analogs from activating the death effector machinery
(caspase 3 activation) (66). Studies are in progress to investi-
gate whether Bcl-2 binds directly to ceramide. Finally, Bcl-2
and/or Bax may form homodimers or oligomers on intracellular
membranes. It has been reported that Bcl-2 can homodimerize
in vitro in the yeast two-hybrid system as well as in immuno-
precipitates (50, 51, 67, 68). Site-directed mutagenesis revealed
that the dimers are formed in a head-to-tail fashion and involve
the same domains that are crucial for the survival activity of
Bcl-2 (BH4 interacts with BH1/BH2) (9, 51, 67, 68). The head-
to-tail arrangement would allow Bcl-2 to form multimers, al-
though such structures have not yet been detected biochemi-
cally. Homodimers or multimers of Bcl-2 or Bax could create
ion channels that maintain the correct ion permeability during
apoptotic stresses. In fact, the three-dimensional structure of
the Bcl-2 homolog Bcl-xL resembles that of pore-forming bac-
terial toxins diphtheria toxin and colicin (26), and purified
Bcl-xL (27) and Bcl-2 (69) reconstituted in a synthetic phospho-
lipid bilayer generate ion fluxes in the absence of any other
cellular protein. However, it remains to be determined whether
Bcl-xL, Bcl-2, or Bax indeed forms ion channels on biological
membranes under physiological conditions and whether ho-
modimerizations or multimerizations play a role in this re-
spect. Further studies are required to validate the proposed
concepts, in particular to determine the kind of effector mole-
cules, if any, which mediate the biologic activities of Bcl-2 and
Bax.
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Slimb-mediated proteolysis and accumulate to high levels. For
example, Ci and Arm may normally be phosphorylated by PKA
and glycogen synthase kinase 3 (GSK3; reviewed in refs 5, 17), and
signalling by Hh and Arm may change the state or degree of their
phosphorylation, blocking their ability to interact with Slimb.
Slimb has ,80% amino-acid identity to b-TRCP, a Xenopus
protein of unknown function25. In Xenopus and mammalian cells,
b-catenin, a homologue of Drosophila Arm, seems to be targeted for
degradation by the ubiquitin/proteasome pathway in the absence of
Wg/Wnt signalling26,27. Hence, the close structural homology
between b-TRCP and Slimb raises the possibility that the two
proteins have a conserved role in destabilizing Arm/b-catenin.
Mutations in other genes which allow b-catenin to escape from
degradation are associated with a wide range of metastatic
disorders28. We therefore speculate that mammalian homologues
of slimb may be tumour-suppressor genes. M
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Methods
Mutations and transgenes. slmb1 and slmb2 are EMS-induced mutations
isolated from a screen for mutations that cause abnormal adult patterns in
somatic clones10. slmb1 and slmb2 are lethal in trans to each other and in trans to
deficiency Df(3R)3-R1, which eliminates the chromosome interval 93B3-5 to
93D2-4. slmb1/slmb2 and slmb1/Df(3R)3-R1 animals survive to the pupal stage;
imaginal discs isolated from slmb1/slmb2 larvae show ectopic Dpp and Wg
expression as well as high levels of Ci and excessive proliferation in anterior
compartment cells. slmb2/Df(3R)3-R1 animals die during early larval life.
slmbP1493 is a P-element insertion mutation at cytological position 93B10-11,
originally called l(3)00295. slmbP1493 behaves like Df(3R)3-R1 in complementa-
tion tests with slmb1 and slmb2, resulting in pupal and early larval lethality,
respectively. Wild-type function can be restored by precise P-element excision.
The smo3, dppd12 and PKA- mutations, as well as the dpp-lacZ3.0 and ci-lacZ
reporter genes, have been described10,11,29. Tuba1-slmb is a transgene containing
the entire slimb ORF under the control of the constitutive Tubulina1
promoter11 inserted on the left arm of the second chromosome (see below).
hsp70-Myc-tagged GFP is a transgene containing the coding sequence for a
Myc-tagged form of green fluorescent protein (GFP) under the control of the
heat-shock inducible promoter of the hsp70 gene (A. Adachi and G. Struhl,
unpublished).
Cloning of slimb. The genomic DNA sequence flanking the insertion site of
slmbP1493 was isolated by plasmid rescue and used as a probe to screen an
ovarian cDNA library. A full-length sequence for the slimb ORF was assembled
from several partial cDNA clones. The identity of the slimb ORF is verified by
rescue experiments: slmb2 or slmbP1493 homozygotes as well as slmb1/slmb2
heterozygotes that carry a single copy of Tuba1-slmb transgene are viable and
show normal morphology, except that 5–10% of the adults exhibit duplications
of the haltere.
Generating clones of marked mutant cells. Clones of mutant cells were
generated by FLP/FRT-mediated mitotic recombination as described10. Geno-
types for generating clones are as follows. slmb mutant clones: y hsp-flp.1/y or Y;
FRT82E slmb1,2 or P1493/FRT82E hsp-CD2, y+ (or hsp70-myc-gfp, w+) with or
without dpp-lacZ 3.0 on the second chromosome. slmb dpp clones: y hsp-flp.1/y
or Y; dppd12 stc FRT 39E/Tuba1-slmb FRT39E; slmb1/slmb2. slmb smo mutant
clones: y hsp-flp.1/y or Y; smo3 stc FRT 39E/Tuba1-slimb FRT39E; slmb1/slmb2.
Imaginal disc staining and western blot analysis. Standard protocols for
immunofluorescence and immunohistochemistry of imaginal discs were
used10. Western blot analysis was performed as described4.
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Following exposure of cells to stimuli that trigger programmed
cell death (apoptosis), cytochrome c is rapidly released from
mitochondria into the cytoplasm where it activates proteolytic
molecules known as caspases that specifically cleave the amino-
acid sequence DEVD and are crucial for the execution of apopto-
sis1–4. The protein Bcl-2 interferes with this activation of caspases
by preventing the release of cytochrome c2–4. Here we study these
molecular interactions during apoptosis induced by the protein
Bax, a pro-apoptotic homologue of Bcl-2 (refs 5, 6). We show that
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in cells transiently transfected with bax, Bax localizes to mito-
chondria and induces the release of cytochrome c, activation of
caspase-3, membrane blebbing, nuclear fragmentation, and cell
death. Caspase inibitors do not affect Bax-induced cytochrome c
release but block caspase-3 activation and nuclear fragmentation.
Unexpectedly, Bcl-2 also fails to prevent Bax-induced cytochrome
c release, although it co-localizes with Bax to mitochondria. Cells
overexpressing both Bcl-2 and Bax show no signs of caspase
activation and survive with significant amounts of cytochrome c
in the cytoplasm. These findings indicate that Bcl-2 can interfere
with Bax killing downstream of and independently of cytochrome
c release.
Rat (R6) embryo fibroblasts and human SK2 melanoma trans-
fected with bax were monitored for Bax expression and cytochrome
c release by immunocytochemistry and for nuclear condensation/
fragmentation by Hoechst staining. Immunostaining of endogen-
ous rat Bax was filamentous (Fig. 1a), whereas that of transfected
human Bax was punctuated (Fig. 1c, e). However, both forms of Bax
Figure 1 Bax co-localizes with mitochondrial cytochrome c oxidase VIc (COX)
and Bcl-2. Anti-Bax (a, c, e), anti-COX (b, d) and anti-Bcl-2 (f) immunocytochemical
analysis on non-transfected (a, b), bax-transfected (c, d) and bax/bcl-2-
transfected (e, f) R6 cells at 8 h post-transfection. Magnification, · 1,000.
Figure 2 Quantification of ectopic Bax expression, cytosolic cytochrome c and
fragmentednuclei following bax transfection into R6 and SK2 cells. The cells were
transfected with bax (black bars) in the absence or presence of Z-DEVD-fmk
(hatched bars) or co-transfected with bax and bcl-2 (white bars) and subjected to
anti-Bax, anti-cytochrome c and Hoechst 33342 analysis at various times post-
transfection as for Fig. 3. The percentages of cells displaying punctuated Bax (a),
diffuse cytochrome c (b) or fragmented nuclei (c) was determined by counting
fluorescent cells on 20 randomly selected fields under the microscope. 100%
represents total cells of the respective fluorescence per field. Data are depicted
as means 6 s:d: from two independent transfections into R6 and SK2 cells,
respectively (total of 80 fields analysed).
Figure 3 Bax induces cytochrome c release irrespective of Bcl-2 inhibition. Anti-
Bax (rhodamine), anti-cytochrome c (fluorescein) and Hoechst 33342 (UV)
fluorescence analysis on bax-transfected (a) and bax/bcl-2-transfected (b) R6
cells at 8 h post-transfection. Hoechst-stained aggregates around the nuclei are
DNA/Superfect complexes that could not be entirely removed after transfection.
Magnification, · 1,000.
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co-localized with the mitochondrial cytochrome c oxidase subunit
VIc (COX) (Fig. 1b, d), indicating that ectopic Bax changed the
mitochondrial morphology from a filamentous to a punctuated
pattern. This change was specific for Bax overexpression as it
occurred in only 0.1% of non-transfected cells (data not shown).
The strong anti-Bax immunostaining allowed cells overexpressing
Bax to be counted by fluorescence microscopy. At 6 h post-transfection,
about 15% of total cells were positive for ectopic Bax (Fig. 2a). This
number increased to 35% at 8 h post-transfection but decreased
thereafter because of cell loss by apoptosis (Fig. 2a).
We next studied the fate of cytochrome c in bax-transfected R6
and SK2 cells. The immunostaining of cytochrome c was filamen-
tous in non-transfectants but was diffuse in cells expressing punc-
tuated Bax, suggesting that ectopic Bax may have provoked a
redistribution of cytochrome c from the mitochondria to the
cytoplasm (Fig. 3a). Cells displaying diffuse cytochrome c staining
were all apoptotic because their nuclei were condensed and/or
fragmented (Figs 2b, c and 3a). To study the role of caspases in
this type of cell death, we treated bax transfectants with cell-
permeable caspase inhibitors, Z-DEVD-fmk (Fig. 2) or Z-VAD-
fmk (data not shown). As shown in Fig. 2, such treatments
prolonged the survival of cells overexpressing Bax after release of
cytochrome c. The nuclei of these cells were not fragmented but
remained condensed, and all cells were detached from the coverslip
at 36 h post-transfection (Fig. 2). These results indicate that caspases
act downstream of cytochrome c to trigger Bax-induced nuclear
fragmentation, but that there is a pathway to cell death that cannot
be blocked by caspase inhibitors.
To confirm our results, we transfected human bax into HEK 293T
cells. Owing to the very high efficiency of transfection, these cells
allowed a biochemical analysis of caspase-3 activation and DNA
fragmentation. Transfectants were identified by X-Gal blue staining
following co-transfection with bax and b-galactosidase (b-gal) as
previously described7. Apoptotic cells were round and blebbing,
whereas surviving cells were elongated in shape (Fig. 4a). Between 6
and 10 h post-transfection, elongated blue cells (Fig. 4b, white bars)
showed increased blebbing (Fig. 4b, black bars) and were shedded
into the medium. Thus, only a few blue cells remained attached to
the plate by 16 h post-transfection (Fig. 4b). Western blot analysis
revealed that between 6 and 10 h post-transfection, 20–40% of total
cytochrome c was redistributed from a membrane to a soluble
fraction (Fig. 4c). This coincided with the conversion of the inactive
32K pro-caspase-3 into the active 17K protease (Fig. 4d) and was
followed by the appearance of nucleosome-sized DNA fragments at
8–16 h post-transfection (Fig. 4e). At 16–24 h post-transfection,
cytosolic cytochrome c, p17 caspase-3, and DNA fragments had all
completely disappeared, presumably because apoptotic cells were
lost (Fig. 4c–e). Again, the caspase inhibitors Z-DEVD-fmk (Fig.
4c–e) and Z-VAD-fmk (data not shown) did not inhibit cyto-
chrome c release but blocked both caspase-3 activation and DNA
fragmentation. Thus, a large number of blue cells still adhered to the
plate (Fig. 4b) and expressed cytosolic levels of cytochrome c at 16 h
post-transfection (Fig. 4c). Most of these cells displayed a blebbing
phenotype (Fig. 4b, filled bars), however, and shedded off the plate
later on, confirming that caspase inhibitors can delay but not
prevent Bax-induced cytoxocity.
Bcl-2 interacts with Bax and blocks Bax-induced apoptosis5,6. We
therefore co-transfected equal amounts of bcl-2 and bax into R6 and
SK2 cells and studied the effect of Bcl-2 on Bax-induced cytochrome
c release, caspase activation and nuclear fragmentation. As pre-
viously seen with Bax and mitochondrial COX (Fig. 1c, d), Bcl-2
and Bax co-immunolocalized in a punctuated pattern (Fig. 1e, f),
indicating that overexpressed Bcl-2 encountered Bax on the mito-
chondria. Consistent with this, Bcl-2 and Bax co-immunoprecipi-
tated from radiolabelled extracts of cells that stably overexpressed
Bcl-2 and Bax8. At any time post-transfection, Bcl-2 coexpression
increased the number of cells positive for punctuated, ectopic Bax
Figure 4 Apoptotic morphology, cytochrome c release, caspase-3 activation and
DNA fragmentation in response to Baxor Bax/Bcl-2 expression in HEK 293Tcells.
At various times after transfection with bax/b-gal or bax/bcl-2/b-gal in the
presence or absence of Z-DEVD-fmk, 293T cells were stained with X-Gal and
counted, or disrupted and analysed for cytochrome c expression, caspase-3
activation and DNA fragmentation as described in Methods. a, Blue-stained, bax-
transfected 293Tcells are round and blebbing (left), whereas the respective bax/
bcl-2-transfectants show an intact, elongated morphology (right). Pictures were
taken at 10 h post-transfection. b, Quantification of blue cells with blebbing and
with normal morphology. The percentage of blebbing blue cells per plate (out of
total cells) are represented by filled bars (black for bax transfectants, hatched for
bax transfectants with Z-DEVD-fmk, shaded for bax/bcl-2 co-transfectants);
results for the respective normal blue cells are represented by white bars. The
data are means 6 s:d: from 20 field countings of three independent transfections.
c, Anti-cytochrome c immunoblot of cytosolic and membrane fractions. d, Anti-
caspase-3 immunoblot of total protein. The positions of the inactive 32K pro-form
and the active 17K form are indicated by arrows. e, DNA fragmentation analysis.
hpt, Hours post-transfection.
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(Fig. 2a), and the nuclei of these cells were not fragmented (Figs 2c,
3b). Some of the bax/bcl-2 co-transfectants even survived for 36 h
(Fig. 2a). Unexpectedly, however, Bcl-2 was incapable of blocking
Bax-induced cytochrome c release because all cells overexpressing
Bax displayed a diffuse immunostaining of cytochrome c (Figs 2b,
3b). Western blot analysis of extracts from HEK 293T cells co-
transfected with bcl-2 and bax confirmed that significant levels of
cytochrome c remained in the cytoplasm for up to 36 h (Fig. 4c).
Both caspase-3 activation and DNA fragmentation were blocked
and only a few blebbing cells were detected after X-Gal staining of
bcl-2/bax/b-gal triple transfectants at any time post-transfection
(Fig. 4a–e). Even at 36 h post-transfection, we still noted blue
adherent 293T cells with an intact, elongated morphology
(Fig. 4b). Thus, Bcl-2 can act after cytochrome c release to
prevent Bax-induced caspase-3 activation, nuclear fragmentation
and cytotoxicity.
We have shown that Bax triggers the same sequence of cellular
events as previously described for other apoptotic agents1–4: the
release of cytochrome c from mitochondria into the cytoplasm,
followed by the activation of death-effector caspases, nuclear
fragmentation and apoptosis. However, two features are different:
(1) Bax provokes a pathway to cell death not blocked by the caspase
inhibitors Z-DEVD-fmk and Z-VAD-fmk9,10, and (2) Bcl-2 seems to
have a caspase-inhibiting activity downstream or aside from cyto-
chrome c release. The latter may be due to an interaction of Bcl-2
with the cytochrome c receptor Apaf-1/CED-4 (ref. 11), a recently
identified mediator of caspase-3 activation by cytochrome c. M
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Methods
Transient transfection into R6 and SK2 cells and immunofluorescence
analysis. 5 3 104 rat R6 embryo fibroblasts or SK2 human melonoma cells
grown on glass coverslips were transfected with either 1 mg of each Bax/
pcDNA3 and pcDNA3 or Bax/pcDNA3 and Bcl-2/pcDNA3 using 10 mg of
Superfect (Qiagen) as described by the manufacturer. In some experiments,
50 mM of the caspase inhibitors Z-VAD-fmk or Z-DEVD-fmk (Bachem) were
added at the beginning and at every 12 h post-transfection. At various times
post-transfection, cells were fixed and permeabilized in 4% paraformaldehyde/
0.05% saponin containing 4 mg ml- 1 Hoechst 33342 dye (Molecular Probes) to
visualize nuclei and DNA. Cells were then treated with hamster monoclonal
anti-Bcl-2 3F11 (Pharmingen), rabbit polyclonal anti-Bax 06-499 (Upstate
Biotechnology), mouse monoclonal anti-cytochrome c 6H2.B4 (Pharmingen)
or mouse monoclonal anti-cytochrome c oxidase subunit VIc (COX) (Mole-
cular Probes) antibodies, and then incubated with rhodamine- and fluorescein-
conjugated secondary antibodies (Jackson Laboratories). The antifading agent
SlowFade (Molecular Probes) was added and cells were viewed under a Zeiss
Axiovert fluorescence microscope. Fluorescent cells were counted on 20
randomly selected fields (40–50 cells per field) under the microscope and the
number of cells positive for punctuated Bax, diffusely stained (cytosolic)
cytochrome c, and fragmented nuclei (per cent of total) were determined.
Transient transfection into HEK 293Tcells and analysis by X-Gal staining.
3 3 105 human embryonic kidney (HEK) 293T cells grown on 35-mm plastic
plates were transfected with either 1 mg each of bax/pcDNA3, b-gal/pcDNA3
and pcDNA3 or bax/pcDNA3, b-gal/pcDNA3 and bcl-2/pcDNA3 using 15 mg
Superfect. After various times, cells were stained with 5-bromo-4-chloro-3-
indoxyl-b-D-galactopyranoside (X-Gal) and examined by phase-contrast
microscopy as described7. To determine the transfection efficiency, we counted
trypsinized blue and white cells in a Neubauer chamber. To determine the
extent of apoptosis, we counted blue cells that were round and blebbing on 20
randomly selected fields under a Nikon inverted microscope at a magnification
of · 400 (phase contrast).
Protein extraction and western blotting. At 6–36 h post-transfection, HEK
293T cells were either directly lysed in a Tris/SDS buffer as described12 (total
extract) or disrupted by Dounce homogenization using buffer STE (10 mM
HEPES, pH 7.4, 1 mM EDTA, 0.25 M sucrose, 2 mg ml- 1 leupeptin, 1 mM
PMSF, 1 mg ml- 1 pepstatin), followed by ultracentrifugation to separate cytosol
and membranes. Equal amounts of protein were subjected to immunoblotting
using either mouse monoclonal anti-cytochrome c 7H8.2C12 (Pharmingen) or
rabbit polyclonal anti-caspase-3 (gift from D. Nicholson13) antibodies, followed
by horseradish peroxidase-coupled secondary antibodies (Jackson Labora-
tories) as described12. Immunodetection was by enhanced chemiluminescence
(Pierce). Cytochrome c was quantified by densitometric scanning of auto-
radiographs.
DNA fragmentation. At 6–36 h post-transfection, HEK 293T cells of a 35-mm
well were washed three times in phosphate-buffered saline and then
immediately lysed in phenol:chloroform:isoamylalcohol (25:24:1). The aqu-
eous phase containing nucleic acids was treated with RNase and loaded onto a
2% agarose gel containing ethidium bromide in order to visualize DNA
fragmentation.
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Trypanosoma brucei1 is a unicellular parasite transmitted between
African mammals by tsetse flies. T. brucei multiplies freely in the
bloodstream of many different mammals, and survives by anti-
genic variation of the main component of its surface coat, variant
surface glycoprotein (VSG)2,3. Trypanosomes take up transferrin
through a heterodimeric transferrin receptor4–9, the genes for
which are expressed in telomeric expression sites along with the
VSG gene. There are up to 20 of these expression sites per
trypanosome nucleus3,10–15, but usually only one is active at a
time. Different expression sites encode transferrin receptors that
are similar but not identical16. Here we show that these small
differences between transferrin receptors can have profound
effects on the binding affinity for transferrins from different
* Present address: Department of Molecular Cell Biology, Utrecht University, P.O. Box 80 056, 3508 TB
Utrecht, The Netherlands.
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Apoptotic crosstalk between the endoplasmic reticulum and mitochondria
controlled by Bcl-2
Ju¨rg Ha¨cki1, Lotti Egger1, Laurent Monney1,2, Se´bastien Conus1, Thierry Rosse´1, Isabelle Fellay1
and Christoph Borner*,1
1Institute of Biochemistry, University of Fribourg, Rue du Muse´e 5, CH-1700, Fribourg, Switzerland
Apoptosis involves mitochondrial steps such as the
release of the apoptogenic factor cytochrome c which
are eectively blocked by Bcl-2. Although Bcl-2 may
have a direct action on the mitochondrial membrane, it
also resides and functions on the endoplasmic reticulum
(ER), and there is increasing evidence for a role of the
ER in apoptosis regulation as well. Here we uncover a
hitherto unrecognized, apoptotic crosstalk between the
ER and mitochondria that is controlled by Bcl-2. After
triggering massive ER dilation due to an inhibition of
secretion, the drug brefeldin A (BFA) induces the release
of cytochrome c from mitochondria in a caspase-8- and
Bid-independent manner. This is followed by caspase-3
activation and DNA/nuclear fragmentation. Surprisingly,
cytochrome c release by BFA is not only blocked by
wild-type Bcl-2 but also by a Bcl-2 variant that is
exclusively targeted to the ER (Bcl-2/cb5). Similar
findings were obtained with tunicamycin, an agent
interfering with N-linked glycosylations in the secretory
system. Thus, apoptotic agents perturbing ER functions
induce a novel crosstalk between the ER and mitochon-
dria that can be interrupted by ER-based Bcl-2.
Oncogene (2000) 19, 2286 – 2295.
Keywords: apoptosis; cytochrome c; caspases; Bcl-2;
ER stress; BFA
Introduction
Apoptosis involves a subset of eector caspase
proteases (caspases-3,-6,-7) which dismantle the cell
by cleaving structural proteins essential for maintaining
nuclear and cytoplasmic architecture and enzymes
essential for repair of damaged cell components (Nun˜ez
et al., 1998; Stroh and Schulze-Ostho, 1998).
Activation of these caspases occurs via mitochondria-
independent and -dependent mechanisms. In the
former case, an adaptor protein such as FADD (Fas-
associated death domain) clusters an initiator caspase
such as caspase-8 so that the protease can autoactivate
and cleave and activate eector caspases (Ashkenazi
and Dixit, 1998; Kumar and Colussi, 1999). In the
latter case, some unknown factors or a caspase-8-
mediated cleavage and mitochondrial translocation of
the Bcl-2 homolog Bid damage mitochondria to release
cytochrome c into the cytoplasm (Green and Reed,
1998; Li et al., 1998; Luo et al., 1998). Cytochrome c
then binds to cytoplasmic Apaf-1 which recruits and
oligomerizes the initiator caspase-9 for autoactivation
and subsequent cleavage and activiation of eector
caspases (Hu et al., 1998b; Li et al., 1997; Srinivasula
et al., 1998).
The activation of eector caspases can be blocked by
anti-apoptotic members of the Bcl-2 family such as Bcl-
2 or Bcl-xL (Adams and Cory, 1998; Reed, 1998). Both
proteins reside on the outer mitochondrial membrane
where they prevent the release of cytochrome c in
response to many apoptotic stimuli (Kharbanda et al.,
1997; Kluck et al., 1997; Yang et al., 1997). The
mechanism of this interference is still unknown. On
one hand it was proposed that Bcl-2 and Bcl-xL
function as docking proteins (Reed, 1997), forming
multiprotein complexes with apoptosis regulatory
molecules including caspase activators such as Apaf-1
(Hu et al., 1998a; Pan et al., 1998) or components of
the mitochondrial permeability transition pore such as
adenine nucleotide translocator (ANT) or voltage-
dependent anion channel (VDAC) (Marzo et al.,
1998; Shimizu et al., 1999). On the other hand it was
shown that Bcl-xL is structurally homologous to pore-
forming bacterial toxins (Muchmore et al., 1996) and
can form ion channels on membranes in vitro (Minn et
al., 1997; Schendel et al., 1998). Such an activity may
maintain the ion homeostasis across the mitochondrial
membranes and thus prevent major mitochondrial
damage.
However, apart from mitochondria, Bcl-2 and Bcl-xL
associate with other cytoplasmic membranes, notably
those of the nuclear envelope and the ER (Givol et al.,
1994; Krajewski et al., 1993) raising the possibility that
they also act at extramitochondrial sites. Indeed, it was
recently reported that a Bcl-2 targeted to the ER via
the C-terminus of cytochrome b5 was capable of
blocking most, albeit not all types of apoptosis (Lee
et al., 1999; Zhu et al., 1996). It has however remained
enigmatic how Bcl-2 performs its survival function on
the ER.
Studying ER abnormalities during apoptosis has
clearly lagged behind that of mitochondria. The ER
surveys the correct folding, glycosylation and sorting of
the proteins in the secretory system (Aridor and Balch,
1999). When these processes are perturbed, two
signaling pathways can be activated; the unfolded
protein response (UPR) pathway leading to the
induction of ER chaperones such as grp78/Bip via
the C/EBP homologous transcription factor CHOP/
Gadd153 (Chapman et al., 1998; Wang et al., 1996)
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and the ER overload response (EOR) pathway leading
to the production of cytokines via the transcription
factor NFkB (Pahl and Baeuerle, 1997). Both pathways
help the cell to cope with incorrectly folded or
accumulated proteins in the ER but may also
contribute to its elimination when abnormalities
become too extensive. Consistent with this idea, both
CHOP/Gadd153 (Brenner et al., 1997; Zinszner et al.,
1998) and NFkB (Baichwal and Baeuerle, 1997) have
been implicated in apoptosis regulation. Moreover,
several ER membrane proteins have been reported
which interact with Bcl-2 family members such as Bax
inhibitor I (Xu and Reed, 1998), Bap31 (Ng et al.,
1997), calnexin (Torgler et al., 1997) and the calcium
pump SERCA (Kuo et al., 1998) although the purpose
of these interactions is yet unknown.
Even though we are getting a better picture of the
role of ER perturbations in apoptosis induction, we do
Figure 1 BFA/CHX provoked dramatic ER dilation. Electron microscopy imaging (magnification 55006) of R6 and R6-Bcl-2#9
cells non-treated or treated with BFA/CHX for 6 h. Note that at this time the BFA/CHX-treated cells display a massively
vacuolarized ER but no typical signs of apoptosis such as plasma membrane blebbing or nuclear condensation/fragmentation. Scale
bar in the lower left corner corresponds to 1 mm
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not yet know how they impinge on the apoptotic
machinery. Here we apply two apoptotic stresses that
produce aberrant protein in the secretory system;
brefeldin A (BFA), which blocks retrograde transport
of Golgi-derived vesicles, leading to a stop in secretion
and the fusion of the Golgi/ER compartments
(Chardin and McCormick, 1999; Fujiwara et al.,
1998) and tunicamycin which inhibits the first reaction
in the dolichol pathway of N-glycosylations of proteins
in the ER lumen (Olden et al., 1982; Tkacz and
Lampen, 1975). Interestingly, both stresses provoke a
release of cytochrome c before or at the time of eector
caspase-3 activation suggesting a crosstalk between the
perturbed ER and mitochondria. This crosstalk does
not involve caspase-8 mediated cleavage and/or
mitochondrial translocation of Bid, but a yet unknown,
caspase-independent mechanism. Moreover, Bcl-2 can
interrupt this crosstalk at the level of the ER and does
not need to be associated with mitochondria to fulfill
its function.
Results
When applied to various cell types in dierent doses,
BFA induced rapid cell death that was not clearly
apoptotic and dicult to monitor biochemically (data
not shown). This was probably due to the massive
accumulation of aberrant proteins in the collapsed
Golgi-ER hybrid compartment. We therefore dimin-
ished the amount of aberrant proteins by slowing down
their synthesis and subsequent transport into the ER
lumen using a low dose of cycloheximide (1 mg/ml)
(CHX) in combination with BFA. This dose of CHX
alone did not induce apoptosis within the time frame
of our experiments (data not shown).
Electron microscopy analysis showed that while
healthy, untreated rat embryo fibroblasts (R6 cells)
contained only few and small vacuoles, their treatment
with 5 mg/ml BFA and 1 mg/ml CHX led to a dramatic
vacuolarization of the ER/Golgi network (Figure 1).
This eect became visible between 4 – 6 h of the drug
treatment, at a time when the cells were still viable
(Figure 2a) and did not display typical signs of
apoptosis such as nuclear condensation (Figure 1) or
DNA fragmentation (Figure 2b). However, after 6 h of
BFA/CHX-treatment, the cells gradually died (Figure
2a) and accumulated nucleosome-sized DNA fragments
(Figure 2b). At 24 h posttreatment, up to 70% of the
cells were shrunken and had condensed and/or
fragmented nuclei (Figure 3a). In the presence of a
fivefold excess of Bcl-2 (R6-Bcl-2#9), BFA/CHX still
provoked massive ER dilation as compared to
untreated cells (Figure 1), but cell shrinkage (Figure
3a) and DNA/nuclear fragmentation (Figures 2b and
3a) were eectively blocked, and cell survival was
prolonged (Figure 2a). Similar findings were obtained
when R6 cells were exposed to tunicamycin (Figure 2a
and data not shown). These data show that ER
damaging agents kill cells by apoptosis, and that Bcl-
2 prevents the killing at a step distal to the damage.
To uncover how the perturbed ER communicates
with the apoptotic machinery, we first determined the
activation of the eector caspase-3. For that purpose,
we subjected BFA/CHX-treated cells to immunofluor-
escence analysis using an antibody specific for the
active p17 form of caspase-3. In addition, we prepared
from these cells a cytosolic extract to detect p17 on
Figure 2 BFA/CHX, tunicamycin and staurosporine induce cell
loss and DNA fragmentation blocked by wild-type and ER-
targeted Bcl-2. (a) Survival of BFA/CHX-, tunicamycin- or
staurosporine-treated R6 (open circles), R6-Bcl-2#9 (filled
squares) and R6-Bcl-2/cb5#6 cells (filled circles) as determined
by the Trypan blue assay. The data represents the microscopic
counting of 60 Neubauer fields for each cell line and are the
means of three independent experiments+s.d. (b) Agarose gel
analysis of genomic DNA from R6 and R6-Bcl-2#9 cells exposed
to BFA/CHX for 0 – 30 h
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Western blots and to measure the respective caspase
activity with the fluorogenic substrate DEVD-AMC
(Ac -Asp -Glu -Val -Asp-[7-amido-4-methylcoumarin]).
While there was a low anti-p17 immunofluorescence
Figure 3 Apoptosis induced by BFA/CHX involves cytochrome c release and caspase-3 activation blocked by wild-type and ER-
targeted Bcl-2. (a) Nuclear staining (Hoechst 33342, blue), anti-cytochrome c (red) and anti-active p17 caspase-3 (green)
immunofluorescence analysis of fixed/permeabilized R6, R6-Bcl-2#9 and R6-Bcl-2/cb5#6 cells, untreated or treated with BFA/CHX
for 24 h. (b) Anti-caspase-3 Western blot analysis of the cytosols of the cells described in (a). (c) Caspase-3 (DEVDase) activity in
the cytosols of R6 (black bars), R6-Bcl-2#9 (open bars) and R6-Bcl-2/cb5#6 (gray bars) cells treated with BFA/CHX for 0 – 24 h.
The data are the means of three independent experiments+s.d. (d) Anti-cytochrome c (7H8.2C12) Western blot analysis of the
cytosols of the various cell types exposed to BFA/CHX for 0 – 24 h
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staining of untreated R6 cells, a 24 h treatment with
BFA/CHX led to a strong diuse staining indicating
the presence of active p17 in the cytoplasm and
probably the nucleus (Figure 3a). Moreover, the
cytosolic extract of BFA/CHX-treated cells had almost
all p32 caspase-3 precursor converted into the active
p17 form (Figure 3b) and displayed a strong activity
towards the DEVD-AMC substrate (Figure 3c).
Importantly, both the formation of p17 caspase-3
(data not shown) and its associated DEVDase activity
were not significantly detected before 10 h of BFA/
CHX treatment (Figure 3c) indicating that they were a
consequence rather than a cause of ER dilation. BFA/
CHX-treated R6-Bcl-2#9 cells neither showed anti-p17
immunofluorescence staining (Figure 3a), nor the
formation of the p17 protein (Figure 3b) or DEVDase
activity (Figure 3c) in the cytoplasm at any time of the
stress period. The treatment of R6 cells with
tunicamycin resulted in a similar degree of caspase-3
activation that was fully blockable by Bcl-2 (Figure
4a). Thus, Bcl-2 protected cells from BFA/CHX- or
tunicamycin-induced apoptosis at a step between the
ER stress and caspase-3 activation.
We next tested whether BFA/CHX or tunicamycin
employed the release of cytochrome c to activate
caspase-3. In the absence of drug treatment, cytochrome
c was immunodetected in elongated, ‘spaghetti’-like-
structures typical for mitochondria in adherent R6 cells
(Figure 3a). This pattern changed to a strong, diuse
staining when the cells were treated with BFA/CHX
indicating that cytochrome c was released to the
cytoplasm (Figure 3a). Because cytochrome c release
and caspase-3 activation occurred almost simulta-
neously, it was dicult to determine the exact order of
events of apoptotic signaling. Western blot analysis
confirmed that, in response to BFA/CHX, cytochrome c
appeared in the cytoplasm almost at the same time as the
generation of active p17 caspase-3 (data not shown) and
its associated DEVDase activity (compare Figure 3c and
d). A similar finding was obtained with tunicamycin
(Figure 4a,b). These data suggest that cytochrome c
release is a signaling event between the damaged ER and
caspase-3 activation in BFA/CHX- and tunicamycin-
induced apoptosis. As Bcl-2 associates with mitochon-
drial membranes and blocks the release of cytochrome c
by many apoptotic agents, it was not surprising that R6-
Bcl-2#9 cells had cytochrome c retained in a ‘spaghetti’-
like pattern (Figure 3a) and did not show detectable
cytosolic cytochrome c on Western blots at any time
point of the BFA/CHX or tunicamycin treatments
(Figures 3d and 4b).
As Bcl-2 is widely distributed throughout the cell
(Krajewski et al., 1993) we wanted to know which
subcellular form was responsible for interfering with
cytochrome c release. Immunofluorescence analysis of
R6-Bcl-2#9 cells revealed a strong immunostaining of
Bcl-2 on the nuclear envelope and its associated
endoplasmic network (Figure 5a). This staining was
not changed when the cells were treated with BFA/
CHX so that Bcl-2 stained around the vacuolarized
ER (Figure 5a). To confirm the predominant associa-
tion of Bcl-2 with the nuclear/ER network, we
performed Western blots on subcellular fractions from
the R6-Bcl-2#9 cell line. These fractions were up to
90% pure as determined by antibodies against
organelle-specific marker proteins (lamin B1 for nuclei,
cytochrome c oxidase (COX) for mitochondria,
calnexin for ER and Lamp-1 for lysosomes) (Figure
5b). As shown in Figure 5b, most of the Bcl-2 was
found in nuclear and microsomal/ER fractions
although it was also present on mitochondria and
other membranes. Again, the treatment of R6-Bcl-2#9
cells with BFA/CHX did not much change this
subcellular distribution of Bcl-2 (Figure 5b). To see
whether ER-bound Bcl-2 could interfere with cyto-
chrome c release and caspase-3 activation, we
generated a version of Bcl-2 that had its C-terminus
exchanged for that of cytochrome b5. Such a Bcl-2/
cb5 chimera had previously been shown to target the
ER membrane and to block apoptosis in certain, but
not all cells (Lee et al., 1999; Zhu et al., 1996). A
stable R6 cell line overexpressing Bcl-2/cb5 (R6-Bcl-2/
cb5#6) showed the same nuclear/ER immunofluores-
cence staining as R6-Bcl-2#9 cells (Figure 5a).
However, the chimeric protein was absent from
mitochondria and exclusively present in nuclear and
microsomal/ER fractions (Figure 5b). When compared
to wild-type Bcl-2, Bcl-2/cb5 was as eective in
interfering with BFA/CHX- or tunicamycin-induced
caspase-3 activation (Figures 3a – c and 4a), cell
shrinkage and nuclear condensation/fragmentation
(Figure 3a) and cell death (Figure 2a). This could be
shown for multiple cell lines of the same genotype
Figure 4 Tunicamycin provokes cytochrome c release and
caspase-3 activation blocked by wild-type and ER-targeted Bcl-
2. (a) Caspase-3 (DEVDase) activity and (b) anti-cytochrome c
immunoblot analysis of the cytosols of R6 (black bars), R6-Bcl-
2#9 (open bars) and R6-Bcl-2/cb5#6 (gray bars) cells treated with
tunicamycin for 0 – 24 h. In certain cases, 100 mM Z-VAD.fmk
was added at the same time as tunicamycin (R6+Z-VAD.fmk).
The data in (a) are the means of three independent experi-
ments+s.d.
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(data not shown). Surprisingly, Bcl-2/cb5 did also
fully impede BFA/CHX- or tunicamycin-induced
cytochrome c release. Neither by immunofluorescence
(Figure 3a) nor by Western blotting (Figures 3d and
4b) did we see any appearance of cytosolic cyto-
chrome c in R6-Bcl-2/cb5#6 cells treated with these
ER damaging agents. These findings suggest that Bcl-2
can function on the ER to inhibit an ER damage-
induced mitochondrial event. Interestingly, the death-
protective eect of Bcl-2/cb5 was not limited to ER
stress agents but also evident (although less pro-
nounced) for apoptotic stimuli such as staurosporine
that are known to act through mitochondrial damage
(Figure 2a) (Kluck et al., 1997).
Figure 5 Subcellular localization of wild-type Bcl-2 and ER-targeted Bcl-2/cb5 in untreated and BFA/CHX-treated R6 cells. (a)
Anti-Bcl-2 (27-6) immunofluorescence analysis of fixed/permeabilized R6-Bcl-2#9 and R6-Bcl-2/cb5#6 cells before and after the
treatment with BFA/CHX for 24 h. (b) Anti-Bcl-2 (27-6) immunoblot analysis of subcellular fractions from untreated and BFA/
CHX-treated R6-Bcl-2#9 and R6-Bcl-2/cb5#6 cells. The fractions were prepared by sucrose gradient centrifugation and tested for
their purity using antibodies against COX (mitochondria), lamin B1 (nuclei), lamp-1 (lysosomes) or calnexin (ER/microsomes) as
described in Materials and methods
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It has been previously shown that cytochrome c
release may be triggered by the activation of the initiator
caspase-8 which cleaves the Bcl-2 family member Bid to
allow its translocation from the cytoplasm to the
mitochondrial membrane (Li et al., 1998; Luo et al.,
1998). We therefore examined whether BFA/CHX or
tunicamycin used such a pathway to crosstalk with
mitochondria. A treatment of JILY B lymphoblasts
with anti-CD95 antibodies for 6 h led to a significant
increase in cytosolic caspase-8 activity (IETDase
activity) (Figure 6a) as well as the cleavage of p24 Bid
into its 15 kD fragment and the translocation of both
proteins to the mitochondrial membrane (Figure 6b).
However, neither BFA/CHX nor tunicamycin provoked
any major activation of caspase-8 (Figure 6a) or
proteolysis/mitochondrial translocation of Bid (Figure
6b) over a time period of 24 h in R6 cells. Moreover,
cytochrome c release induced by both BFA/CHX (data
not shown) or tunicamycin (Figure 4b) was not blocked
in the presence of the general caspase inhibitor Z-
VAD.fmk (Z-Val-Ala-Asp.fluoromethylketone) (data
not shown) indicating that none of the known caspases
were involved in conveying stress signals from the
damaged ER to mitochondria. Thus, the ER-mitochon-
dria crosstalk in response to BFA/CHX or tunicamycin
involves a novel, caspase-independent signaling path-
way.
Discussion
How can a damage in the ER compartment be translated
into an apoptotic response that involves the release of
cytochrome c from mitochondria? As the caspase-8/Bid-
mediated pathway does not seem to play a role, we
propose alternative ways of crosstalks. One possibility is
that the ER and mitochondria communicate via
membranes as they can be in close contact and easily
exchange lipids, calcium and glycoproteins (Chandra et
al., 1998; Rizzuto et al., 1998). A possible mediator may
be the sphingolipid ceramide which is generated by
sphingomyelin hydrolysis in response to various apopto-
tic stimuli (Kolesnick and Kro¨nke, 1998), including BFA
(Linardic et al., 1996) and has recently been shown to
directly act on mitochondria to stimulate cytochrome c
release (Ghafourifar et al., 1999). We have found that
BFA/CHX indeed provoked ceramide production in R6
cells that preceded cytochrome c release (data not
shown), but due to the lack of appropriate agents that
block ceramide signaling we cannot yet say whether this
lipid is required for BFA-induced apoptosis. In addition,
it has been disputed whether ceramide plays any role in
apoptosis induction (Hofmann and Dixit, 1999). Alter-
natively, an ER-mitochondrial crosstalk could be
mediated via yet unidentified proteins that are either
released from the damaged ER lumen due to an
Figure 6 Neither BFA/CHX nor tunicamycin activate caspase-8 and the cleavage and mitochondrial translocation of Bid. (a)
Caspase-8 (IETDase) activity of the cytosols of R6 cells treated with BFA/CHX (black bars) or tunicamycin (open bars) for 0 – 24 h
or of the cytosol of JILY B lymphoblasts treated with anti-CD95 for 6 h (grey bar). The data are the means of three independent
experiments+S.D. (b) Anti-Bid Western blot analysis of cytosolic and mitochondrial fractions of R6 cells treated with BFA/CHX
for 24 h and JILY cells treated with anti-CD95 for 6 h. Mitochondria were prepared by sucrose gradient centrifugation as described
in Materials and methods
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increased membrane permeability or cleaved from the
ER membrane by a caspase-independent mechanism.
Finally, such a crosstalk may involve components of the
unfolded protein (UPR) and ER overload (EOR)
response pathways (Pahl and Baeuerle, 1995). The
transcription factor CHOP/Gadd153, a component of
the UPR pathway, has been shown to mediate apoptosis
triggered by tunicamycin (Brenner et al., 1997; Olden et
al., 1982; Zinszner et al., 1998). CHOP-regulated genes
relevant for apoptosis regulation have not yet been
identified but may include pro-apoptotic molecules such
as the Bcl-2 family member Bax, a known trigger of
cytochrome c release on mitochondria (Rosse´ et al.,
1998). On the other hand, it is known that activation of
the transcription factor NF-kB via the EOR involves
reactive oxygen species (ROS) which are produced from
the oxidizing environment of the ER lumen and the
action of cytochrome p450 on the ER membrane (Pahl
and Baeuerle, 1997; Schreck et al., 1992). ROS can
mount an oxidative stress that damages membranes,
including those of mitochondria (Kowaltowski and
Vercesi, 1999). Indeed, preliminary data from our
laboratory show that antioxidants such as N-acetylcys-
teine or pyrrolidine dithiocarbamate (PDTC) can
partially protect R6 cells from BFA/CHX-induced
cytochrome c release and apoptosis (data not shown).
It has previously been reported that Bcl-2 prevents
BFA-induced apoptosis (Guo et al., 1998; Olivier et al.,
1997), but its mode and intracellular site of action have
not yet been unveiled. Here we show that BFA or
tunicamycin induces mitochondrial cytochrome c
release and caspase-3 activation which are both
blocked by a version of Bcl-2 targeted to the ER.
How could Bcl-2 control mitochondrial events from
the ER membrane? Again, the simplest explanation
would have been that Bcl-2 sequesters Bid away from
its mitochondrial action as the two proteins are known
to interact. However, based on our results here, other
processes are likely to occur. First, Bcl-2 may bind to
and/or neutralize potentially pro-apoptotic ER compo-
nents such as Bap31 (Ng et al., 1997) or yet unknown
ceramide targets. Second, Bcl-2 may interfere with the
generation or action of ROS as it has been shown to
function as an antioxidant (Hockenberry et al., 1993).
Third, Bcl-2 may modulate ER membrane permeability
by either forming an ion channel or regulating ER-
based channels or pumps such as the IP3-receptor
calcium channel or the Ca2+ ATPase pump (SERCA)
(Berridge et al., 1998). Bcl-2 can interact with SERCA
and either maintain calcium uptake into the ER or
reduce calcium eux of the ER in cells treated with the
SERCA inhibitor thapsigargin (Kuo et al., 1998; He et
al., 1997). Finally, we propose that Bcl-2 may act on
any intracellular membrane to sequester yet unknown
cytoplasmic activators of cytochrome c release. Thus, a
Bcl-2 targeted to lysosomal or plasma membranes
should retain such an activity, a possibility which we
are currently testing. The present study however
already shows that Bcl-2 does not need to associate
with mitochondria to exert a cytochrome c release
inhibiting function. Thus, it cannot be the sole role of
Bcl-2 to bind and regulate mitochondria-specific
proteins such as VDAC (Shimizu et al., 1999) or
ANT (Marzo et al., 1998) or to directly form ion
channels in the mitochondrial membrane as recently
proposed (Schendel et al., 1997). Our cellular system
using BFA/CHX or tunicamycin and ER-targeted Bcl-
2 will help us to isolate other targets of Bcl-2 and
delineate a novel ER/mitochondrial crosstalk pathway
for apoptosis induction.
Materials and methods
Cell lines and treatments
Rat 6 (R6) embryo fibroblasts expressing the retroviral vector
pMV12 (controls) or the vector containing mouse Bcl-2 (R6-
Bcl-2#9) were generated and cultured as previously described
(Borner, 1996). R6 derivatives expressing the ER-targeted
Bcl-2/cb5 were produced by transfecting the Bcl-2/cb5/
pcDNA3 plasmid in the presence of Superfect (Qiagen)
followed by antibiotic selection on 400 mg/ml geneticin
(G418) (Life Technologies). A clone expressing Bcl-2/cb5 to
similar levels as wild-type Bcl-2 in R6-Bcl-2#9 was used for
further studies (R6-Bcl-2/cb5#6). The various cell lines were
either treated with 5 mg/ml BFA and 1 mg/ml CHX or 5 mg/
ml tunicamycin (all Sigma) or 250 nM staurosporine in the
presence or absence of 100 mM of the general caspase
inhibitor ZVAD.fmk (Bachem). Human JILY B lympho-
blasts were cultured as described (Borner, 1996) and exposed
to 100 ng/ml anti-CD95 antibody (anti-APO-1, IgG3, kindly
provided by P Krammer, Heidelberg, Germany) where
indicated.
Generation of ER-targeted Bcl-2/cb5
To create the Bcl-2/cb5 fusion gene, we amplified by
polymerase chain reaction (PCR) the DNA fragment
corresponding to the hydrophobic C-terminus of rat
cytochrome b5 (aa 100 – 134) (cDNA kindly provided by
Stephen Sligar, Urbana, USA and Nica Borgese, Milano,
Italy) by using a 5’ primer with an introduced SphI site (for
subcloning into the site corresponding to Met203 of mouse
Bcl-2) and a 3’ PCR primer with an introduced XbaI site (for
subcloning into the multiple cloning site of Bcl-2/pcDNA3).
The amplified fragment was purified by Jetsorb (Genomed),
cut with SphI and XbaI and ligated into the corresponding
sites of Bcl-2/pcDNA3 yielding the Bcl-2/cb5/pcDNA3
plasmid. The corresponding ligation product was tested for
the correct reading frame by DNA sequencing (Microsynth).
Survival/apoptosis assays
To estimate cell survival, the various cells were trypsinized
and mixed with 0.2% (w/v) of the Trypan blue dye. Cells
were counted on 20 fields in a Neubauer chamber and the
proportion of white (live) to total cells determined. The
experiments were repeated at least three times. Genomic
DNA fragmentation was tested on 2% agarose gels as
previously described (Rosse´ et al., 1998).
Subcellular fractionation
The various R6 cell derivatives were washed twice in PBS and
once in extraction buer STE (10 mM HEPES, pH 7.4, 1 mM
EDTA, 0.25 M sucrose, 2 mg/ml aprotinin, 10 mg/ml leupep-
tin, 1 mM PMSF, 1 mg/ml pepstatin) followed by scraping
into STE and lysing in a tight-fitting Dounce homogenizer
with 20 – 30 strokes. The extract was inspected under the
microscope and only processed further when 90% of the cells
were lysed. The homogenate was then applied to a linear
gradient of sucrose (0.73 – 1.9 M) and centrifuged at 20 000 g
for 1 h. The banded organelles were recovered by syringe,
diluted with an equal volume of 10 mM HEPES buer and
sedimented by centrifugation at the speed appropriate for the
respective organelles. The purity of the organelles was
determined on Western blots using antibodies against specific
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organelle markers (lamin B1 for nuclei, COX for mitochon-
dria, lamp-1 for lysosomes/peroxisomes, calnexin for micro-
somes/ER). For the preparation of cytosols (anti-cytochrome
c and anti-caspase-3 immunoblots) the homogenate was
precentrifuged at 750 g for 10 min to remove nuclei and
unbroken cells followed by a centrifugation at 100 000 g for
1 h to clear o the membranes.
Western blotting
30 – 50 mg of protein was subjected to 12 – 15% SDS –PAGE
followed by blotting to a PVDF membrane as previously
described (Borner et al., 1994). The membrane was blocked in
3% milk and incubated with either mouse monoclonal anti-
cytochrome c (1 : 1000) (clone 7H8.2C12, Pharmingen), rabbit
polyclonal anti-caspase-3 (1 : 10 000) (generous gift of D
Nicholson, Merck-Frosst, Quebec, Canada), rabbit polyclo-
nal anti-Bcl-2 (27-6, 1 : 5000) (Borner et al., 1994), mouse
monoclonal anti-cytochrome c oxidase subunit VIc (COX)
(1 : 1000) (Molecular Probes), mouse monoclonal anti-lamin
B1, clone L-5 (1 : 1000) (Zymed), mouse monoclonal anti-rat
Lamp-1 (1 : 5000) (generous gift of W Hunziker, University of
Lausanne, Switzerland), mouse monoclonal anti-calnexin
(1 : 2000) (Transduction Laboratories), or goat polyclonal
anti-Bid (1 : 1000) (R&D Systems) followed by peroxidase-
coupled anti-mouse, anti-goat or anti-rabbit secondary
antibodies (1 : 5000) (Jackson Laboratories) and detection
by enhanced chemiluminescence (Socochim, Pierce).
Caspase assays
Caspase-3 and caspase-8 activities were measured in the
cytosol using the fluorogenic peptide substrates DEVD-AMC
and IETD-AMC, respectively. Briefly, cytosol was prepared
from untreated and BFA/CHX- or tunicamycin treated R6
cell derivatives by four cycles of freeze-thawing (7808/258C)
in buer A (25 mM HEPES/KOH, pH 7.4, 2 mM EGTA,
2 mM MgCl2, 2 mM DTT, 5 mg/ml cytochalasin B, 100 mM
PMSF, 25 mg/ml leupeptin, 5 mg/ml aprotinin, 1 mg/ml
pepstatin) followed by ultracentrifugation at 100 000 g.
10 ml of cytosol (100 – 300 mg protein) was mixed with 90 ml
of assay buer (100 mM HEPES, pH 7.5, 2 mM DTT) and
1 ml of a 6 mM solution of the DEVD-AMC or IETD-AMC
peptide substrates (Alexis). The specific liberation of AMC
from these peptides was monitored during 30 min in black-
coated 96 well microtiter plates (Nunc) using a Lambda
fluoro FL600 microplate fluorescence reader (MWG Biotech)
and 360-nm excitation and 460-nm emission wavelengths.
Quantitation was performed using the KC-4 program
developed by MWG Biotech.
Immunofluorescence analysis
A modified protocol described by Rosse´ et al. (1998) was
used. Briefly, the cells were seeded onto 12 mm glass
coverslips at a denstiy of 26104 cells/ml. On the next day,
the cells were exposed to 5 mg/ml BFA and 1 mg/ml CHX and
kept for 24 h at 378C. The coverslips were removed from the
medium without washing (in order not to lose slightly
detached cells) and directly placed in 4% paraformaldehyde
for 10 min (fixation), followed by washing in PBS and
treatments with 0.05% saponin for 5 min and acetone for
10 min (permeabilization). After washing in PBS the cells
were incubated with mouse monoclonal anti-cytochrome c
(clone 6H2.B4, 1 : 50), rabbit polyclonal anti-active p17
caspase-3 antibodies (1 : 1000) (both Pharmingen), or poly-
clonal anti-Bcl-2 (27-6, 1 : 200) for 90 min followed by
secondary Texas-Red conjugated goat anti-mouse and
fluorescein-conjugated goat anti-rabbit antibodies (both
1 : 75) (Jackson Laboratories). The cells were then postfixed
for 10 min in 4% paraformaldehyde containing 2 mg/ml of
the Hoechst 33342 stain (Molecular Probes), washed and
treated with Slow Fade (Molecular Probes) to prevent fading.
The coverslips were viewed under an Axiovert fluorescence
microscope (Zeiss) and pictures taken with a Contax 167 MT
camera at magnification of 10006.
Electron microscopy
Adherent R6 cells were washed in phosphate buer (0.1 M
phosphate, pH 7.2), fixed in 2.5% glutaraldehyde at 48C for
30 min and postfixed in 1% OsO4 at room temperature for
20 min. The cells were then dehydrated with increasing
concentrations of alcohol (30, 50, 70% plus 1% uranylace-
tate, 80, 95, 100%), embedded in a mixture of Epon/alcohol
(1 : 3 for 15 min, 1 : 2 for 30 min, 3 : 1 for 30 min and pure
Epon for 2630 min) and polymerized at 608C for 2 days.
The solidified blocks were cut into slices of 50 – 60 nm
thickness. These slices were contrasted in 5% uranylacetate as
well as in Reynolds solution (80 mM Pb(NO3)2, 120 mM
sodium citrate, 160 mM NaOH) and then viewed under the
electron microscope.
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2.6 ADDITIONAL RESULTS : The cloning of new survival factors. 
2.6.1 Materials and Methods 
  
Reagents 
 
Geneticin (G418) was purchased from Life Technologies, hygromycin B from Juro 
Supply/Calbiochem and DNase-free RNase from Boehringer Mannheim. Staurosporine 
(dissolved in DMSO) was kindly provided by Novartis and MG132 (dissolved in DMSO) was 
a gift from Proscript Inc. (formerly Myogenics Inc.). 
 
cDNAs 
 
The cDNA for human Bcl-2 (hBcl-2) was subcloned into the EcoRI site of the pcDNA3 
vector (Invitrogen) as previously described (Borner et al., 1994). The premade cDNA 
phagemid library from a human Burkitt Lymphoma RNA source (Invitrogen; primary 
recombinants: 2.9x106 colonies; premade amplified titer: 3.3x107 colonies/ml) was uni-
directionally subcloned between the BstXI and NotI sites into the multiple cloning site of the 
pcDNA3 vector (Invitrogen) as described by the manufacturer. 
 
Cells 
 
Vector control (pMV12) and Bcl-2-overexpressing (Bcl-2) rat 6 embryo fibroblasts (R6) were 
generated by retroviral transduction of the pMV12hygro plasmid lacking or containing the 
murine Bcl-2 cDNA. Construction of the viruses was exactly as described (Borner et al., 
1994). Following infection, cells were selected on 200 mg/ml hygromycin for 10 days. 
Resistant clones were picked, expanded into cell lines and checked for Bcl-2 expression by 
anti-Bcl-2 Western blot analyses. R6Bcl-2#9, expressing high level of murine Bcl-2, as well 
as the vector control cell line R6pMV12, were used for further analyses. 
R6pMV12 and R6Bcl-2#9 cells were grown in Dulbecco’s modified Eagle medium 
containing 5% fetal calf serum (FCS) and low amounts (50 mg/ml) of hygromycin to maintain 
Bcl-2 expression. 
  
Transfection Efficiency Assay by X-Gal Staining 
 
3 x 105 R6pMV12 cells grown on 35-mm plastic plates were transfected with either 10 mg or 
5 mg of b-Gal/pcDNA3 using 12.5 ml, 25 ml or 50 ml of Superfect (Qiagen) or Fugene6 
(Boehringer Mannheim) as described by the two manufacturers. At 24 h post-transfection, 
cells were stained with 5-bromo-4-chloro-3-indoxyl-b-D-galactopyranoside (X-Gal). To 
determine the transfection efficiency, trypsinized blue cells were counted in a Neubauer 
chamber on 20 randomly selected fields under a Nikon inverted microscope at a 
magnification of x1000 (phase contrast). The results are the means of three independent 
experiments. 
 
Cell Viability Assay 
 
Cells (R6pMV12 and R6Bcl-2#9) were seeded at 2 x 105 in triplicate into 35-mm wells. The 
next day, the cells were treated with 100 nM staurosporine, 500 nM staurosporine or 500 nM 
MG132 to induce apoptosis. After 24-72 h, viable cells were counted on triplicate plates using 
the trypan blue exclusion assay. The results are the means of three independent experiments. 
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Titering of the premade cDNA phagemid  library 
 
To verify the titer of the pre-amplified library given by the manufacturer, a small portion of 
bacteria were scraped from the top of the tube without thawing them. Bacteria were 
transferred to a sterile eppendorf tube and serial dilutions of 103, 106, 107, 3x107, 108 in LB or 
LB-Amp (75 mg/ml ampicillin) media were prepared. 100 ml of each dilution was plated onto 
100 mm agar plates containing or lacking the ampicillin (75 mg/ml) antibiotic and the plates 
were incubated overnight at 37 °C. The colonies on each plate were counted and the titer was 
calculated by multiplying the number of colonies by the dilution factor. The titer was adjusted 
by taking the means of three independent experiments giving 6.3x106 colonies/ml as a new 
premade amplified titer.  
 
Preparation of pure plasmidial DNA from the premade cDNA phagemid library 
 
To respect a ratio of 1:6 between primary recombinants and total colonies (6 fold security that 
all recombinants are present), 2 ml of the cDNA phagemid library infected in E. coli was 
diluted in 20 ml of LB-Amp (75 mg/ml) medium and grown overnight at 37 °C. 20 x 250 ml of 
this latter solution were plated individually onto 150 mm agar plates containing 75 mg/ml 
ampicillin as antibiotic and the 20 plates were incubated overnight at 37 °C. The colonies of 
each plate were scraped, put into 30 ml of LB-Amp (75 mg/ml ampicillin) medium and grown 
overnight at 37 °C until a constant OD599 of about 1.5. DNA was separately isolated and 
purified following the manufacturer’s protocol (Macherey-Nagel) giving 20 pure DNA pools 
ready to be screened for the presence of putative survival factors. 
 
Transfection, selection and drug treatment into eukaryotic cells 
 
R6pMV12 cells were grown on 100 mm plates until 60-70% confluency and transfected with 
10 mg of the pcDNA3 vector, the hBcl-2/pcDNA3 plasmid (positive control) or the 12th 
purified DNA pool using 25 ml of Superfect (Qiagen) as described by the manufacturer. After 
3 h, the Superfect-DNA complex was removed and cells were cultured for another 45 h in 
fresh medium. At 48 h post-transfection, cells were trypsinized, transferred on 150 mm plates 
and an antibiotitc selection on 200 mg/ml geneticin (G418) was applied. As negative control, a 
plate containing non-transfected R6pMV12 cells was used. As soon as this negative control 
plate showed no more cells, cells on the other plates were trypsinized and grown on another 
100 mm plate with fresh DMEM, in the presence of 200 mg/ml geneticin (G418), until 80-
90% confluence so as to avoid the formation of clusters. Then, cells were treated either with 
500 nM or 100 nM staurosporine until all R6pMV12 cells transfected with the pcDNA3 
vector died (3 days). Finally, the stressed medium was removed and cells were grown in 
DMEM containing 200 mg/ml G418 until 100% confluence. 
 
DNA isolation, PCR amplification and subcloning into pcDNA3 
 
After reaching 100% confluency, cells were washed twice in ice-cold phosphate-buffered 
saline (PBS) and lysed in 1 ml of a solution containing 0.6% sodium-dodecylsulfate (SDS) 
and 10mM EDTA with a pH of 7.5. After an incubation of 10 minutes at room temperature 
(RT), the lysates were scrapped and kept on ice in separate 4 ml polyallomer tubes. 250 ml of 
5 M NaCl was added and each tube was mixed by inverting slowly 10 times. These mixtures 
were incubated overnight at 4 °C on ice and centrifuged at 100’000 g and 4 °C for 30 minutes. 
Genomic/extrachromosomal DNA was extracted from the supernatant. To rescue the 
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transfected cDNA encoding a putative survival factor, the insert region of the pcDNA3 DNA 
was amplified by polymerase chain reaction (PCR) using primers annealing to the 5’ and 3’ 
sites of the insert/multiple cloning site (MCS) region. The same primers were used to anneal 
just before and after the EcoRI site used to create the hBcl-2/pcDNA3 plasmid which served 
as the positive control. The amplified DNA fragments were all together purified by JetSorb 
(Genomed), cut with BstXI/NotI and ligated into the corresponding sites of the pcDNA3 
vector. 
 
2.6.2 Principle of the method 
 
For a better understanding, the text written into the different boxes correlates with the 
chapters described in the previous “Materials and Methods” section so as to find directly the 
protocol used for each step (Figure 11).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11 : Schematic presentation of the method to clone new survival factors. 
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To minimize the risk of amplifying false-positive factors, a second cycle was performed using 
the same steps (Figure 11, steps 9, 10 and again steps 4 and 5). At the end of this second 
cycle, genomic/extra-chromosomal DNA was isolated, amplified by PCR using multiple 
cloning site (MCS) primers, and each amplified DNA fragment was subcloned individually 
into the pcDNA3 vector. All different constructions were sequenced (Microsynth) and 
compared with the BLAST database to search for known factors. The sequences were 
screened manually to find the BstXI/NotI sites, a start codon in frame with a stop codon, a 
Kozak consensus sequence and eventually a poly(A) sequence just before the NotI site 
because the cDNA library was prepared from a human Burkitt Lymphoma RNA source by 
using oligo dT and/or random primers. Finally, the most interesting cloned factors were tested 
for their survival activity by using the cell viability assay as described above. 
 
2.6.3 Results 
 
Establishing the best conditions for transfection and cell killing in R6 cells. 
 
In this project, the first step was to establish the best conditions for the transfection/killing 
process. For that purpose, a transfection efficiency assay was performed by transfecting 
R6pMV12 cells with b-Gal/pcDNA3 using Superfect (Qiagen) or Fugene6 (Boehringer 
Mannheim), because these transfection reagents were supposed to be effective for R6 cell 
lines (Figure 12).  
 
 
Figure 12 : Transfection efficiency assay by X-Gal staining into R6pMV12 cells. 
                   R6pMV12 cells were transfected with different ratios mg b-Gal/pcDNA3 versus ml 
Superfect or Fugene6 and stained with X-Gal at 24 h post-transfection. Transfection 
efficiency was monitored by counting trypsinized blue cells in a Neubauer chamber. The 
displayed cell counts are the means of three independent experiments. 
 
 
As seen in Figure 12, the best transfection was obtained with Superfect and with a ratio 
between mg b-Gal/pcDNA3 versus ml Superfect of 10 to 25. Fugene6 was not as good as 
predicted by the manufacturer (Figure 12). Therefore, we tested other transfection reagents 
(like Lipofectamine and Effectene) on R6 cell lines but none was better than Superfect (data 
not shown). Moreover, we transfected other cell lines like HEK293 or human epithelioid 
cervical carcinoma (HeLa) cells. They gave better transfection efficiency than R6 cells (about 
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3 times more blue cells), but were less sensitive to drug treatments as judged by a cell 
viability assay in response to staurosporine or MG132 (data not shown and Figure 13).  
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Figure 13 : Cell viability assay after stresses with MG132 and staurosporine into R6 cell lines. 
 Subconfluent R6pMV12 (vector control cells, panel A) or R6Bcl-2#9 (stably survival 
factor-overexpressing cells, panel B) cells were treated with 100 nM staurosporine, 500 
nM staurosporine or 500 nM MG132 for 3 days, and each day the cell viability was 
determined by trypan blue exclusion. The data are the means of three independent 
experiments. 
 
 
Maximal sensitivity to apoptotic stresses is a crucial point to choose the best cell line, because 
we want cells lacking survival factors to die completely such that cells which obtained 
survival factors by transfection can grow out. Therefore, we decided to take for our 
experiments the R6 cell line which permitted a good transfection efficiency using Superfect 
and was maximally killed (~90%) in response to 100 nM or 500 nM staurosporine (Figure 12 
and Figure 13, panel A). Bcl-2 effectively protects these cells from apoptosis. MG132 was too 
potent as cell killing agent because it also induced apoptosis in R6Bcl-2 cells (Figure 13, 
panel B). 
We also had to make sure that each of the transfected cDNA clone was represented in the 
transfected R6 cells. For that purpose, our transfection efficiency had to be at least 10% which 
was indeed the case. 
In conclusion, we chose R6pMV12 cells, transfected them with the ratio of 10 mg b-
Gal/pcDNA3 and 25 ml Superfect followed by a stress of 100 nM or 500 nM staurosporine for 
3 days. 
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Heavily diluted hBcl-2 cDNA can be recloned by our strategy. 
 
The next step was to test whether we can clone a known survival factor with our strategy.  For 
that purpose, we chose the hBcl-2/pcDNA3 plasmid because we knew that Bcl-2 is well 
expressed in R6 cell lines and is a potent survival factor (Otter et al., 1998). R6pMV12 cells 
were either non-transfected or transfected with a DNA solution containing a ratio between 
hBcl-2/pcDNA3 and pcDNA3 of 1:5’000, 1:10’000 or 1:20’000 so as to be in the same range 
as a particular cDNA in the library (2 ml in 20 ml of LB-Amp medium giving a dilution of 
1:10’000). At 48 h post-transfection, cells were selected with G418 until all non-transfected 
R6pMV12 cells were killed, stressed with 100 nM staurosporine for 3 days and lysed to 
extract genomic/extra-chromosomal DNA. Finally, extracts were amplified by PCR and all 
amplified DNA fragments were analyzed on an agarose gel for the detection of the fragment 
corresponding to Bcl-2 (Figure 14).  
 
Figure 14 : PCR amplification on genomic/extra-chromosomal DNA extracts from R6pMV12 
cells transfected with diluted hBcl-2. 
 By using MCS primers, a 40 cycles-polymerase chain reaction (PCR) was performed on 
pcDNA3 alone (lane a, negative control) or on genomic/extra-chromosomal DNA extracts 
from R6 cells transfected with hBcl-2 diluted 1:5’000 in pcDNA3 (lane b), hBcl-2 diluted 
1:10’000 in pcDNA3 (lane c) or hBcl-2 diluted 1:20’000 in pcDNA3 (lane d). As positive 
control, a genomic/extra-chromosomal DNA extract from R6 cells stably overexpressing 
Bcl-2 was amplified (lane e). Note that Bcl-2 is present in the lanes b, c and d, while there 
is no specific amplification in lane a. 
 
As seen by the presence of a DNA fragment corresponding to Bcl-2 (Figure 14, compare lane 
e with lanes b, c and d), we were able to clone again this survival factor even though hBcl-2 
was 20’000 times less abundant than pcDNA3. We obtained three other DNA fragments 
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(Figure 14, lanes b, c and d), which were cross-reacting bands, because if we performed a 
PCR on an extract from non-transfected R6pMV12 cells, we detected them as well (Figure 
15, lane h). This indicated that our method was suitable to isolate new putative survival 
factors.  
 
Cloning of new possible survival factors from the library. 
 
After establishing the experimental conditions, we directly screened the library for novel 
survival factors. We chose the 12th of the 20 DNA pools prepared from the library 
(pool#12/pcDNA3). R6pMV12 cells were either non-transfected or transfected with 
pool#12/pcDNA3 or hBcl-2/pcDNA3. Cells were selected with G418 as described in the 
previous section, stressed with 100 nM or 500 nM staurosporine, lysed to obtain 
genomic/extra-chromosomal DNA and the DNA was amplified by PCR. The amplified DNA 
fragments were analyzed on an agarose gel to detect all transfected and selected DNA 
fragments (Figure 15). 
 
Figure 15 : PCR amplification on genomic DNA extracts from R6 cells transfected with pool#12 
after the first cycle  
 By using MCS primers, a 30 cycles-polymerase chain reaction (PCR) was performed on 
pcDNA3 plasmid alone (lane a, negative control), on genomic/extra-chromosomal DNA 
extracts from R6 cells stably overexpressing hBcl-2 (lane b, positive control), on hBcl-
2/pcDNA3 plasmid alone (lane c) or on genomic/extra-chromosomal DNA extracts from 
R6 cells transfected with hBcl-2/pcDNA3 and stressed with 100 nM staurosporine (lane 
d), hBcl-2/pcDNA3 stressed with 500 nM staurosporine (lane e),  pool#12/pcDNA3 
stressed with 100 nM staurosporine (lane f) or pool#12/pcDNA3 stressed with 500 nM 
staurosporine (lane g). A genomic/extra-chromosomal DNA extract from non-transfected 
R6pMV12 cells was also used as a second negative control (lane h). Note that we obtained 
a lot of bands in the lanes f and g indicating that putative survival factors were amplified. 
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As shown in Figure 15, we faithfully amplified hBcl-2 from stably transfected R6 cells as 
well as different DNAs with sizes up to 1.5 kb from R6 cells transfected with pool#12 (Figure 
15, compare lane b with lanes f and g). Some DNA fragments appeared to be unspecific 
because they were also present when we amplified genomic/ extra-chromosomal DNA 
extracts from non-transfected R6pMV12 cells (Figure 15, compare lane h with lanes f and g). 
To increase the probability of cloning only survival factors, we cut out all amplified pool#12 
DNA fragments up to 1.5 kb and subcloned them into pcDNA3. We then performed the same 
transfection/selection process for a second time. At the end, we amplified the genomic/extra-
chromosomal DNA by PCR and analyzed it on an agarose gel (Figure 16). 
 
Figure 16 : PCR amplification on genomic DNA extracts from R6 cells transfected with pool#12 
after the second cycle. 
 A 30 cycles-polymerase chain reaction (PCR) was performed on  genomic/extra-
chromosomal DNA extracts from R6 cells either non-transfected (lane e, negative control) 
or transfected with hBcl-2/pcDNA3 and stressed with 500 nM staurosporine (lane a), 
pool#12/pcDNA3 stressed with 500 nM staurosporine (lane b), hBcl-2/pcDNA3 stressed 
with 100 nM staurosporine (lane c) or pool#12/pcDNA3 stressed with 100 nM 
staurosporine (lane d). In the lane f, we loaded an amplified genomic/extra-chromosomal 
extract from R6 cells transfected with pool#12 after the first cycle. Note that some upper 
bands disappeared and that others were stronger if we compared the lane f with the lanes b 
and d. 
 
 
As before, we amplified our positive Bcl-2 controls (Figure 16, lanes a and c, the upper band) 
and cross-reacting bands (Figure 16, compare lane e with lanes b and d). In the pool#12 
sample, DNA bands which were amplified the second time seem to correspond to the sizes of 
the first cycle (Figure 16, compare lane f with lanes b and d). However, two upper bands were 
lost which could be false positives or weak survival factors which did not “survive” a second 
selection. Due to the enrichment during the second cycle, we obtained some stronger DNA 
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bands. These DNA fragments were interesting because they should correspond to survival 
factors. To characterize these factors, we individually purified each DNA band (Figure 16, 
lanes b and d), subcloned them one by one into the pcDNA3 vector and sequenced them at 
Microsynth (CH). All sequences were screened for the presence of BstXI/NotI sites, a start 
codon in frame with a stop codon, a Kozak consensus sequence and eventually a poly(A) 
sequence just before the NotI site indicating that these cloned factors were from the library. 
We then used the BLAST database to see whether these cDNAs were already known (Table 
2). 
 
 
 
BLAST  
database name  
(human proteins) 
Identity 
(%) 
Number of similar 
amino acids versus 
full-length protein 
BstXI/NotI 
sites 
Kozak 
sequence 
PolyA 
sequence 
Small nuclear 
ribonucleoprotein U2 
89 
(227/255) 
227/255 Yes Yes Yes 
Ribosomal protein 
L13 (60S subunit) 
87 
(183/210) 
183/210 Yes Yes Yes 
New protein FIS-
Clone 
87 
(89/102) 
89/250 
( middle part) 
Yes Yes Yes  
Ribosomal protein 
L18 (60S subunit) 
100 
(187/187) 
187/187 Yes Yes Yes 
Ribosomal protein 
S2 (40S subunit) 
100 
(79/79) 
79/293 
(only the C-term) 
Yes Yes Yes 
Truncated hBcl-2 
(BH4 + loop region) 
100 
(72/72) 
72/239 Yes Yes Yes 
  
 
Table 2 : Presentation of all cloned factors after two cycles. 
 
 
 
Six known human cDNAs have been found in the BLAST database (Table 2). In fact, we 
obtained more than 6 DNA fragments after the second cycle (Figure 16, lanes b and d), but all 
others were contaminations as determined by sequencing. Interestingly, we amplified a new 
cDNA encoding a protein (FIS) which is not yet well characterized. Otherwise, we obtained a 
ribonucleoprotein, 3 ribosomal proteins and a truncated form of human Bcl-2 (hBcl-2). More 
importantly, some publications mentioned human ribosomal proteins, such as L13, as cell 
proliferating regulators which either induce apoptosis or maintain cell survival (Chen and 
Ioannou, 1999). In addition, a publication showed that the BH4 domain of anti-apoptotic Bcl-
2 family members inhibits apoptotic mitochondrial changes and cell death (Shimizu et al., 
2000). 
 
We therefore verified whether these factors were able to protect cells from apoptosis. For that 
purpose, R6pMV12 cells were either non-transfected or transfected with hBcl-2/pcDNA3, 
each selected cDNA, or pcDNA3 alone for 24 h. Cells were then stressed with 500 nM 
staurosporine for 3 days. Each day, viable cells were counted on triplicate plates using the 
trypan blue exclusion assay (Table 3). 
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Transiently 
transfected factors  
Stress time  
(24h) 
Stress time 
(48h) 
Stress time 
(72h) 
No transfection + - - 
hBcl-2 +++++ ++++ ++++ 
Small nuclear 
ribonucleoprotein U2 
+(+) + + 
Ribosomal protein 
L13 (60S subunit) 
+++ +++ ++ 
New protein FIS-
Clone 
++++ ++++ ++++ 
Ribosomal protein 
L18 (60S subunit) 
++(+) +(+) +(+) 
Ribosomal protein S2 
(40S subunit) 
+++(+) +++ ++(+) 
Truncated hBcl-2 
(BH4 + loop region) 
+(+) +(+) + 
pcDNA3 (+) - - 
 
Table 3 : Cell viability assay into R6 cell lines. 
 
 
As shown in Table 3, while pcDNA3 transfectants readily underwent apoptosis, the cells 
transfected with the various cDNAs were all more or less protected. Best protection was 
achieved with the FIS clone  which had almost the same survival potency as Bcl-2. The least 
protection was attained with the BH4 truncated Bcl-2. This finding is inconsistent with the 
hypothesis of Shimizu et al. indicating that the BH4 domain could be an anti-apoptotic factor. 
In their disfavor, they performed an in vitro study by using reconstituted liposomes which did 
not reflect the physiological conditions. Therefore, their results may not represent the reality, 
because it has also been published and widely accepted that the BH1, BH2 and BH4 domains 
are all required for death protection (Adams and Cory, 1997).  The ribosomal and ribonuclear 
proteins were weak death protectors but their effect was significant. Ribosomal proteins are 
often overexpressed in human tumors (Loging and Reisman, 1999), explaining why we 
probably obtained a lot of such factors at the end of our process.  
 
In conclusion, we isolated one very interesting factor : the new protein FIS. Further 
investigations will be necessary to characterize this factor. For example, it would be 
interesting to test its protective  function against other physiological stresses, such as IL-3 or 
serum withdrawal, in cell lines other than R6 and to perform a clonogenicity assay to see if it 
is capable of protecting and rescuing cells in a more generalized way. Moreover, 19 other 
pools remain to be screened in which we could find new anti-apoptotic factors.  
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3. DISCUSSION 
 
Life requires the death of cells at correct places and times. Multicellular organisms eliminate 
redundant, damaged, or infected cells by a stereotypic program of cell suicide termed 
apoptosis (Kerr et al., 1972). Interest in the control of apoptosis has grown exponentially with 
the recognition of its vital roles in normal development, tissue homeostasis, and defense 
against pathogens (Raff, 1992; Vaux et al., 1994), and the realization that disturbed apoptosis 
may contribute to diseases (Adams and Cory, 1998).  
Significant parallels exist between the prototypic system C. elegans and mammalian systems. 
Developmentally programmed cell death in the nematode has been shown to be controlled by 
small number of genes, all of which have counterparts that are conserved across evolution 
(Ellis and Horvitz, 1986). The ced-3 gene encodes a protein that corresponds to the caspases 
family. It is activated by association with the product of ced-4, which shares homology with  
Apaf-1 (Zou et al., 1997), Nod1/CARD4 (Bertin et al.,1999; Inohara et al., 1999), Nod2 
(Ogura et al., 2001), DEFCAP (Hlaing et al., 2001) and NAC (Chu et al., 2001). Cell death is 
prevented by the expression of ced-9, which is homologous to the Bcl-2 family members. 
Based on overexpression studies in heterologous systems, it has been concluded that CED-9, 
which is localized to the mitochondrial membrane, binds CED-4 and prevents its interaction 
with CED-3 (Chinnaiyan et al., 1997). Expression of EGL-1 (mammalian homologue: Bax) 
displaces CED-4, permitting apoptosis to proceed (Del Peso et al., 2000; Gottlieb, 2000). 
Vertebrate apoptotic machinery is substantially homologous to that of invertebrates, although 
it is more elaborate and degenerate: caspases, Bcl-2 and IAP family proteins, and survival 
signaling pathways all exist in bewildering multiplicity, consistent with the more 
sophisticated needs for control of apoptosis in vertebrate tissues (Meier et al., 2000). As in 
invertebrates, a variety of transcriptional mechanisms are important in the regulation of 
developmental apoptosis in vertebrates such as the classical apoptotic paradigm of interdigital 
cell death which is determined by the transcriptional readout of the transforming growth 
factor-b  signaling pathway (reviewed in Merino et al., 1999). Nonetheless, mammalian 
apoptosis is also significantly regulated, in both development and throughout life, by two non-
transcriptional signaling systems whose exact counterparts are either absent or have proven 
elusive in the worm. 
First, mammals possess a family of death receptors whose ligation can directly trigger 
activation of specific initiator caspases (like caspase-8, -10 and –2) through induced assembly 
of discrete apoptosome complexes. No equivalent of death receptors has yet been identified in 
C. elegans.  
Second, in mammals, many pro-apoptotic insults seem to impact directly upon mitochondria 
to induce their leakiness and the release of various pro-apoptotic polypeptides. However, 
there is no evidence for any involvement of mitochondria in cell death in the worm. Thus, it 
remains unclear whether vertebrates have evolved a more complex elaboration of the 
apoptotic machinery that incorporates the mitochondrion or whether C. elegans represents a 
stripped down version of a more evolutionarily ancient mechanism (Meier et al., 2000).  
 
Mitochondria as central players of apoptosis 
 
Nevertheless, for mammals, it is now clear that mitochondria have an important function in at 
least some apoptotic signaling cascades (Newmeyer et al., 1994; Kroemer, 1997b; Green and 
Reed, 1998). Following a death stimulus, many proteins from the mitochondrial 
intramembrane space, including cytochrome c, adenylate kinase, Smac/DIABLO, pro-
caspases, and apoptosis- inducing factor (AIF), have been reported to be released into the 
cytosol (Bossy-Wetzel et al., 1998; Single et al., 1998; Kohler et al., 1999; Lorenzo et al., 
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1999; Du et al., 2000; Verhagen et al., 2000). Cytochrome c exit is an almost universal 
feature of apoptotic cell death. However, in some cases, it is a late event. For example, 
apoptosis induced by death receptors often bypasses the mitochondrial pathway (Scaffidi et 
al., 1998). As might be expected, such deaths are relatively insensitive to protection by Bcl-2 
(Scaffidi et al., 1998), and cytochrome c release into the cytosol is likely to be the result of 
caspase activation, rather than its cause (Hengartner, 2000). 
But is release of pro-death factors from mitochondria really the point of no return ? Several 
lines of evidence suggest that cells can occasionally still be rescued at this stage, at least for a 
while. First, pharmacological inhibitor of caspases will often, but not always, rescue cells 
from apoptosis or simply prolonged the survival of cells which, for example, overexpress Bax  
(Nicholson, 1996; Rossé et al., 1998; Robertson et al., 2000). Second, caspase-3- and 
caspase-9-knockout mice show reduced neuronal apoptosis during development and a 
significant defect in apoptosis following insult (Earnshaw et al., 1999; Zheng et al., 1999; 
Wang and Lenardo, 2000). Third, mammals, as well as the fruitfly Drosophila and some 
viruses, carry a family of genes that encode potent caspase inhibitors, known as the inhibitor-
of-apoptosis proteins (IAPs) (Budihardjo et al., 1999; Miller, 1999). There would be little 
reason for such proteins to exist if they could not influence the apoptotic process (Hengartner, 
2000). 
Therefore, it might seem that cells suffer from a terminal case of indecisiveness when it 
comes to apoptotic cell death, letting apoptotic signaling go down endless trails but never 
fully committing. But, quite to the contrary, the apoptotic pathway contains a number of 
amplification steps and positive feedback loops that insure that a cell will either fully commit 
to death or completely abstain from it (Hengartner, 2000). For example, the fact that pro-
caspases are caspase substrates insures rapid and complete conversion of a pool of pro-
enzymes even if only a few molecules were initially activated (Thornberry and Lazebnik, 
1998). Similarly, there is likely to be positive feedback between caspase activation and 
cytochrome c exit from mitochondria (Green and Kroemer, 1998; Green and Reed, 1998). 
But positive feedback loops do require the presence of buffers and/or dampeners, or even the 
smallest perturbation would eventually lead to full activation and apoptotic death of the cell. 
The IAP proteins act as such dampeners. These proteins function by directly binding to and 
inhibiting caspase function (Deveraux and Reed, 1999b), because the tight regulation of these 
enzymes is critical to the normal development and survival of an organism (Goyal, 2001). 
Thus, they serve either to inhibit both initiator and effector caspases, laying roadblocks in 
both the mitochondrial and the death receptor-mediated apoptotic pathways (Goyal, 2001), or 
also to squelch spurious spontaneous caspase activation. This is further supported by the 
recent identification of a mammalian IAP inhibitor, known as Smac (Du et al., 2000) or 
DIABLO (Verhagen et al., 2000), which binds to IAP family members and neutralizes their 
anti-apoptotic activity. Thus, if a cell is committed to apoptotic death such that it releases its 
mitochondrial contents, then Smac/DIABLO will sequester the IAP proteins and insure that 
they do not attempt to stop the program in its track (Hengartner, 2000). 
 
Bcl-2 family members as regulators of apoptosis 
 
By analogy, anti-apoptotic Bcl-2 family members can be thought as buffers. In mammals, the 
principal action of Bcl-2 proteins, and of the survival signaling pathways that impact on them, 
seems to be the stabilization of mitochondrial integrity and prevention of release of these pro-
apoptotic polypeptides (Meier et al., 2000).   
This differs from the role of nematode CED-9, which acts by directly interfering with the 
ability of CED-4 to activate CED-3 (Meier et al., 2000). Such an interaction between 
mammalian CED-9 and CED-4 homologues, based also on the findings that Bcl-2 could act 
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after Bax- induced cytochrome c release in cells stably overexpressing both Bcl-2/Bax (Rossé 
et al., 1998) and that apoptosis induced by microinjection of cytochrome c is strongly reduced 
by Bcl-2 overexpression (Zhivotovsky et al., 1998), has even been tested in mammals. 
Unfortunately, Bcl-xL or nine other Bcl-2 family members, whose Bcl-2 and Bax, do not co-
immunoprecipitate (Moriishi et al., 1999; Conus et al., 2000a) or co- localize (Hausmann et 
al., 2000) with Apaf-1 inside cells. This was clearly confirmed in this thesis. Moreover, in 
vitro assays and cells deficient in Apaf-1 show that Bcl-2 and Bcl-xL do not require Apaf-1 
for their caspase- inhibiting and death protective function (Haraguchi et al., 2000; Newmeyer 
et al., 2000). Thus, Apaf-1 seems to constitutively reside in the cytoplasm to await the release 
of cytochrome c for the activation of caspase-9. Nevertheless, it would be interesting to test if 
Bcl-2 family members could interact with one of the four newly identified CED-4 
homologues, Nod1/CARD4 (Bertin et al., 1999; Inohara et al., 1999),  Nod2 (Ogura et al., 
2001), DEFCAP (Hlaing et al., 2001) and NAC (Chu et al., 2001), although they are majorly 
involved in NF-kB activation than caspase activation, because it is still possible that a CED-4 
homologue functions directly or indirectly upstream of mitochondria to initiate the release of 
cytochrome c and other apoptogenic factors.  
So, how Bcl-2 could prevent caspase-3 activation and DNA degradation even when 
significant levels of cytochrome c remained in the cytoplasm (Rossé et al.,  1998)? The 
explanation could provide from the formation of the apoptosome. In fact, it has been shown 
that the apoptosome contains, cytochrome c, dATP/ATP, oligomerized Apaf-1, active 
caspase-9, active caspase-3 and XIAP (Bratton et al., 2001). In such a scenario, apoptosome-
bound IAPs would serve to immediately inhibit caspase-9 and –3 and/or prevent release of 
caspase-3 from the apoptosome. After a modest stress (corresponding to a slight excess of 
Bax molecules compared to that of Bcl-2 in cells stably overexpressing Bax and Bcl-2), in 
which only a small portion of cytochrome c is released and caspases are activated, these IAPs, 
and not Bcl-2 itself, would probably prevent apoptosis (Bratton et al., 2001). When 
cytochrome c is microinjected, the activation of too many apoptosome complexes and active 
caspases would overcome the protective effect of IAPs. In addition, the result of caspase 
activation would be the release of cytochrome c, and other apoptogenic factors like 
Smac/DIABLO which also counteracts the protective effect of IAPs, serving as an 
amplification loop and resulting in a very efficient apoptosis. Thus, in this case, the 
overexpression of Bcl-2 would not allow the release of pro-apoptotic factors from the 
intermembrane space of mitochondria impeding the amplification loop to proceed and 
delaying considerably cell death.   
However despite intensive research, it is still unknown how the Bcl-2 family really act on 
mitochondria. Recently, the three dimensional solution structure of the full- length Bax protein 
has been solved by NMR (Suzuki et al., 2000). The Bax structure shows a high similarity to 
the overall conformation of the two other Bcl-2 family proteins for which structural 
information is available, the anti-apoptotic protein Bcl-xL and the BH3 domain-only protein 
Bid (Muchmore et al., 1996; Chou et al., 1999; McDonnell et al., 1999). The proteins contain 
central hydrophobic helices (a5 and a6) surrounded by amphipathic helices. Of the three 
proteins, the Bax structure is the only one that contains the C-terminal hydrophobic domain. 
This domain forms a helix (a9) that protects the BH3-containing hydrophobic cleft on the 
protein. The structures of the Bcl-2 proteins are reminiscent of diphteria toxin and the colicins 
A and E1. These toxins are pore-forming proteins that function as membrane channels 
allowing passage of ions or small polypeptides. Bax and other Bcl-2 family proteins have 
been shown to possess channel–forming activity in artificial membranes (Antonsson et al., 
1997; Minn et al., 1997; Schendel et al., 1997; Schlesinger et al., 1997). In this way of 
reasoning, it has been shown in cells exposed to the apoptosis inducer staurosporine or UV 
irradiation, that Bax forms oligomers with itself and probably also with yet unidentified 
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mitochondrial membrane proteins (Antonsson et al., 2001). In addition, the formation of these 
Bax oligomers involves a series of events, including a change in Bax conformation triggered 
by Bid or other “BH3-only” proteins (Desagher et al., 1999) and insertion into the outer 
mitochondrial membrane (Eskes et al., 2000). Therefore, Bax oligomerization and insertion in 
the outer mitochondrial membrane resulting in a Bax-only channel or hybrid channels formed 
by Bax binding to lipid, VDAC or ANT represent the possible mechanism to permit the 
release of apoptogenic factors like cytochrome c (Antonsson et al., 2001). But the exact 
protein composition of these oligomers remains to be determined, although we already know 
that the core structure is composed of several Bax subunits. Moreover, it remains to be 
determined whether these large Bax oligomers really constitute the cytochrome c-conducting 
channel in mitochondria (Antonsson et al., 2001).  
Surprinsingly, despite their great sequence homology, anti-apoptotic proteins like Bcl-2 and 
Bcl-xL behave differently from Bax. First of all, it has been reported that the crystal structure 
of soluble, anchorless Bcl-xL is a monomer (Muchmore et al., 1996). Then, as we show here 
Bcl-2 does not require homodimerization for its survival activity (Conus et al., 2000b) and 
unlike Bax, Bcl-2 and Bcl-xL monomers did not oligomerize in the presence of various 
detergents (Antonsson et al., 2000; Conus et al., 2000b). In fact, the quaternary structures of 
Bcl-2 and Bcl-xL do not change significantly during apoptosis (Antonsson et al., 2001), 
allowing them to retain their globular structure so as to bind crucial death-regulatory proteins 
(including BH3-containing proteins), instead of changing their conformation to expose their 
BH3 domains for an oligomerization. Interestingly, it has also been found that Bax 
oligomerization does not occur in Bcl-2-overexpressing cells that are resistant to 
staurosporine- induced apoptosis (Estoppey et al., 1997; Antonsson et al., 2001). This result is 
consistent with previous data showing that Bcl-2 prevents the conformational change of Bax, 
which precedes its activation and membrane insertion (Desagher et al., 1999; Eskes et al., 
2000). Therefore, it seems that one of the main function of anti-apoptotic proteins is not to 
form channels on mitochondria, but simply to impede the homo-oligomerization of pro-
apoptotic proteins such as Bax by heterodimerization. This hypothesis is reinforced by our 
findings that no other cellular protein associates stably with Bcl-2, Bax or the Bcl-2-Bax 
heterodimer, and that Bcl-2/Bax co-localize to the same subcellular compartment and form 
strong, equimolar heterodimers in both normal and exposed to apoptotic stimuli cells (Otter et 
al., 1998). 
Even more amazingly, Bcl-2 and Bcl-xL seem to possess additional activities inside cells. 
Although they have a direct action on the mitochondrial membrane due to their subcellular 
localization, they also reside in the cytosol (Desagher and Martinou, 2000; personal data) and 
on other membranes such as the nuclear envelope and the endoplasmic reticulum (ER). 
Indeed, as we show here some Bcl-2 mutants that are not addressed to the mitochondrial 
membrane retain significant ability to inhibit apoptosis induced by agents like Brefeldin A 
(BFA) or tunicamycin which both provoke the release of cytochrome c into normal cells 
(Oltvai et al., 1993; Zhu et al., 1996; Lee et al., 1999; Häcki et al., 2000). Therefore, how 
could Bcl-2 control mitochondrial events from the ER membrane? The easiest explanation is 
that Bcl-2 sequester yet unknown cytoplasmic activators of cytochrome c which may stem 
from any parts of the cell. This factor is not necessarily Bid, because Bid is not involved in 
apoptosis induced by ER stresses (Häcki et al., 2000).  
The increasing evidence for a role of the ER-targeted Bcl-2 in apoptosis, and also the fact that 
anti-apoptotic proteins have been shown to protect the mitochondrial integrity by reducing, 
for example, the ROS levels (Vander Heiden et al., 1999b), suggests that the regulation of 
apoptosis by Bcl-2 family proteins is more complex than previously thought and needs further 
investigations to understand how it really works. It seems that these anti-apoptotic proteins, 
which mainly sequester pro-apoptotic proteins, including BH3-only proteins, act at several 
 103 
sites within the cell, like the cytosol, the mitochondrial membrane, the ER membrane and 
perhaps other membranes. Nevertheless, for the moment, no other protein than Bcl-2 has been 
shown to control apoptosis from the ER or other membranes. Moreover, the presence of anti-
apoptotic proteins in the cytosol is a mystery, as nobody has ever shown whether this pool can 
prevent the conformational change that Bax undergoes during apoptosis (Desagher and 
Martinou, 2000) or sequester BH3-only proteins. Despite that, cytoplasmic Bcl-2 has been 
shown to be still partially active to protect cells from apoptosis (Borner et al., 1994). 
Therefore, the identification of new anti-apoptotic proteins could answer some questions 
about how apoptosis in general, and Bcl-2 family proteins in particular, are regulated. That is 
why it is interesting to clone new survival factors as has been started in other groups and also 
done in the present work. However, such studies are not easy because they require a lot of 
tests, like a series of different stresses on different cell lines followed by a clonogenicity assay 
to confirm that the cloned factors really act by protecting and rescuing cells from apoptosis in 
a wide range of situations. As we have now at least one or even more putative survival factors 
in hand, we next have to examine under which conditions and how they work.  
For all of these reasons, cell death will continue to be a lively field for the foreseeable future ! 
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